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ABSTRACT 
 
C-reactive protein (CRP) and complement component C3 are both plasma proteins involved 
in antigen recognition by the innate immune system. They may play a role in the 
pathogenesis of immune-mediated diseases including systemic lupus erythematosus (SLE) 
and coronary heart disease. CRP is heritable, but there is uncertainty over the key genetic 
variants influencing expression. C3 heritability has not been demonstrated, although a single 
report suggests C3 variation influences serum C3 level and susceptibility to SLE.  
 
This thesis presents an association analysis of CRP genotype and serum CRP from four 
ethnically diverse cohorts. Two cohorts were diseased based (UK European and Filipino SLE 
family cohorts) allowing the additional analysis of CRP genotype/disease association, and 
one (UK rheumatoid arthritis cases) consisted of individuals with active inflammatory 
disease. CRP genotype was associated with serum CRP in all cohorts. Analysis of an African-
American cohort (which had an informative pattern of linkage disequilibrium at CRP) 
highlighted a single CRP SNP, rs3091244, likely to be a key regulator of expression at this 
locus. No association was observed between CRP genotype and SLE.  
 
The UK European SLE cohort was also used to demonstrate C3 heritability and explore 
associations between C3 genotype, serum C3 and SLE. Cis-acting associations were 
identified with both serum C3 and SLE. The recognition that serum CRP and C3 levels are, in 
part, genetically determined traits has implications for their use in the monitoring and 
diagnosis of disease. For neither protein does a single cis-acting variant explain most of the 
variation in serum level: this may be determined by multiple interacting variants, many of 
which have yet to be identified. 
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INTRODUCTION 
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1.1: The Innate Immune System – An Introduction 
 
Classically, the components of the human immune system are divided into two broad 
categories: the adaptive immune system and the innate immune system. The adaptive 
immune system evolved relatively recently in chordate species (Pancer & Cooper 2006). It is 
characterised by high specificity receptors generated by the somatic recombination and 
diversification of receptor gene segments. Following antigen recognition a sophisticated 
response is orchestrated, resulting either in the activation of highly effective antigen 
clearance mechanisms or the down-regulation of immune responses resulting in antigen 
tolerance. A key function of the adaptive immune system is the generation of immunological 
memory: the production of antigen-specific memory cells that enable a more rapid and robust 
response when specific antigen is encountered for a second time (Murphy et al 2008). 
 
In contrast, the basic components of the innate immune system are phylogenetically ancient, 
with human molecule homologues widespread in protostome species (Danilova 2006). 
Foreign antigen is recognised through germ-line encoded receptors which, unlike those of the 
adaptive immune system, are often non-specific and capable of recognising numerous 
antigens found on the surface of pathogenic micro-organisms or altered human cells. They 
are expressed on prevalent immune cells (such as neutrophils and macrophages) or as 
circulating plasma proteins, and they trigger a rapid immune response (Murphy et al 2008).  
 
The innate and adaptive immune systems do not, however, function in isolation, but work in 
tandem: recognition of antigen by the innate immune system can recruit and prime an 
adaptive response, and in turn adaptive components can trigger highly effective innate 
bacterial killing mechanisms (Murphy et al 2008).  
19 
 
For convenience, the innate immune system can be divided into cellular and humoral arms. 
Recognition of antigen by the cellular branch is mediated by cell-surface or intracellular 
receptors recognising unique pathogen-associated molecular patterns, including protein, 
carbohydrate and nucleic acid antigens. The Toll-like receptor family is the best described, 
but there are others including the NOD/NALP receptor family, NK receptors and Scavenger 
receptors (Beutler 2008; Papadimitraki et al 2007; Peiser et al 2002; Petrilli et al 2007; 
Vivier et al 2008). These receptors are among the first components of the immune system to 
recognise foreign antigen. Cellular responses triggered in response to receptor binding, for 
example the release of type 1 interferons (IFN) or interleukin-1β (IL-1β), are critical in 
directing the course of the subsequent innate and adaptive immune response (Lee & Kim 
2007). The humoral branch of the innate immune system will be discussed in the next 
section. 
 
1.2: Complement 
 
A key component of the humoral arm of the innate immune system is a network of proteins 
comprising the complement system, so called because they “complement” the function of 
antibody (Walport 2001). The central components of this system are zymogen proteins that 
circulate in the plasma in an inactive state. Activation of the early complement components 
initiates a cascade of protein activation, with each component in turn activated by proteolytic 
cleavage, resulting in the generation of molecules that are biologically active and contribute 
to host defence.  
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1.2.1: Complement – An Outline. 
 
An outline of the central components of the complement cascade is presented in figure 1.1. 
The sequence of activation and functions of these central components is now well established 
and a number of comprehensive texts and review articles are referenced. There are three 
pathways of activation, each culminating in the cleavage of C3 (Frank & Fries 1991; Muller-
Eberhard 1988; Murphy et al 2008; Walport 2001). The first component of the classical 
pathway is C1q, a member of the collectin family of proteins. C1q is either activated directly 
by binding certain antigens on pathogens or altered cells, or by binding cross-linked 
immunoglobulin (i.e. immunoglobulin complexed with antigen, either on cell surfaces or in 
immune complexes). Finally C1q can be activated by another important component of the 
innate immune system called C-reactive protein (CRP). CRP is a small molecule that 
recognises a wide range of antigens found on bacteria or altered human cells, and it will be 
discussed in detail in subsequent sections. Following antigen recognition, C1q binds the 
zymogens C1r and C1s, and the C1 complex in turn activates components C4 and C2 by 
proteolytic cleavage. Together the large fragments of C4 and C2 (C4b2b) form a C3 
convertase which is able to activate C3, the pivotal molecule of the cascade. 
 
The second pathway of complement activation is the Mannose-binding lectin (MBL) pathway 
(Endo et al 2006; Turner & Hamvas 2000). MBL is a collectin homologous to C1q. It binds 
mannose residues, and certain other sugars, which lie exposed on the surface of many 
bacterial cell walls. MBL forms a complex with MBL-associated serine proteases, MASP1 
and MASP2, which are homologous to C1r and C1s, and the activated MBL complex is able 
to cleave C4 and C2 in the same way as the classical pathway. 
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Figure 1.1. The complement cascade summarising three pathways of activation 
 
Classical 
pathway
Alternative 
pathway
Mannose-binding 
lectin pathway
Triggers
apoptotic cells
bacteriaC-reactive 
protein
bacteria
(carbohydrate 
antigens)
spontaneous 
hydrolysis of C3
C5b6789 - Membrane attack 
complex
C1q, C1r, C1sEarly 
components
MBL, MASP1, 
MASP2
+
Cleavage of C2 
into C2a and C2b
Cleavage of C4
into C4a and C4b
C3 Convertase C2b4b
Cleavage of C3 
into C3a and C3b
Cleavage of C5 
into C5a and C5b
C3a and C5a - 
Chemotaxis
C3b - Opsonisation
C3
C5
C3bBb
Cleavage of Factor B 
D
 
 
MBL – Mannose binding lectin, MASP – MBL-associated serine protease. 
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The final pathway of complement activation is the alternative pathway (Harboe & Mollnes 
2008). Circulating C3 undergoes a low rate of spontaneous hydrolysis to C3(H2O), and 
hydrolysed C3 is able to bind Factor B, a protein homologous to C2. Bound factor B can 
undergo cleavage by factor D resulting in C3(H2O)Bb, which has C3 convertase activity. 
Unbound C3b is rapidly inactivated by hydrolysis but if any C3b produced through the 
alternative pathway does bind a cell surface it can bind factor B again and, following 
cleavage by factor D, form a stable C3 convertase, C3bBb. It is critical to host survival that 
spontaneously produced C3b does not bind to normal host cells, and a series of circulating 
and membrane bound regulatory proteins have evolved to inactivate C3b when deposition on 
normal cells occurs. A full discussion of these is beyond the scope of this thesis. 
 
C3 will be discussed further in later sections but, in summary, activation results in the 
generation of biologically active fragments that form the effector arm of complement system. 
C3 can exist in a number of conformational states, and can be cleaved into a number of 
fragments with distinct biological activity. Fragment C3a acts via specific receptors to 
mediate local inflammatory responses including increased vascular permeability, 
upregulation of endothelial adhesion molecules, and recruitment of inflammatory cells. 
Fragment C3b remains bound to the surface on which it was activated and facilitates uptake 
by phagocytic cells carrying specific complement receptors, a process known as opsonisation. 
Proteolytic alteration of C3b results in the formation of fragments iC3b and C3dg, which also 
function as opsonins, and C3c. The incorporation of C3b into the C3 convertase (to form 
either C4b2b3b or C3bBb3b) generates a complex which cleaves C5 into C5a and C5b. C5a 
has potent pro-inflammatory effects similar to C3a, while C5b initiates the formation of the 
membrane attack complex (consisting of complement components C5b, C6-8 and multiple 
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copies of C9) which is capable of killing cells directly by forming a membrane destabilising 
pore, leading to cell lysis (Haas & van 2007; Muller-Eberhard 1986).  
 
1.2.2: Complement – Physiological Functions 
 
Complement is highly effective at mediating bacterial killing through its three effector arms: 
opsonisation of bacteria, recruitment of inflammatory cells and bacterial lysis via the 
membrane attack complex. The importance of this role is highlighted by the increased 
susceptibility to infection seen in individuals with hereditary complement deficiencies. 
Primary homozygous C3 deficiency is exceptionally rare, but is characterised by recurrent 
bacterial infection from organisms such as Haemophilus influenzae, Streptococcus 
pneumoniae and Neisseria meningitidis (Reis et al 2006). Deficits in the membrane attack 
complex components are particularly associated with susceptibility to infection by Neisseria 
meningitidis (Ross & Densen 1984; Wurzner et al 1992). 
 
In addition to its role in bacterial clearance, complement promotes the clearance of unwanted 
host cells, or cellular components in the form of circulating immune complexes. Apoptosis or 
“programmed cell death” is a key physiological mechanism by which unwanted host cells 
die, leading to rapid clearance by phagocytosis without a damaging inflammatory response. 
The cellular signals that control this process are incompletely understood but it is clear that 
complement has a crucial role (Pittoni & Valesini 2002). Cells undergoing apoptosis exhibit 
characteristic changes to the lipid and protein constituents of their cell walls. Both the C1q 
and MBL components of complement are able to bind these altered cell walls leading to 
complement activation and deposition of iC3b on the surface of the apoptotic cell (Hansen & 
Holmskov 1998; Korb & Ahearn 1997; Mevorach et al 1998a). The iC3b fragment of C3 is 
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able to mediate the uptake of these cells by phagocytes bearing complement receptor 3 
(CR3), but does not form a C5 convertase, hence the pro-inflammatory and direct cytotoxic 
aspects of complement function are limited. Similarly CRP binds avidly to apoptotic cells and 
activates the classical complement pathway, but again prevents the formation of the terminal 
membrane attack complex (Gershov et al 2000). 
 
Complement is also important in the clearance of cellular components released into the 
circulation from dead bacteria or host cells. Typically these antigens bind to specific 
immunoglobulin to form small immune complexes, either within tissues or within the 
circulation. Complement limits the physical size of these immune complexes, and maintains 
their solubility, thus preventing immune complex mediated tissue injury (Miller & 
Nussenzweig 1975; Naama et al 1984; Schifferli et al 1982; Schifferli et al 1985). Secondly, 
complement mediates the uptake of immune complexes by phagocytic cells, expressing CR3, 
which recognise iC3b deposited on the complexes (Arnaout et al 1983; Brown et al 1988). 
Immune complexes located in tissues are taken up directly by phagocytes, while immune 
complexes in the circulation are initially transported to the spleen by erythrocytes which 
express CR1 and bind C3b on the complex. Phagocytes within the spleen then efficiently 
remove and destroy immune complexes from the surface of erythrocytes by the mechanism 
described above (Davies et al 1993; Schifferli et al 1988). 
 
1.2.3: Complement and Systemic Lupus Erythematosus 
 
Systemic lupus erythematosus is the archetypal systemic autoimmune disease. It is 
characterised by presence of pathogenic autoantibodies directed against ubiquitous cellular 
components, including nucleoproteins and negatively charged membrane phospholipids. 
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These antibodies may be directly pathogenic, or may cause damage when deposited in tissues 
in the form of immune complexes. Clinically the result of this immunological dysfunction is 
a disease characterised by inflammation in multiple organs including kidney, skin, joints and 
central nervous system (Lahita 2004). SLE is a heterogeneous disease, presenting differently 
from patient to patient, and with no single clinical or immunological feature required to make 
a formal diagnosis (Tan et al 1982). For at least 30 years we have known that there is a strong 
genetic basis to SLE: a disease concordance of 2-5% in dizygotic compared with 24-57% in 
monozygotic twins and a sibling risk ratio (λs) of 20-29 (Alarcon-Segovia et al 2005; Block 
et al 1975; Deapen et al 1992; Hochberg 1987). Progress in understanding the immune 
pathology underlying SLE has been slow, and it is only over the last five years or so that we 
have developed a more detailed understanding of which are the key genetic variants 
influencing disease susceptibility (Rhodes & Vyse 2007; Rhodes & Vyse 2008). 
 
An apparent paradox of SLE pathogenesis is how a strong autoimmune response is generated 
against antigens that are primarily located in the intracellular compartment. A convincing 
explanation for this arose from the observation that cells undergoing apoptosis display many 
of these intracellular antigens on their cell surface. It was also noted that mice injected with 
apoptotic cells develop lupus-like antibodies against ssDNA and negatively charged 
membrane phospholipids (Casciola-Rosen et al 1994; Mevorach et al 1998b). Apoptotic cells 
may therefore be the source of auto-antigen in SLE, and any impairment of apoptotic cell 
clearance could predispose to autoimmunity. This hypothesis has become known as the 
“waste-disposal hypothesis”. It is supported by a number of lines of evidence including the 
direct observation of impaired phagocytosis of apoptotic cells by macrophages from SLE 
patients, and the high prevalence of SLE-like illness in individuals deficient in C1q and other 
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early components of the classical complement cascade (Baumann et al 2002; Herrmann et al 
1998; Pickering & Walport 2000).  
 
The mechanism by which an impairment of complement associated apoptotic cell clearance 
leads to autoimmunity is unknown. Normally the uptake of iC3b opsonised apoptotic cells by 
dendritic cells is generally accompanied by a suppression of inflammation and a release of 
anti-inflammatory mediators, without dendritic cell maturation (Morelli et al 2003; 
Verbovetski et al 2002; Voll et al 1997). It is possible that a delay in clearance allows 
apoptotic cells to progress into more inflammatory necrotic cells, and that the resulting pro-
inflammatory environment  allows dendritic cell maturation and the expression of a pro-
inflammatory cytokine response, triggering a break in tolerance (Manderson et al 2004). 
 
There is considerable evidence, from murine models and in vitro experiments, to demonstrate 
that complement abnormalities play a central role in the impaired uptake of apoptotic cells in 
SLE: this literature has been reviewed elsewhere (Manderson et al 2004). The important role 
played by complement is also emphasised by the high prevalence of lupus-like illness in 
individuals with complement component deficiencies (Manderson et al 2004; Pickering & 
Walport 2000). Homozygous C1q deficiency is extremely rare, but over 90% of individuals 
develop moderate to severe lupus (Walport et al 1998). Similarly the even rarer deficiencies 
of C1r and C1s are associated with high risk of disease (Pickering & Walport 2000). A 
variety of MBL promoter SNPs have been associated with reduced MBL expression, while a 
structural exon-1 SNP has been associated with SLE (Garred et al 2001; Huang et al 2003).  
 
Moderately severe SLE develops in up to 33% of patients with homozygous C2 deficiency 
(Pickering & Walport 2000). A C2Q*0 null allele is carried on a rare DRB1*1501 containing 
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MHC haplotype on chromosome 6 and is usually due to a 28 base pair deletion creating a 
premature stop codon (Johnson et al 1992). Heterozygous C2 deficiency does not seem to 
confer an increased risk (Hartung et al 1989). Although C4 deficiency is also associated with 
SLE, the genetics of C4 is particularly complex making it difficult to conclusively ascribe an 
effect to this gene. C4 is transcribed from two MHC genes, C4A and C4B, which have 
slightly different sequences and function; C4A being better able to bind immune complexes 
(Schifferli et al 1986). The C4 genes are inherited in a discrete “RCCX module”, which 
contains one C4 gene (either C4A or C4B) along with three neighbouring genes. The Class III 
MHC carries between one and four copies of this module; hence each diploid genome has 
between two and eight C4 genes, which may be either C4A or C4B (Yang et al 2007). 
Carrying less than 2 copies of C4A has been identified as a risk factor for SLE (Yang et al 
2007). MHC sequencing, however, reveals that the common AH8.1 (DR3), SLE associated 
haplotype contains a monomodular RCCX unit with a single C4B gene and no C4A (Stewart 
et al 2004). It is therefore possible that the observed C4A association is present due to linkage 
disequilibrium between the gene copy number and functional variants in other MHC genes. 
We will only be able to answer this question when we have a comprehensive analysis 
incorporating both C4A copy number analysis and a dense MHC SNP map.  
 
Interestingly, although individuals with complete C3 deficiency are at high risk of bacterial 
infection they seem to develop less severe autoimmune features. Nonetheless, the most 
comprehensive review to date reports autoimmune manifestations (most commonly a rash) in 
26% of patients with complete C3 deficiency (Reis et al 2006). The majority of individuals 
with severe manifestations (including mesangiocapillary glomerulonephritis or full-blown 
SLE) are Japanese, suggesting that disease severity in this population may be determined by 
an interaction between C3 deficiency and another, unknown, genetic locus (Reis et al 2006). 
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Complete deficiency of any of the complement components is extremely rare and unlikely to 
contribute to the genetic basis of the relatively common sporadic SLE. In the majority of 
cases SLE susceptibility is likely to be determined by relatively common variants that are 
found throughout the population, each of which only contributes modestly to disease risk; this 
has been termed the “common disease, common variant” hypothesis (Becker 2004). Although 
complete complement deficiencies may not be relevant in this context they do highlight that 
complement proteins, and molecules associated with complement activation may be suitable 
gene candidates in the search for common variants associated with SLE. The recent 
identification of ITGAM (integrin αM – the α-subunit of complement receptor 3) as a major 
susceptibility gene in human SLE emphasises this point (Nath et al 2008). 
 
In addition to a specific role for complement there is evidence that the innate immune system 
plays a wider role in SLE pathogenesis; much of this evidence has come from genetic studies. 
For example, there is biological plausibility for a role for the toll-like receptors that I 
introduced in section 1.1. TLRs 7 and 9 bind single stranded RNA and unmethylated CpG 
DNA respectively. Small sections of CpG rich, hypomethylated DNA may be released during 
apoptosis while endogenous ssRNA may be found in the context of small nuclear 
ribonucleoprotein (snRNP) immune complexes (Barrat et al 2005; Krystosek 1999). In vitro 
evidence suggests that ssRNA and CpG DNA are capable of stimulating autoreactive B-cells 
via TLR 7 and 9 respectively (Lau et al 2005; Viglianti et al 2003). In murine models tlr9 
knockout has been association with the development of autoimmunity while the SLE 
enhancing effects of the Yaa region of the lupus-prone BXSB mouse may, in part, be due to a 
tlr7 gene duplication (Christensen et al 2006; Pisitkun et al 2006). To date, however, no 
human studies have demonstrated an association between SLE and variation at TLR7 or TLR9 
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(De Jager et al 2006; Hur et al 2005; Kelley et al 2007; Ng et al 2005). There is also strong 
evidence for a role for type 1 interferons (IFN-α and IFN-β), cytokines released from innate 
immune cells as part of the early response to antigen. It has been noted that there is a general 
up-regulation of interferon inducible genes in SLE (Baechler et al 2003; Bennett et al 2003). 
Subsequently genetic studies have shown an association between variation in a number of 
interferon pathway genes and SLE, most notably IRF5, the gene encoding interferon 
regulatory factor-5 (Kozyrev & Alarcon-Riquelme 2007). 
 
Before leaving this section it should also be noted that complement levels fluctuate in SLE as 
part of the disease process itself, presumably because the rate of complement activation by 
immune complexes exceed the rate of synthesis. A decrease in the levels of the complement 
components C4 and, particularly, C3 are often observed in patients with SLE, although the 
correlation with disease activity varies from patient to patient (Jonsson et al 1995; Valentijn 
et al 1985). 
  
In the work presented in this thesis I will concentrate on two specific components of the 
innate immune system outlined above. Firstly CRP, the non-specific pattern recognition 
molecule which is a potent activator of the classical complement cascade and, secondly, C3 
itself, the pivotal molecule at the centre of the complement cascade. In particular I will 
consider the possibility that common variation in the CRP or C3 genes may influence gene 
expression, and that this, in turn, may predispose to the development of disease. 
In the following sections I will therefore introduce some basic genetic concepts that are 
important for the understanding of genetic association studies, before outlining our current 
understanding of both the biological functions of CRP and C3, and the genetic basis of their 
expression.  
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1.3: Complex Trait Genetics – An Introduction 
 
In this section I will summarise our current understanding of human genetics, genetic 
variation and the association between genetic variation and human biological traits. I will also 
discuss relevant methodological issues surrounding the design of genetic association studies. 
 
1.3.1: Genes, Genetic Variation and Phenotype 
 
The human genome consists of approximately 3.2 billion base pairs of DNA, and encodes 20-
25,000 genes capable of translation to a protein product (McPherson et al 2001; The 
International Human Genome Sequencing Consortium 2004). With a few exceptions every 
somatic cell carries two copies of this genome, divided between 22 homologous pairs of 
autosomes and two sex chromosomes.  
 
Apart from monozygotic (identical) twins, the genome varies from person to person, and this 
structural genetic variation takes a number of different forms. Perhaps best described is the 
single nucleotide polymorphism (SNP). A SNP is present when, within the population, two or 
more different nucleotides (alleles) are observed at the same position in the genome. The 
traditional definition of a “polymorphism” states that the frequency of the minor (or rare) 
allele in the population has to exceed 0.01. It has been estimated that there are 9-10 million 
SNPs with a minor allele frequency <0.05, over 3.1million of which have been characterised 
in four human populations by the International HapMap Project (www.hapmap.org) (Frazer 
et al 2007). SNPs arise as a result of rare mutations due to DNA damage or defective DNA 
replication. They can alter the function of the gene (and hence increase disease susceptibility) 
in a number of ways. Non-synonymous SNPs in gene exons can alter the amino acid 
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sequence, and hence function, of the final protein product. Alternatively SNPs may affect 
gene regulatory elements, perhaps altering promoter function, gene splicing, mRNA stability 
or translational efficiency (Knight 2005). The majority of SNPs lie in intergenic regions and 
may have no function; they have arisen by chance and persist because they are not subject to 
the forces of natural selection. 
 
It should be noted that there are other sources of genetic variation. In particular we are 
increasingly realising that the large scale duplication or deletion of DNA segments known as 
copy-number variation (CNV) is a major source of human genetic variation, affecting up to 
12% of the genome (Redon et al 2006). The study of CNV is in its infancy and will not be 
considered further here. 
 
All humans differ from each other; from observable phenotypes such as height or weight, to 
measurable biological parameters such as plasma protein levels; from behavioural 
characteristics to the likelihood of developing disease. To a greater or lesser extent the 
variation in each of these phenotypic characteristics is determined by underlying genetic 
variation of the kind introduced above. Some phenotypes (so called Mendelian traits) are 
determined by variation of a single gene, although few are entirely unmodified by 
background genetic effects as well (Nadeau 2001). Mendelian traits are characterised by 
simple patterns of inheritance within families, to the extent that it is possible to predict with a 
reasonable level of certainty an individual’s risk of expressing that phenotype. The majority 
of common human diseases and all quantitative biological traits, however, are determined by 
variation at multiple genes, with trait expression determined by a potentially complex 
interaction between genes and between genes and the environment: these are termed complex 
genetic traits. Complex genetic traits are characterised by complex patterns of inheritance; 
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typically there is modest trait concordance among first degree relatives, with a rapid tailing 
off of concordance in more distantly related individuals (Risch 1990). Identifying the variants 
underlying complex genetic traits presents a major challenge in modern genetic research. 
 
1.3.2: Confirming the genetic basis of a trait – Family Studies 
 
The clustering of a disease, or phenotypic trait, within families suggests that the trait has an 
underlying genetic basis, even if the causal mutation is unknown (Burton et al 2005). A 
common approach to quantifying this is to compare trait concordance in monozygotic 
(genetically identical) twins to that observed in dizygotic (on average 50% identical) twins 
(Martin et al 1997). An alternative measure is the sibling risk ratio, λs (i.e. the incidence of 
disease in the siblings of affected individuals compared with the incidence of disease in the 
general population). As an example, Table 1.1 outlines the twin concordance and λs for a 
number of diseases with a proposed genetic basis. 
 
 
Table 1.1. Familial clustering of complex genetic diseases 
Disease Monozygotic 
concordance (%) 
Dizygotic 
concordance (%) 
Sibling risk 
ratio (λs) 
SLE 24-57 2-5 20-29 
MS  25 0-5 20 
T1D  30-50 0-13 15 
RA  12-15 3-4 5-10 
CHD  39(♂) 44(♀) 26(♂) 14(♀) 2-3 
Abbreviations, and study references are as follows: 
SLE – Systemic lupus erythematosus (Alarcon-Segovia et al 2005; Block et al 1975; Deapen et al 1992; Hochberg 1987), MS – 
Multiple sclerosis (Kalman & Lublin 1999), T1D – Type 1 diabetes mellitus (Hirschhorn 2003; Redondo et al 2001), RA – 
Rheumatoid arthritis (Silman et al 1993; Wordsworth 1995), CHD – Coronary Heart Disease (Allen et al 1967; Scheuner 
2001). 
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An alternative measure of genetic effect which is often applied to quantitative traits (but can 
also be applied to binary data) is heritability (Visscher et al 2008). The observed variation in 
any phenotype within the population can be expressed as the sum of the variance due to 
environmental effects and the variance due to genetic effects, even if the nature of these 
actual effects is unknown. Heritability is the proportion of the variance in phenotype that can 
be attributed to variance in genotype. Genetic variance itself can be partitioned into additive 
genetic effects (where the mean effect in the offspring is determined by the sum of all the 
average genetic effects of the parental genes), dominance effects (where non-additive 
interactions occur between alleles at a locus) or epistatic effects (where non-additive 
interactions occur between alleles at different loci). Since non-additive genetic effects may 
only be estimated effectively in the setting of twin studies, heritability (h2) is often used in the 
strict sense of the proportion of phenotypic variance that can be attributed to variance in 
additive genetic effects. Heritability may be estimated in a number of different ways, but all 
depend on measuring how phenotypic effects cluster within families, in the light of what we 
would expect given the relatedness of the individuals and the assumed genetic and 
environmental causes. There has been some controversy over the use of heritability estimates, 
particularly when applied to human behavioural traits (Visscher et al 2008). Nonetheless, in 
the context of a quantified plasma protein in a particular population, heritability provides a 
useful measure of the fraction of variation in plasma protein levels due to genetic effects.  
 
1.3.3: SNP discovery in Complex Genetic Disease 
 
Figure 1.2 illustrates a typical approach to the identification of functional genetic variants in 
complex genetic disease. The “classical” approach has been successfully used in the 
identification of rare, high-risk, Mendelian traits; but has also been commonly applied to  
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Figure 1.2. A classical approach to the identification of functional genetic variants. 
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gene discovery in complex genetic traits (Botstein & Risch 2003; Glazier et al 2002). The 
initial step in investigation is the linkage study, which allows the relevant genetic variation to 
be localised to a particular physical region of the genome, even if the actual mutation of 
interest is unknown (Teare & Barrett 2005). Linkage scans are ideally conducted in large 
families with multiple affected individuals. A panel of genetic markers (typically a few 
hundred to a few thousand), spanning the entire genome, is typed, and markers that segregate 
with the trait of interest are used to localise the genomic region in which the functional effect 
lies (Weeks & Lathrop 1995). 
 
Although non-parametric/model free linkage analysis has been applied to the study of both 
binary and quantitative complex genetic traits, it is notable that this has proven less 
successful than in the study of single gene disorders (Altmuller et al 2001). This may be 
largely due to inadequate power of current studies to identify multiple susceptibility genes 
each with only a modest effect on disease susceptibility. Using SLE as an example, the six 
whole genome linkage scans performed to data have identified multiple linkage regions, but 
all are large and contain many genes of potential functional significance (Sestak et al 2007). 
Furthermore the key gene candidate, IRF5, which has demonstrated a strong association with 
SLE in both candidate gene and genome-wide association studies does not lie in any of these 
linkage regions (Sestak et al 2007). In the study of complex genetic disease, the selection of 
candidate genes has often been based on other lines of evidence suggesting biological 
plausibility for a particular gene, rather than the classical approach of selecting genes from 
within a narrow linkage region. 
 
The key advances in our understanding of complex trait genetics have really been made using 
the genetic association (candidate gene) study. In contrast to the linkage study, these studies 
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look for an association between a genetic variant (usually a SNP) and a particular trait in a 
population cohort, rather than in a pedigree of related individuals. The aim is still to identify 
genetic variants that are found more frequently in individuals with a particular trait of 
interest, but because of extensive recombination occurring during the entire genetic history of 
the population, the physical distance over which association operates is small and determined 
by population linkage disequilibrium (Cordell & Clayton 2005). Linkage disequilibrium (LD) 
is a property of the genome by which there is a high degree of correlation between genetic 
variants located in close physical proximity to each other. Since the correlation between 
adjacent SNPs will be destroyed if recombination occurs between them during meiosis, the 
presence of high LD implies that recombination has not occurred, even over the tens of 
thousands of generations since the founding of the population under study.  
 
Considerable effort has been devoted to understanding and mapping the pattern of linkage 
disequilibrium across the human genome (Daly et al 2001; Frazer et al 2007; Gabriel et al 
2002). It has been shown that the majority of the genome is divided into discrete haplotype 
blocks. Within these blocks all the SNPs are in strong LD with each other, to the extent that it 
is often possible to select a small number of SNPs (tagSNPs) that are representative of all the 
genetic variation seen within the block (Johnson et al 2001). Between blocks are regions 
termed “recombination hotspots” where there has historically been a high rate of 
recombination, leading to a rapid fall in LD. Without LD, genetic association could only be 
identified if the actual causative marker was genotyped in an experiment (direct association); 
because of LD, indirect associations can also be identified for a range of non-functioning 
neighbouring SNPs within the haplotype block. 
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Until recently, it has only been technologically or financially possible to type a limited 
number of SNPs in an association study. Even given the presence of LD, this has made it 
possible to look for association over a small genetic interval only, hence the selection of 
“candidate genes” for study. Recently, technological advances have allowed for the 
simultaneous genotyping of hundreds of thousands of SNPs simultaneously, and this density 
of markers allows us to perform hypothesis-free Genome Wide Association (GWA) analyses 
(Xavier & Rioux 2008). The GWA study is a major departure from the “classical” approach 
to the identification of functional genetic effects, and promises to revolutionise the 
identification of genetic effects underlying a number of traits and diseases. 
 
The identification of a positive association signal in a single study is only the start of the 
process of refining and confirming the genetic effect, and elucidating the role of the 
functional variant. It is notable, or indeed notorious, that genetic associations, particularly 
from earlier studies, are not consistently reproduced. Indeed, in a review of 166 association 
studies only six were reproduced  by >75% of subsequent published studies (Hirschhorn et al 
2002). A single report of association should therefore be considered only suggestive of a true 
effect, and a key part of the SNP discovery process should be replication in at least one 
independent cohort. 
 
While the existence of LD helps us to identify genetic effects arising from a particular gene, 
once an effect has been found LD hinders attempts to narrow the genetic signal down to a 
true functional variant from among a potentially large number of indirect associations. This 
has made it particularly difficult to identify functional variants in regions of the genome 
where strong LD can extend over large distances, for example the Major Histocompatibility 
Complex on chromosome 6 (Fernando et al 2008). The problem may be even more complex 
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if more than one SNP in a gene is functional, particularly if the LD between them is high. To 
some extent this problem can be overcome by the use of large cohorts, with the power to 
differentiate between SNPs even when the allele frequencies are similar and the LD between 
them is strong. Methodologically a conditional regression based analysis, combined with an 
appropriate model choice procedure, may allow the delineation of multiple functional SNP 
effects. A better approach, however, may be to search for functional effects in cohorts of 
different ethnicity. Haplotype mapping data suggests relatively limited haplotype diversity in 
European populations (mean block length 22kb, mean number of haplotypes per block 4.2), 
compared with Africans (mean block length 11kb, mean number of haplotypes per block 5) 
(Gabriel et al 2002). These genetic differences reflect different population histories, with the 
most likely explanation for the stronger LD in Europeans being a population bottleneck 
occurring during the founding of the modern European population (Reich et al 2001). These 
differences in haplotype structure, combined with different allele frequencies may allow 
genetic association studies conducted in diverse ethnic populations to dramatically narrow the 
genetic interval in which a functional SNP is to be found. 
 
Even when DNA sequencing has identified all genetic variation in a region, and these have 
been subject to association analysis, there will always be an argument that the observed 
genetic association is due to correlation rather than causation. The final stage in the pathway 
of functional SNP identification must therefore be functional experimentation to confirm that 
the SNP can alter the phenotype of interest. In mice this may be feasible by genetic 
modification of the gene of interest; in humans obtaining this functional proof may be harder. 
It is perhaps notable that there is frequently a discrepancy between genetic association, and in 
vitro functional data, suggesting either there are a large number of false positive associations 
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reported, or alternatively our ability to perform physiologically relevant in vitro assays is 
limited (Ioannidis & Kavvoura 2006). 
 
1.3.4: Methodological Issues in Genetic Association Studies 
 
Although the essence of the genetic association study is straightforward there are a number of 
methodological issues that need to be considered if we are to avoid the problems of false 
positive and false negative results.  Firstly it is important to ensure that we do not report 
associations due to confounding as a result of population stratification. In particular, subtle 
differences in the genetic ancestry of the cohort, between cases and controls when binary data 
is considered, or across the distribution of values for a quantitative trait, may lead to false-
positive associations (Clayton et al 2005; Ewens & Spielman 1995). An extreme example of 
this is the study of admixed populations such as the African-American population. The 
majority of the African-American genome shares ancestry with current West African 
populations, however, a significant proportion (perhaps 10-30%) may arise from recent 
admixture with European populations (Wassel Fyr et al 2007). Even within European 
populations notable stratification has been described, suggesting this issue should be 
considered for any association study (Seldin et al 2006; Tian et al 2008c). A number of 
methods for circumventing this problem have been proposed. One commonly used approach 
is the family based study design, with related controls ensuring appropriate matching for 
ethnicity. The classic statistical test of family-based association is the transmission 
disequilibrium test (TDT) which utilises genetic data from a proband and their two parents 
(Spielman et al 1993). The null hypothesis for this test is that the transmission of alleles from 
parent to offspring is random. We would expect an allele associated with disease, or 
particular distribution of a quantitative trait, to be transmitted to an affected offspring more 
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commonly than expected by chance. Although providing a robust solution to the problem of 
population stratification, the use of a family-based design comes at the expense of reduced 
power, because information on allele transmission is only available from heterozygous 
parents. An additional problem with the classic TDT is that information is required for both 
parents, making the collection of large cohorts harder. A number of modifications to the TDT 
have been developed and I have used two of these in the analysis of data presented in this 
thesis. Firstly, TRANSMIT, which can infer parental genotypes using genetic data from 
additional siblings, thus allowing the inclusion of families with missing parental data and, 
secondly, qTDT, which allows for the analysis of quantitative data (Abecasis et al 2000; 
Clayton 1999).  
 
An alternative approach to the issue of population stratification is to employ a traditional 
case-control design, but to ensure adequate control for the ethnic background of the 
population under study (Tian et al 2008a). With the increasing availability of population 
specific genotype data it has been possible to identify SNPs that are unique to one ethnic 
population or another, or at least have very different minor allele frequencies, leading to the 
concept that an individual’s ethnic ancestry can be defined genetically. Either the ancestral 
origin of a particular gene can be determined by the selection of ancestry informative SNPs 
specific to that locus, or, increasingly popular in larger genetic studies, a genome wide panel 
of ancestry informative markers can be typed to control for admixture at a genome-wide level 
(Halder et al 2008; Kosoy et al 2009). 
 
A major cause for the reporting of false positive associations is inadequate adjustment for the 
testing of multiple hypotheses (Elston et al 2002). The universally accepted measure of 
statistical proof is to demonstrate that the probability of observing, by chance, a difference 
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equal to or more extreme than the one actually observed, is less than 5% (in classical 
statistics P<0.05); in other words the false positive rate is 1 in 20. Clearly as more genetic 
variants are tested against the phenotypic trait of interest, the false positive rate will increase 
(if we tested 20 independent SNPs we would expect one false positive, if we tested 100 we 
would expect five false positives). In order to avoid this increased type 1 error rate it is 
necessary to adjust downwards the P-value we accept as “significant”. Simple tests such as 
the Bonferroni correction (P-value multiplied by the number of tests) are very stringent, 
particularly when many of the SNPs tested in an association study are not truly independent, 
but are correlated to some extent due to LD. This becomes a particular issue when 
considering genome-wide levels of significance but it is also important in association studies 
on the scale presented in this thesis. A number of approaches have been described. A simple 
but pragmatic approach that I have used in parts of this thesis is to adjust the Bonferroni 
correction for the degree of correlation between markers tested; no correlation between 
markers would result in a standard Bonferroni correction while complete correlation between 
SNPs would lead to an adjusted P=0.05 (Armitage & Parmar 1986; Sankoh et al 1997). An 
alternative approach that I have also used is a permutational correction; following calculation 
of P-values in the original data set, multiple iterations are performed on simulated datasets, to 
directly observe the frequency with which P-values more extreme than the one we have 
observed are generated by chance (Westfall & Young 1993).  
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1.4: C-reactive Protein 
 
1.4.1:  CRP - Structure and Physiological Function 
 
C-reactive protein (CRP) was identified in the 1930’s as a plasma protein in the blood of 
patients infected with Streptococcus pneumoniae and was named because it precipitated the 
pneumococcal cell wall “C” polysaccharide (Tillett & Francis 1930). It is a member of the 
pentraxin family of proteins and has a pentameric structure consisting of five identical 206 
amino acid subunits non-covalently bound in an annular configuration around a 30Å central 
pore (Shrive et al 1996). CRP can bind a variety of ligands but has the highest affinity for 
phosphocholine (found in pneumoccocal “C” polysaccharide) which is bound in a Ca2+-
dependent manner (Volanakis & Kaplan 1971). Each CRP subunit has a phosphocholine 
binding site consisting of two calcium ions bound to protein side chains. The binding sites are 
aligned so that, in the complete pentamer, they are all exhibited on one face of the CRP 
annulus (Thompson et al 1999). Other CRP ligands include ribonucleoproteins, such as the D 
protein of Sm and the 70kDa protein of snRNPs, chromatin-histone complexes and extrinsic 
ligands including glycans, phospholipids and numerous bacterial, fungal, parasitic and plant 
components (Du Clos et al 1988; Du Clos 1989; Jewell et al 1993; Pepys & Hirschfield 
2003). CRP is also able to bind to apoptotic and necrotic cells and oxidised low density 
lipoproteins (LDL), although it is likely that the actual target ligand in these cases is exposed 
phosphocholine (Chang et al 2002; Gershov et al 2000; Pepys et al 1985; Volanakis & Wirtz 
1979). 
 
CRP interacts with other components of the immune system through binding sites which lie 
on the reverse face of the protein to the ligand binding regions. As I have already discussed, 
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CRP binds to the C1q component of complement resulting in potent activation of the classical 
complement pathway (Agrawal & Volanakis 1994; Mold et al 1999; Volanakis 1982). 
Although initially controversial, there now a body of evidence demonstrating that CRP 
directly binds immunoglobulin Fcγ-receptors, providing a bridge between innate and adaptive 
immune mechanisms, and allowing CRP to interact with a wide range of leucocytes 
(Bharadwaj et al 1999; Marnell et al 1995). Following binding to Fcγ receptors, CRP induces 
a range of downstream intracellular signalling events including tyrosine phosphorylation and 
activation of the SYK and ERK MAPK signalling pathways (Chi et al 2002; Wang et al 
2005). Ultimately CRP may result in diverse effects including an enhancement of 
phagocytosis and the production of cytokines, including important inflammatory mediators 
TNF-α and IL-1β (Ballou & Lozanski 1992; Mold et al 2001; Mold et al 2002b; Mold & Du 
Clos 2006; Wang et al 2005).  
 
The function of CRP as a classical innate immune system receptor recognising a wide range 
of antigens, combined with its ability to interact with humoral and cellular components of the 
adaptive immune system suggests it plays a pivotal role in immune system function. The 
critical nature of this role is emphasised by the observation that human CRP deficiency has 
never been observed, suggesting its function is crucial to human viability. Despite this, 
however, data on what the key function of CRP actually is in vivo is surprisingly limited. 
CRP certainly provides protection against bacterial infection. By binding to bacterial cell wall 
components, such as phosphocholine, CRP promotes bacterial killing by activation of the 
complement cascade and induction of phagocytosis (Mold et al 2002a; Mold & Du Clos 
2006). Human CRP is protective against infection by Streptococcus pneumoniae, 
Haemophilus influenzae and Salmonella enteritica in mice and CRP gene polymorphism has 
been associated with increased mortality from Streptococcus pnuemoniae bacteraemia 
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(Eklund et al 2006a; Mold et al 1981; Szalai et al 2000; Weiser & Pan 1998). However, a 
number of other human pattern recognition receptors would seem able to perform a similar 
function, and it is possible that the role of CRP is more complex. 
 
It has been suggested that the primary role of CRP is actually anti-inflammatory or 
immunoregulatory. A host of in vitro anti-inflammatory effects have been documented for 
CRP.  Anti-inflammatory effects include up-regulation of anti-inflammatory cytokines IL-1 
receptor antagonist and IL-10, inhibition of neutrophil chemotaxis, inhibition of neutrophil 
adhesion due to L-selectin shedding and inhibition of the neutrophil respiratory burst (Buchta 
et al 1988; Kew et al 1990; Szalai et al 2002b; Tilg et al 1993; Zouki et al 1997). CRP also 
has binding sites for the complement regulatory protein Factor H (Jarva et al 1999). Factor H 
inhibits the complement C5 convertase thus limiting complement activation to the early 
opsonising components rather than the later inflammatory elements of the cascade (Mold et 
al 1984; Mold et al 1999). CRP has been shown to be protective against inflammatory 
conditions including a rabbit model of alveolitis, a murine experimental allergic 
encephalomyelitis model and a murine antigen induced arthritis model. (Heuertz et al 1994; 
Jiang et al 2006; Szalai et al 2002b; Webster et al 1994) Several groups have also reported a 
protective role for CRP in lipopolysaccharide induced inflammation, both in mice expressing 
a rabbit CRP transgene and in mice administered human CRP by injection (Mold et al 2002b; 
Xia & Samols 1997). These more complex functions for CRP are not, however, universally 
recognised, and some authors suggest that many of these reports are false positive results due 
to impurities in the CRP preparation or cross species differences in CRP structure 
(Hirschfield et al 2003). The difference in the expression and function of human CRP 
compared with rodent species is notable. The protein sequence itself is 70% identical between 
humans and mouse or rat. Mouse CRP, however, is expressed only at low level, with serum 
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amyloid P constituting the key murine acute-phase pentraxin. In rats, CRP is an acute-phase 
regulated protein but differs functionally in comparison with humans, in particular it is unable 
to activate complement (Pepys & Hirschfield 2003). 
 
1.4.2:  CRP – Gene Expression and Genetic Architecture 
 
CRP is expressed at low, basal, levels in apparently healthy individuals. In a study of healthy 
young adult blood donors, the median CRP level was 0.8mg/L and the 99th centile was 
10mg/L (Shine et al 1981). In the presence of infection or inflammation CRP levels can 
increase dramatically to over 500mg/L as part of the human acute-phase response (Gabay & 
Kushner 1999; Pepys & Hirschfield 2003). Scintigraphic studies demonstrate rapid renal 
clearance of CRP, with a half-life of 19hrs, suggesting the rate of synthesis is the main 
determinant of serum CRP concentration (Vigushin et al 1993). Hepatocellular synthesis is 
by far the most important source of serum CRP, although synthesis of CRP by other cells has 
also been reported, including vascular endothelium and smooth muscle cells, neuronal and 
renal tissue, alveolar macrophages and peripheral blood mononuclear cells (Calabro et al 
2003; Dong & Wright 1996; Jabs et al 2003; Kushner & Feldmann 1978; Murphy et al 1991; 
Venugopal et al 2005; Yasojima et al 2000). It seems unlikely that extrahepatic sources of 
CRP contribute significantly to circulating acute-phase CRP, but it remains unknown whether 
they contribute to measurable basal CRP levels. 
 
CRP maps to human chromosome 1q23 where it is located adjacent to the gene encoding the 
related protein Serum Amyloid P (APCS) and is likely to have arisen by ancestral gene 
duplication. Figure 1.3 demonstrates CRP in its genomic context in relation to neighbouring 
genes.  
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Figure 1.3. CRP in its genomic context on chromosome 1. 
 
 
 
 
In the top section of this figure 250kb of DNA sequence in annotated to show CRP in its genomic location in 
relation to the neighbouring genes which encode serum amyloid P (APCS), Dual specificity phosphatase 23 
(DUSP23) and Fc-receptor-like 6 (FCRL6). The lower section of the diagram is a Haploview plot demonstrating 
the pattern of LD between genotyped markers (data release 24, European (CEPH) population) within the same 
genetic interval. The position of the 414 genotyped SNPs relative to the genes is indicated by the black lines 
above the LD plot. The pairwise LD between any two SNPs is indicated by the colour coding of the 
corresponding square of the LD plot. High LD is indicated by a pink/red colour scheme (the dark red squares are 
linked with a D′ = 1 and a LOD score ≥ 2)  
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Figure 1.3 also demonstrates that, genetically, CRP is situated within a well defined 
haplotype block with minimal long range LD with neighbouring genes. The CRP gene spans 
2.1kb: it has two exons, a single intron and a long 3′-untranslated region. Figure 1.4 
demonstrates the conservation of DNA sequence in humans compared with lower mammals, 
illustrated using a genomeVISTA plot (http://genome.lbl.gov/vista/index.shtml). The high 
level of sequence conservation between human and chimpanzee is to be expected but, outside 
the protein coding regio the level of sequence conservation between humans and murids is 
relatively low. This is strikingly for the 3′ UTR, a region with potentially regulatory function. 
It is notable that, with the exception of the coding region, no common SNPs (minor allele 
frequency >1%) are found in the areas of high conservation.  
 
Consistent with the dramatic increase in CRP expression during active inflammation it has 
been identified that the main stimulus for gene expression is interleukin-6 (IL-6), with 
interleukin-1β (IL-1β) acting synergistically but not in isolation (Ganter et al 1989). Both 
TNF-α and interleukin-17 (IL-17) also stimulate CRP expression independently of IL-6 and 
IL-1β (Choi et al 2007; Patel et al 2007). Experiments in both human hepatoma cell lines and 
transgenic mice have identified regions upstream and downstream to CRP that are essential 
for the regulation of gene expression. A number of transcription factors involved in gene 
expression have also been identified. Figure 1.5 demonstrates the proposed binding sites for 
these with reference to the DNA sequence of the CRP proximal promoter.  The 90 base-pairs 
upstream of the transcriptional start site are essential for any CRP to be expressed. This 
region contains the TATA box as well as sequences which bind C/EBPβ (bp -48 to -58) and 
HNF-1α (bp -61 to -73) (Li & Goldman 1996a). Further upstream are an additional C/EBP 
family binding site (bp -225 to -211) and a binding site for transcription factor STAT-3 (bp -
112 to -105) (Zhang et al 1996). There is evidence that C/EBPβ is the key transcription factor  
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Figure 1.4. Cross-species DNA sequence conservation at CRP 
 
 
The GenomeVISTA plot provides a graphical representation of the level of  DNA sequence conservation 
between the human genome reference sequence (Build 36) and the current genome reference sequences for the 
Chimpanzee, Mouse and Rat. The x-axis represents genomic location relative to CRP (which is shown at the 
top). The y-axis represents the level of cross-species conservation, with each data point plotted according to the 
percentage conservation of the 100 base pairs centred on the plotted point. Conservation levels >50% are 
plotted, and the graph is coloured when the levels of conservation exceeds 75% (coded DNA sequence in 
purple, 3′ UTR sequence in blue and non-coded sequence in pink). For reference, the location of three key CRP 
SNPs has been indicated. It should be noted that, with the exception of synonymous exonic SNP rs1800947, no 
common human SNP (MAF>1%) is located in a region with >75% conservation compared with rat or mouse. 
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Figure 1.5. Transcription factor binding sites at the CRP promoter 
 
 
-350                               rs3093062 
ACTCTATGATTTGGGCTGAAGTAGGTGTTGGAGAGGCAGCTACCAC[G/A]TGC 
          Possible E-box 
 
-300       rs3091244             
ACCCAGATGGCCAC[T/C/A]CGTTTAATATGTTACCATTTCCCATTATTTTCGCA 
       Possible E-box 
 
        
-250 
GATAGATAGCCAAAGTGGAGCCCTGAGAGATTTCTTCATTTTTCCTGTCA 
       C/EBP site 
 
 
-200 
TAAAGAATTGGTAATTCAGTAGTCATAGGAGTTTGTAATAAATAACTCAC 
              HNF-1α site 
 
 
-150 
ATTGATTTCTCTGTTCTGAAATAATTTTGCTTCCCCTCTTCCCGAAGCTC 
   HNF-3 site              STAT-3 site   
  
 
         HNF-3-like site  
-100            
TGACACCTGCCCCAACAAGCAATGTTGGAAAATTATTTACATAGTGGCGC 
       Possible E-box     HNF-1site  C/EBPβ site 
                 Octamer-like site 
 
-50          
Non-consensus κB site 
AAACTCCCTTACTGCTTTGGATATAAATCCAGGCAGGAGGAGGTAGCTCT 
     TATA-box 
 
 
1           +50 
AAGGCAAGAGATCTAGGACTTCTAGCCCCTGAACTTTCAGCCGAATACAT 
 
 
The sequence of the 350bp of DNA upstream of the CRP transcription start site has been annotated to 
demonstrate the position of all proposed and confirmed transcription factor binding sites. Sequence has been 
highlighted in red where there is good functional evidence for transcription factor binding (see text). The two E-
boxes highlighted in blue contain known polymorphic bases (indicated by brackets and shading). Some 
functional evidence exists for transcription factor binding to these sites (Szalai et al 2005) but, as I discuss in 
section 8.4.6, the evidence put forward in relation to the E-box containing rs3091244 is weak. An E-box centred 
at base -95 has been proposed on the basis of sequence, but there is no functional data. 
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responsible for cytokine induced acute-phase CRP production, and we now have a reasonably 
detailed understanding of the proteins involved in this process (Young et al 2008). The 
binding of C/EBPβ to promoter DNA requires the presence of  members of the NF-κB/Rel 
family of proteins, in particular c-Rel which binds to C/EBPβ directly and Rel p50 which is 
capable of binding to a non-consensus κB sequence adjacent to the C/EBPβ site (Agrawal et 
al 2003). Furthermore, Rel p50 interacts with the protein β-catenin, which itself interacts with 
TCF/LEF proteins bound to distal regulatory elements located about 700 bp downstream of 
CRP exon 2 (Choi et al 2007). STAT-3 and the upstream C/EBPβ site may act synergistically 
with the proximal promoter to produce maximal induced CRP expression. The expression of 
cytokine induced CRP therefore depends on a complex of transcriptional proteins interacting 
with both proximal and distal DNA regulatory elements. 
 
Less well characterised are the presence regulatory proteins similar to HNF-3 and Octamer 
that may also bind the proximal promoter region (bp -56 to -66) (Li & Goldman 1996b). 
Recently 4 potential E-box elements have been identified in the CRP promoter. E-boxes are 
CAnnTG consensus sequences that can bind a variety of transcription factors including Max, 
Myc and USF (Upstream stimulatory Factor) and transcription may be inhibited or stimulated 
according to the combination of factors bound (Baudino & Cleveland 2001; Sirito et al 
1998). USF-1 has been proposed to bind to an E-box centred at bp -497 and modulate CRP 
expression (Szalai et al 2005b). In transgenic mice further regulatory elements may be 
located at greater distances from the CRP coding region. In particular the intervals between 
bp -1270 and -541 and +7510 and +10050 appear to contain elements that suppress the 
production of CRP in resting cells (Murphy et al 1995). These experiments have also shown 
the 3′ poly-A tail sequence is essential for gene expression. 
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1.4.3:  CRP – Genetic Variation and its Relation to Gene Expression 
 
A number of studies have now estimated the heritability of basal CRP levels. Figures vary 
across studies, in part a consequence of the different methodologies employed and the use of 
either twin or family cohorts, but are all within the range of 10-56% (Austin et al 2004; Fan 
et al 1996; Fox et al 2008; Lange et al 2006a; MacGregor et al 2004; Pankow et al 2001; 
Saunders & Gulliford 2006; Vickers et al 2002; Wessel et al 2007). It is also notable that 
basal CRP in any one person is remarkably consistent over a long period of time, certainly 
many years (Danesh et al 1998; Kivimaki et al 2007; Ridker et al 1999). Given these 
observations it would certainly appear feasible to identify genetic variants which account for 
this heritability, and naturally efforts have focussed on CRP itself. 
 
The first two reports of CRP polymorphisms affecting basal CRP level appeared in 2002. 
These were a GT dinucleotide repeat polymorphism in the CRP intron, and a SNP, rs1800947 
in the second exon (Szalai et al 2002a; Zee & Ridker 2002). Subsequently other reports of 
SNPs and haplotypes associated with basal CRP have been published. Tables 1.2 and 1.3 
summarise the data from studies that were published at the time these doctoral studies were 
commenced. These studies vary in their size (ranging from less than 100 patients to over 
1000) and in their methodology. In particular the larger studies tended to model the alleles at 
each SNP as additive traits, while the smaller studies tended to pool genotypes from 
heterozygous individuals and those homozygous for the minor allele. The majority of these 
studies were conducted in cohorts of white European ancestry; studies in other ethnic 
populations are much more limited. Figure 1.6 demonstrates the position of these published 
SNPs in relation to the CRP. It should be noted with reference to figure 1.3, that all these 
SNPs fall well within the single LD block, predicted from the HapMap European (CEPH) 
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population, that encompasses CRP and the surrounding upstream and downstream sequence. 
Those studies (table 1.3) utilising a haplotype analysis on their own data also confirm that 
these SNPs fall within a single block of high LD. 
 
There are some notable points about the data presented in tables 1.1 and 1.2. Firstly multiple 
SNPs are often associated with serum basal CRP, often within the same cohort. Secondly, no 
single SNP is associated with serum CRP in every study where it has been tested, indeed for 
the commonly tested SNPs results range from a very strong association to no association at 
all. The only consistent effect, in fact, is the lack of association observed with SNP 
rs2794521. The number of studies inferring CRP haplotypes and analysing the haplotypic 
association with serum CRP are much more limited, and given the different selection of SNPs 
used by these authors it is difficult to directly compare the results of these studies. 
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Figure 1.6. The position of CRP SNPs reported in the published literature. 
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The location of CRP SNPs that appear in publications up to 2006 when these doctoral studies were planned 
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Table 1.3. Summary of published CRP haplotype association data 
Reference CRP Single Nucleotide Polymorphism Freq CRP level 
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05
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30
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4 
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6 
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9 
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8 
rs
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22
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2 
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27
94
51
7 
rs
31
16
65
4 
rs
31
16
65
3 
  
(Szalai et al 2005c)           C G        a Low b 
(U)          T G        a High b 
          A G        a High b 
          T A        a Low b 
                     
(Russell et al 2004)      G T  G  T         0.28 High 
(E)     A C  G  C         0.24 Low 
     G C  G  C         0.23  
     G C  G  A         0.06  
     A C  C  C         0.05 Low 
                     
(Miller et al 2005)      G T  G T T  A T      0.30 Highc 
(E)     A C  G A C  A T      0.29 Low 
     G C  G A C  G T      0.26  
     A C  C A C  A T      0.06  
     G C  G A A  A C      0.06 High 
     G C  G A C  A T      0.02  
                     
(Carlson et al 2005)d    A G  C G T T    A     0.29 High 
(E)    G G  C G A C    A     0.28  
    A A  C G A C    A     0.28 Ref e 
    A G  C G A A    A     0.06 High 
    A A  C C A C    A     0.06  
    A G  C G A C    A     0.02  
                     
(Carlson et al 2005) d    A G  A G A A    A     0.22  
(AA)    A A  C G A C    A     0.18 Ref e 
    G G  C G A C    A     0.17  
    A G  C G A T    T     0.17 High 
    A G  C G T T    A     0.12 High 
    A G  C G A C    A     0.09  
    A G  C G A A    A     0.03 High 
    A A  C C A C    A     0.01  
                     
(Kathiresan et al 2006)  G C T A G T  G T T     G C T G 0.29 High 
(E) A C T G G C  G A C     A T T C 0.19  
 G C T A A C  G A C     A C C C 0.12  
 G G T A A C  G A C     A C T C 0.09  
 G C T G G C  G A C     A T T C 0.08  
 G C G A G C  G A A     A C T C 0.05 High 
 G C T A A C  C A C     A C T C 0.05  
 G C T A A C  G A C     A C T C 0.05 Low 
The five studies to analyse associations between CRP haplotype and serum CRP level have been annotated 
according to the ethnicity of their participants: E – White European, AA – African-American, U – Unspecified 
(although likely to be predominantly African-American) 
a Study only analysed homozygous individuals. Population frequencies not given. 
b Only an overall haplotype P-value presented in paper. High and Low haplotypes inferred from graphical data. 
c Data from three cohorts presented in this paper. The significance of the CRP association with this haplotype 
varied from very significant (P<0.0001) to just significant (0.01) 
d Although Carlson et al presents haplotype frequency data for each ethnicity the CRP association analysis was 
performed on a combined cohort. 
e These studies have modelled their haplotype associations in comparison with a reference haplotype, annotated 
here as “ref” 
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In addition to the candidate gene studies described above, four genome-wide association 
(GWA) studies and a single meta-analysis of existing publications have also recently been 
published. Since these were published after the majority of work in this thesis was performed, 
a full discussion of these papers, and how they fit in with my results will be presented in 
Chapter 8. 
 
All the studies discussed so far have aimed to address the question of association between 
genetic variants and basal CRP, a potentially different question is which genetic variants are 
associated with CRP levels in the context of an acute-phase response. I will argue later that 
this question is equally important and it may, in fact, turn out to be of greater clinical 
relevance. For reasons that I will discuss later in section 6.4.3, this is a difficult question to 
answer and work in this field is therefore limited. An early study looking at the role of CRP 
genetics in determining CRP levels in patients with periodontitis suggested the rare allele of 
rs1130864 was associated with higher CRP, however, the magnitude of the acute-phase 
stimulus was fairly modest (D'Aiuto et al 2005). CRP rises acutely following myocardial 
infarction and the magnitude of rise predicts overall outcome, so there has been interest in 
whether the magnitude of this rise is influenced by CRP genetics (Pietila et al 1996; Ueda et 
al 1996). The only current study to address this question found higher post-myocardial 
infarction CRP levels in carriers of the A allele of rs3091244 and the rare allele of 
rs3093059, with dramatically higher levels in individuals homozygous for these variants. 
Furthermore the haplotype containing these two alleles was also associated with higher CRP. 
Conversely lowest post MI CRP was seen in carriers of the rare alleles of rs1800947 and 
rs1205 and a haplotype containing both of these (Suk et al 2006). A similar pattern of 
association was seen in another study looking at the magnitude of acute-phase CRP following 
coronary artery bypass surgery, in particular confirming the lower level of acute-phase CRP 
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rise in carriers of the minor allele of rs1800947 (Perry et al 2009). An association between 
rs3091244 and higher CRP was also observed (but with only borderline significance 
following a conservative Bonferroni correction), although interestingly these authors, using a 
mixed ethnicity population, observed their strongest association with the T allele. Neither of 
these papers addressed the question of whether these variants were also associated with 
clinical outcome. 
 
No studies to date have considered whether CRP variants influence the magnitude of acute-
phase CRP in the context of chronic inflammatory disease. Potentially this is a very important 
question since serum CRP is measured extensively in clinical practice to diagnose and 
monitor infection and inflammatory diseases across a whole range of clinical specialities. 
Surprisingly little published data exists on the inter-individual variability of acute-phase CRP. 
This is particularly important if CRP is used to make prognostic decisions, or to make 
comparisons between individuals, say as part of a clinical scoring system. Rheumatoid 
arthritis is a case in question. The original DAS28 scoring system was based on erythrocyte 
sedimentation rate (ESR), a tender and swollen joint counts and a global assessment by 
patient and physician (Prevoo et al 1995). Recently it has been suggested that CRP could 
replace ESR as the objective measure of inflammation (Inoue et al 2007; Paulus et al 1999). 
Some authors have suggested the ESR DAS28 and CRP DAS28 could be used 
interchangeably, however if there is a significant CRP genetic effect then an adjustment for 
genotype may need to be considered. In addition it has been suggested that a prognostic 
algorithm, incorporating CRP level among its parameters can be used to predict the course of 
disease in patients with early, undifferentiated arthritis (van der Helm-van Mil et al 2007; van 
der Helm-van Mil et al 2008). The introduction of a genetic adjustment to the acute-phase 
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CRP level observed in these patients may well increase the prognostic power of this 
algorithm. 
 
Finally, in addition to the cis-acting effects described above there are a number of trans-
acting genetic variants reported to influence basal CRP levels. At the time the work presented 
here was planned, published data focussed on three genes, IL6, IL1B and APOE. Of these, the 
most studied are the genes encoding the acute-phase cytokines IL-1β and IL-6. The number 
of studies incorporating genotyping at IL6 and IL1B are extensive, and the literature is 
particularly complicated by the heterogeneity of the cohorts in which studies are undertaken. 
Cohorts vary from healthy individuals to those with metabolic or potentially pro-
inflammatory conditions such as diabetes mellitus or CHD. A detailed discussion of this 
literature is beyond the scope of this thesis, although a summary is given below, and further 
discussion may be found in section 8.5.1.  
 
For IL6 most work has focussed on promoter SNP rs1800795, located 174 bp upstream of the 
transcriptional start site. Numerous authors have demonstrated an association between 
rs1800795 and levels of serum CRP (Eklund et al 2006b; Libra et al 2006; Vickers et al 
2002; Walston et al 2007). There are also, however, also a number of negative reports 
(Latkovskis et al 2004; Potaczek et al 2007). A second variant that also appears frequently in 
the literature is rs1800796, also found in the IL6 promoter, 572 bp upstream of the 
transcriptional start site. Again there is inconsistency over the reported association between 
this variant and serum CRP. There are a number of positive reports, notably from populations 
of East Asian ancestry, where the minor allele frequency is much more common than that 
observed in European studies (Jang et al 2008; Paik et al 2007; Wong et al 2007). There are 
also several negative studies (Latkovskis et al 2004; Walston et al 2007). Furthermore, it has 
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also been proposed that basal CRP is influenced by an interaction between these two variants 
(Ferrari et al 2003). 
 
There is less published literature concerning the role of IL1B variation in determining serum 
CRP levels. Earlier papers tended to focus on synonymous exonic SNP rs1143634 with a 
number of reported associations with serum CRP (Berger et al 2002; Eklund et al 2005; 
Latkovskis et al 2004). Subsequently there has been interest in promoter SNP rs16944, and 
some suggestion that both SNPs influence mediate the effects of IL1B variation on CRP 
(Eklund et al 2003; Sainz et al 2008). 
 
Several authors report that apolipoprotein E type is associated with basal CRP (Apo ε type is 
determined by a haplotype of two coding SNPs in APOE, rs429358 and rs7412). The ε2 
variant appears to be associated with higher CRP than the ε4 variant, but the effect of the ε3 
variant has not been consistently reported (Austin et al 2004; Chasman et al 2006; Judson et 
al 2004; Lange et al 2006a; Manttari et al 2001; Marz et al 2004; Rontu et al 2006).  
 
Other reported CRP associations from candidate gene studies include the genes encoding 
TNF-α, LAMIN A/C, haptoglobin, CD14, the glucocorticoid receptor, the β-adrenergic 
receptor, tyrosine hydroxylase and cyclooxygenase 2 (Cipollone et al 2004; Hegele et al 
2003; Hubacek et al 2003; Lakka et al 2006a; van Rossum & Lamberts 2004; Wessel et al 
2007; Wuyts et al 2002). Finally, linkage has been demonstrated between CRP and a 
quantitative trait locus on chromosome 20q13 (Lakka et al 2006b). The recent Genome-wide 
Association studies have also identified novel trans-acting effects and these will also be 
discussed further in chapter 9. 
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1.4.4: CRP – Functional and Genetic Role in Systemic Lupus Erythematosus 
 
CRP has been implicated in the pathogenesis of two important diseases: systemic lupus 
erythematosus and coronary heart disease (along with other forms of arterial disease sharing 
atherosclerosis as the primary pathological lesion). We have already discussed a possible role 
for CRP in protecting against autoimmunity, by promoting clearance of apoptotic cells and 
autoantigen containing immune complexes. A failure of these clearance mechanisms may 
contribute to the pathogenesis of SLE so, potentially, deleterious CRP genetic variation could 
increase susceptibility to SLE, perhaps by resulting in lower levels of CRP expression. There 
are several lines of evidence that support this hypothesis. Firstly there is a long standing 
observation that patients with SLE have acute-phase CRP levels that are somewhat less than 
one would expect for any given level of active inflammation; certainly less than that induced 
by infection (Pereira Da Silva et al 1980). Secondly there is recent experimental evidence 
from mouse models that CRP, either expressed by a transgene or administered parenterally, 
can ameliorate or delay the onset of immune mediated glomerulonephritis (Rodriguez et al 
2005; Rodriguez et al 2006; Szalai et al 2003). Interestingly this effect appears not to be 
mediated by complement but rather by CRP-induced production of anti-inflammatory IL-10. 
 
There is also some genetic evidence to support a role for CRP in determining susceptibility to 
SLE. The CRP genetic interval on chromosome 1q23 has been identified as an SLE linkage 
region in a number of genome wide studies, although it should be noted that this region also 
contains a number of other immunologically relevant genes (Cantor et al 2004; Edberg et al 
2002; Moser et al 1998). Four studies (three of which were published during or after the 
course of the work contributing to this thesis) have now reported an association between SLE 
and CRP genetic variants. The first, a result of earlier work in my supervisor’s laboratory, 
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reported the association of SNP rs1800947 with SLE in a large family based study (Russell et 
al 2004). An association between rs1800947 and lupus nephritis was also demonstrated in a 
second study, but a third study suggested the association was with a different SNP, 
rs3091244 (Edberg et al 2008a; Jonsen et al 2007). A more recent study identified no disease 
association with five commonly studied CRP SNPs but did report an association between 
CRP haplotypes, and SLE (Shih et al 2008). The genetic data is therefore inconsistent and 
requires clarification through further study. 
 
1.4.5: CRP – Functional and Genetic Role in Cardiovascular Disease 
 
In the mid-1990’s evidence arose to suggest that basal CRP in otherwise healthy individuals 
was a predictor of future coronary events (Thompson et al 1995). This was confirmed both in 
individuals with unstable angina (but no myocardial necrosis), and in the general population 
(Haverkate et al 1997; Kuller et al 1996; Liuzzo et al 1994). A meta-analysis of 22 
prospective studies showed an odds ratio of 1.45 (1.25-1.68) for an acute coronary event 
between individuals with basal CRP in the upper third compared with an individual with CRP 
in the lower third (Danesh et al 2004). These observations led some groups to recommend 
that serum CRP could be used as a clinical measure of coronary risk (Danesh et al 2004; 
Pearson et al 2003). There is now a large amount of evidence demonstrating that elevated 
basal CRP is associated with all forms of atherosclerotic vascular disease, including stroke 
and peripheral vascular disease (Bassuk et al 2004). 
 
Various theories have been proposed to explain the association between CRP and coronary 
disease. CRP may be a marker of inflammation occurring within atheromatous plaques 
themselves, or alternatively it may reflect low grade systemic inflammation, perhaps caused 
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by pathogens such as Chlamydia pneumoniae or Helicobacter pylori (Danesh et al 1997; 
Ross 1999). Alternatively CRP may simply be a marker of other known cardiovascular risk 
factors such as smoking and obesity (Lagrand et al 1999). Finally there has been much 
interest in whether CRP is proatherogenic and proinflammatory itself.  
 
It is clear that a number of acute-phase markers are associated with cardiovascular disease, 
including serum amyloid A, fibrinogen, albumin and leukocyte count, and this is suggestive 
of a general inflammatory effect rather than a special role for CRP (Danesh et al 1998). 
Certainly many studies have found that classical cardiovascular risk factors, including 
smoking, obesity, and diabetes are associated with CRP levels, and can explain much of the 
CRP effect (Danesh et al 1999; Ford 1999). Some authors have suggested that CRP may 
actually have a rather poor predictive value for coronary risk, but despite this a consensus 
opinion would be that a residual association between CRP and coronary events does persist 
even after adjustment for multiple covariates in large studies (Levinson et al 2004).  
 
There is circumstantial evidence to suggest that CRP may have a role in causing direct 
vascular damage. Firstly, in addition to the immunological targets discussed so far, CRP can 
bind to oxidised or otherwise modified LDL, a key constituent of atheromatous plaques 
(Bhakdi et al 1999; Chang et al 2002; Taskinen et al 2002; Taskinen et al 2005). Once 
bound, CRP is capable of activating complement (de Beer et al 1982). It is also capable of 
stimulating macrophages into producing procoagulant tissue factor, and forming foam cells 
(Cermak et al 1993; Zwaka et al 2001). Finally, CRP has been demonstrated to stimulate 
vascular smooth muscle proliferation, another characteristic of atheromatous plaques (Wang 
et al 2003).  
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Although CRP is frequently found in atheromatous plaques, its presence does not prove it has 
a role in plaque pathogenesis; indeed, some authors suggest CRP may actually be playing a 
protective role (Zhang et al 1999). It has been suggested that CRP may actually prevent foam 
cell formation, that it may limit complement activation and induce apoptosis of vascular 
smooth muscle (Bhakdi et al 2004; Blaschke et al 2004; Singh et al 2008a). In addition there 
have been suggestions that the pro-inflammatory effects observed in many early studies may 
be due to contamination of the CRP preparations, or degradation of the intact CRP molecules 
(Singh et al 2008b; Taylor et al 2005). The contradictory results from in vitro studies have 
been matched by contradictory results from mouse models of atherosclerosis. CRP was 
initially suggested to be proatherogenic in the apoE-/- knockout mouse model of 
atherosclerosis (Paul et al 2004; Schwedler et al 2005). Subsequent authors, however, have 
been unable to demonstrate any such effect (Hirschfield et al 2005; Tennent et al 2008; Trion 
et al 2005). 
 
Perhaps some of the most compelling evidence for an important role for CRP comes from 
studies relating to the use of HMG-CoA reductase inhibitors (Statins). Statins are cholesterol 
lowering drugs known to improve long-term cardiovascular morbidity. They are also known 
to lower CRP, although the exact mechanism for this is unknown (Ridker et al 1999). A study 
has suggested that the beneficial effect of statins is similar between people with elevated LDL 
cholesterol and people with elevated CRP but normal LDL cholesterol (Ridker et al 2001). 
 
Even this brief review of the current literature highlights ongoing controversy over the true 
role of CRP in cardiovascular disease: genetic studies have the potential to clarify this 
situation. The finding of a consistent association between CRP genotype and cardiovascular 
disease would provide further evidence for a functional role for CRP; current data however 
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remains far from convincing. The only replicated association is for rs2794521, with a fairly 
strong effect reported in a Han Chinese population, and a rather weak effect in men from the 
Physicians Health Study; interestingly this SNP has never been associated with CRP levels 
(Chen et al 2005; Miller et al 2005). The AA genotype of rs3091244 has also been associated 
with CHD, but only in the non-Hispanic white subset of the large NHANES III cohort. 
(Crawford et al 2006). Numerous other studies, however, have only reported negative 
findings (Hage & Szalai 2007; Kardys et al 2006; Kathiresan et al 2006; Wang et al 2006; 
Zee & Ridker 2002). A more convincing demonstration that CRP plays a direct causal role in 
atherosclerosis would be to demonstrate a CRP genetic variant that influences CRP levels and 
also increases cardiovascular risk by a magnitude that could be predicted given the known 
association between serum CRP and cardiovascular risk; the so-called “Mendelian 
Randomisation” experiment (Davey & Ebrahim 2003; Hingorani & Humphries 2005). An 
initial attempt to demonstrate this three way relationship was unsuccessful, although only a 
single CRP SNP was included for analysis (Casas et al 2006). Recently, a more extensive 
Mendelian Randomisation study has been published (Zacho et al 2008). An extensive array 
of CRP SNPs was genotyped in four cohorts consisting of nearly 50,000 participants. The 
usual association between genotype and serum CRP was seen, but no association with 
cardiovascular disease was observed, even though it could be predicted that the relevant 
genetic variants should increase the CHD risk by 32% given the effect on CRP level. 
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1.5: The C3 component of complement 
 
An outline of the components and function of the human complement cascade has already 
been presented in section 1.1, here I will consider in more detail the central component of this 
cascade, C3. 
 
1.5.1: C3 - Structure and Physiological Function 
 
Complement component C3 is a member of the α2-macroglobulin family of proteins and, like 
CRP, it is a phylogenetically ancient molecule. Homologues have been described in primitive 
chordates (urochordata (tunicates)), echinodermata (sea urchins/starfish) and, more recently, 
C3-like genes have been reported in the cnidaria (coral/jellyfish) suggesting C3 evolved at 
least one billion years ago (Al-Sharif et al 1998; Azumi et al 2003; Dishaw et al 2005; 
Nonaka et al 1999). It is synthesised as a 1663 amino acid precursor molecule, prepro-C3. 
Post-translational modifications include removal of a 22-residue signal peptide from the N-
terminal end and a quadruplet of argenine molecules from the centre of the pro-C3 amino 
acid chain, resulting in a secreted molecule consisting of 2 distinct chains: a 645 amino acid, 
70kDa α-chain and a 992 amino acid, 115kDa β-chain (de Bruijn & Fey 1985). The crystal 
structure of C3 has now been resolved and each chain has been shown to contribute 6 
domains to the final molecule, with a 13th domain made up of residues from both chains 
(Janssen et al 2005). The core of the molecule is made up of eight homologous 
macroglobulin (MG) domains. A key functional feature of C3, and other related molecules 
including C4, is the presence of an internal thioester bond which mediates the covalent 
attachment of C3 to target surfaces (Law et al 1979; Law & Levine 1977). This bond is 
formed by the side chains of residues Cys988 and Gln991, both of which are within the 
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thioester domain, and access to this thioester site is limited in the intact C3 molecule by its 
location tucked against domain MG8 (Fredslund et al 2006; Janssen et al 2005). Activation 
of C3 by the C3 convertases occurs by cleavage between Arg727 and Ser727 which yields 
C3a from the N-terminal region of the α-chain (de Bruijn & Fey 1985; Janssen et al 2005). 
This cleavage also results in marked conformational changes in C3b, exposing the reactive 
thioester site (Nishida et al 2006). Further rounds of proteolytic cleavage, catalysed by 
complement factor I (but dependent on other co-factors) generate the bioactive fragments 
iC3b and C3dg and, finally, fragment C3c (Gros et al 2008; Harrison & Lachmann 1980). 
 
I have already introduced some of the biological functions of these C3 fragments in section 
1.2.1.; these will be discussed in further detail here. The initial activation of C3 yields a small 
77 amino acid fragment, C3a. C3a and C5a (and possibly C4a) share many biological 
functions and are known collectively as anaphylotoxins (Kohl 2001). Their effects are 
mediated via a seven-transmembrane, G-protein coupled cell-surface receptor. C3a acts as a 
chemoattractant, recruiting inflammatory cells to the site of complement activation and can 
triggers an oxidative burst in phagocytic cells, thus enhancing bacterial killing. Finally it can 
influence the local microcirculation by increasing vascular permeability and inducing 
vascular smooth muscle contraction. 
 
C3 cleavage fragments C3b, iC3b, C3dg and C3c differ in their ability to bind the 
complement receptors CR1-4 and CRIg, and this, in turn, leads to a range of physiological 
consequences. The key receptors for C3b are CR1 and CRIg. We have already discussed the 
role of CR1 in transporting circulating C3b opsonised immune complexes to the spleen for 
removal. CR1 is also borne on neutrophils where it induces phagocytosis of the opsonised 
particle (Sengelov et al 1994; van Lookeren et al 2007). CRIg is expressed on a limited range 
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of tissue macrophages and receptor binding triggers phagocytosis (Helmy et al 2006). iC3b 
can also bind CRIg, but its key receptors are CR2-4. CR2 is predominantly a B-cell receptor 
and when co-ligated with the B-cell receptor, B-cell immunity is enhanced (Fearon & Carroll 
2000; Weis et al 1984). CR3 and CR4 are integrin receptors which share a common β-chain 
(CD18) and differ in their α-chain (CD11b and CD11c respectively). CR3 is expressed 
predominantly on macrophages and neutrophils, and plays a role in mediating phagocytosis; 
CR4 is poorly characterised but is expressed on the same cells and is likely to have a similar 
function (Ross & Lambris 1982; Ross & Vetvicka 1993; van der Vieren et al 1995). C3dg 
binds CR2 only and therefore triggers adaptive, but not innate effector responses (Weis et al 
1984). C3c is generally considered biologically inactive, although, theoretically at least, it can 
bind to CRIg, so this opinion may need to be revised (Wiesmann et al 2006). 
 
It should be emphasised that the summary of events presented here is simplistic and the 
reader is referred to the referenced articles for further detail. In particular it should be noted 
that complement receptors often work in co-operation with other families of receptors in 
determining the overall cellular response. For example binding to both CR3 and associated 
immunoglobulin FcγRs is required to trigger migration and ingestion by phagocytic cells 
(Krauss et al 1994; Xiong et al 2006). It should also be noted that activation of the various 
complement receptors may also lead to immunomodulatory events, including feedback on the 
complement pathway itself. For example, activation of CR1 inhibits both the classical and 
alternative pathway through convertase inhibition, and also acts as a co-factor for the 
cleavage of C3b to iC3b and C3dg (Krych-Goldberg & Atkinson 2001). 
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1.5.2: C3 – Gene Expression and Genetic Architecture 
 
C3 is expressed in relatively large amounts in the serum of healthy individuals; only albumin 
and immunoglobulin are present in greater quantity. A suggested reference range of 0.8-
1.9mg/mL has been proposed, although it should be noted that there is no internationally 
recognised standard assay or normal range (Ritchie et al 2004). Like CRP, the expression of 
C3 is regulated as part of the acute-phase response, and levels increase in the presence of 
infection or inflammation (Gabay & Kushner 1999). In contrast to CRP, the rise in C3 tends 
to be more modest, with only an approximate doubling of serum concentration (Baumann 
1989).The main source of C3 synthesis is the hepatocyte (Alper et al 1969). A number of 
extrahepatic sources of C3 have been described including monocytes/macrophages, renal 
tubular epithelial and interstitial cells, fibroblasts, endothelial cells, alveolar and intestinal 
epithelial cells and glial cells (Barnum et al 1993; Beatty et al 1981; Brooimans et al 1991; 
Johnson & Hetland 1988; Katz & Strunk 1988; Moon et al 1997; Strunk et al 1988; Ueki et 
al 1987; Warren et al 1987; Welch et al 1993; Zhao et al 2000). 
 
The C3 gene is located on chromosome 19p13.2-3. It is a large gene spanning nearly 43kb, 
and consisting of 41 exons. Exons 1-16 encode the C3 β-chain and exons 17-41 encode the α-
chain (Fong et al 1990). Figure 1.7 demonstrates C3 in its genomic context in relation to 
neighbouring genes. The majority of studies attempting to delineate the role of cytokines in 
influencing C3 expression have been conducted in vitro, using hepatocyte derived cell lines. 
A number of cytokines have been shown to increase C3 expression, including IL1α, tumour 
necrosis factor-α (TNF-α) and transforming growth factor-β (TGF-β) (Andrews et al 2003; 
Mackiewicz et al 1990; Perissutti & Tedesco 1994). However, the key cytokines that, 
individually, trigger C3 expression in these cell lines are IL-6, IL-1β and interferon-γ (IFN-γ),  
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Figure 1.7. C3 in its genomic context on chromosome 19. 
 
 
 
 
 
In the top section 150kb of DNA sequence in annotated to show C3 in its genomic location in relation to the 
neighbouring genes which encode the tumour necrosis factor (ligand) superfamily, member 14 (TNFSF14), the 
G-protein coupled receptor 108 (GPR108) and the thyroid hormone receptor interactor 10 (TRIP10). The lower 
section of the diagram is a Haploview plot demonstrating the pattern of LD between genotyped markers (data 
release 24, CEPH population) within the same genetic interval. The position of the 220 genotyped SNPs relative 
to the genes is indicated by the black lines above the LD plot. The pairwise LD between any two SNPs is 
indicated by the colour coding of the corresponding square of the LD plot. High LD is indicated by a pink/red 
colour scheme (the dark red squares are linked with a D′ = 1 and a LOD score ≥ 2)  
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although studies disagree whether IL-1β can induce C3 expression alone, or only in the 
presence of IL-6 or IFN-γ. Nonetheless, in a pattern that mirrors that seen with CRP, IL-6 and 
IL-1β appear to act synergistically to induce maximal C3 expression (Andrews et al 2003; 
Darlington et al 1986; Falus et al 1990).  
 
Compared with CRP, our knowledge of the specific transcription factors involved in C3 
expression, or the important C3 promoter elements, is limited. A dissection of the C3 
promoter using luciferase constructs suggests that the key region mediating the synergistic 
response to IL-6 and IL-1β lies between base pairs -127 to -70 (Wilson et al 1990). This 
region contains one, or possibly two, CCAAT/enhancer binding protein regions. The key 
transcription factor binding this region in IL-1β stimulated cells is C/EBPδ (in contrast to 
C/EBPβ which is the key transcription factor stimulating CRP production). C/EBPα also 
binds this region and potentially mediates the expression of basal level C3 (Juan et al 1993). 
Additional promoter elements have also been described. Located approximately 150 base 
pairs upstream of the transcriptional start site is a consensus sequence that forms a farnesoid 
X receptor (FXR) target. FXR acts as an intracellular bile acid receptor and binding to the C3 
promoter has been shown to increase C3 expression. It has been proposed this pathway may 
be important in regulating gene expression in intestinal epithelial cells (Li et al 2005). The C3 
promoter also contains three oestrogen response elements (positions -235 to -223, -212 to -
180 and -180 to -152) that can bind intracellular oestrogen receptors and stimulate gene 
expression (Fan et al 1996). 
 
An important question, analogous to the problem with CRP, is whether extrahepatic 
expression of C3 is regulated in the same way as hepatic production. There is limited data on 
which to draw any conclusions. The key IL-6/IL-1β responsive promoter element would 
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appear to be functioning in glial cells, suggesting regulation similar to the hepatocellular 
models (Maranto et al 2008). However, a family has been described with C3 deficiency in 
whom hepatic C3 production was almost completely abrogated, but macrophage C3 
expression was maintained; similarly murine models with mutated C3 have been developed 
in which C3 mRNA was undetectable in hepatic tissue but was measurable in a variety of 
other tissues (Circolo et al 1999; Fey et al 1983). Both these lines of evidence suggest there 
may be tissue specific differences in the genetic regulation of C3 expression. 
 
1.5.3: C3 – Genetic Variation, Expression and Disease Susceptibility 
 
Even prior to the delineation of specific genetic mutations a number C3 structural variants 
were identified within the population. The best characterised of these variants was termed C3 
fast (C3F) and C3 slow (C3S) according to their rate of migration through an agarose gel 
(Alper & Propp 1968; Wieme & Demeulenaere 1967). Subsequently the molecular basis of 
this variation was identified as a non-synonymous SNP (now labelled rs2230199) in exon 
three leading to an argenine to glycine change at amino acid position 102 (R102G) (Botto et 
al 1990). On the basis of in silico protein modelling it has been suggested that this mutation 
may have functional consequences. The R102G residue lies in the C3 MG1 domain, which, 
after C3 activation to C3b, lies in close proximity to the thioester domain. It has therefore 
been proposed that this mutation could affect thioester activity, or influence the binding of 
other molecules to the thioester domain, in particular the regulatory protein complement 
factor H (Jokiranta et al 2006; Yates et al 2007). Direct function studies, however, have given 
rather inconsistent results. Although an initial report suggested differences in the ability of 
the two variants to bind mononuclear cells, subsequent studies showed no difference between 
the variants in their ability to solubilise immune complexes or bind complement receptors 
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(Arvilommi 1974; Bartok & Walport 1995; Welch et al 1990). Similarly, there is no evidence 
that carrying either of these variants results in a quantitative difference in C3 level 
(Bronnestam 1973). Despite this lack of functional evidence, there is now considerable 
evidence that the C3F/S variant is associated with disease. The strongest evidence is for an 
association with age-related macular degeneration (AMD) (Maller et al 2007; Yates et al 
2007). An association has also been reported with IgA nephropathy, systemic vasculitis, PR3 
ANCA-positive vasculitis, partial lipodystrophy and membranoproliferative 
glomerulonephritis type II (MPGNII) and long-term graft survival following renal 
transplantation (Brown et al 2006; Finn et al 1994; Finn & Mathieson 1993; McLean & 
Winkelstein 1984; Persson et al 1999). Although a number of other structural variants of C3 
have been identified, none have been shown to be functionally different or to be associated 
with disease. 
 
In addition to these non-synonymous C3 SNPs there are nearly 1000 additional SNPs that are 
either intronic or found in close proximity to the gene, and hence have the potential to alter 
regulatory sequences. Compared with the non-synonymous polymorphisms, these SNPs are 
less well studied, and it is only recently that authors have begun to employ a more 
comprehensive screen of all C3 variants in their studies. Only four studies to date have 
proposed an association between disease and any of these non-coding SNPs. Three papers 
have shown an association between C3 variation and bronchial asthma: an initial report and a 
larger follow-up from a Japanese cohort and a study in an African-American cohort (Barnes 
et al 2006; Hasegawa et al 2004; Inoue et al 2008). In both cohorts haplotypes were 
identified that were associated with asthma, and this effect did not appear to be accounted for 
by the presence of known coding SNPs. The identified regions were different in the two 
cohorts (spanning intron 19-23 in the African-Americans and a large block incorporating all 
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of the 5′ end of the gene downstream of exon 23 in the Japanese), and clearly further work is 
required to delineate these effects in more detail. 
 
The final C3 disease association that has been reported is with SLE (Miyagawa et al 2008). 
Given the strong biological plausibility for a role for C3 in the pathogenesis of SLE and the, 
albeit mild, autoimmune phenotype observed in individuals with C3 deficiency, it is perhaps 
surprising that this association has only been reported in a single study. The key association 
was seen for SNP rs7951, and haplotypes containing the minor allele of this SNP. This SNP 
results in a synonymous base pair substitution in exon 37 although, of course, this may not be 
a functional variant but simply in strong linkage disequilibrium with a true functional variant 
elsewhere. Importantly, however, these authors also find SNP rs7951 to be associated with 
reduced C3 levels in 87 SLE patients on whom serum C3 readings were collected. This not 
only provides a potential mechanism for the association with SLE, but also represents the 
first direct association of C3 variation with serum C3 levels. Prior to this it has not even been 
demonstrated that serum C3 is a genetically determined trait. 
 
1.6: Summary and Aims of Thesis 
 
Although they are structurally unrelated molecules, CRP and C3 share many functional 
characteristics. Both are phylogenetically ancient plasma proteins that are constitutively 
expressed in healthy humans. The expression of both molecules is regulated so that serum 
levels increase in the presence infection or inflammation; this is most notable for CRP, which 
forms a key component of the human acute-phase response. Both molecules are considered 
components of the innate immune system, being able to recognise ubiquitous pathogen-
expressed molecules. In the case of CRP this recognition occurs directly while in the case of 
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C3 it is indirect, through activation of the classical, alternative, or mannan-binding pathways 
of complement. Both molecules also have typical innate immune effector functions, most 
notably through the opsonisation of potentially pathogenic or immunogenic material, for 
clearance by phagocytes. In higher animals, both molecules also play sensory and effector 
roles within the evolved adaptive immune system. This is most notable for C3, which can be 
potently activated through the classical complement pathway by cross-linked 
immunoglobulin. There is also growing evidence that CRP can interact directly with 
immunoglobulin receptors, and hence it may have complex adaptive immune functions which 
are not yet fully elucidated.  
 
Serum levels of both proteins are measured in routine clinical practise for diagnostic 
purposes, while there are several lines of evidence to implicate both these molecules in 
specific disease processes, most notably systemic lupus erythematosus (a clinical syndrome 
reflecting the development of systemic autoimmunity) and, for CRP,  ischaemic heart disease 
(a clinical syndrome reflecting the development of atherosclerosis). 
 
Numerous authors have reported an association between CRP genotype and serum CRP 
expression, but there is little consistency in the literature, with no single SNP associated in 
each study where it has been tested. CRP variation has also been associated with both SLE 
and CHD but again data is limited. For C3 the genetic data is much more limited with only a 
single study reporting an association between C3 genotype and serum C3 levels. 
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The aims of the work presented in my thesis are therefore as follows: 
 
• To explore the association between CRP variation and serum basal CRP expression. 
• To replicate findings in cohorts of differing ethnicity and to employ a variety of 
methodological strategies to ensure the robustness of the observed association. 
• To use ethnic diversity at the CRP locus to clarify the complex pattern of association 
reported in the literature. 
• To consider the effect of trans-acting genetic effects on basal CRP expression. 
• To perform a pilot study analysing the role of CRP variation in determining acute-
phase CRP expression in patients with chronic inflammatory disease. 
• To re-evaluate the association between CRP variation and SLE. 
• To demonstrate serum complement C3 level is a genetically determined trait by an 
analysis of familial clustering and heritability. 
• To determine the association between C3 genotype, serum C3 levels and SLE.
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CHAPTER 2 
 
M ATERIALS AND METHODS 
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2.1: Study Cohorts 
 
Four cohorts were used for the analyses presented in this thesis: these are described below. 
 
2.1.1: UK white European SLE families (Cohort 1). 
 
This cohort constituted a growing collection of predominantly simplex SLE families recruited 
through United Kingdom rheumatology clinics or by direct patient contact following media 
publicity. Each proband met ACR 1982 revised criteria for diagnosis (Tan et al 1982). 
Clinical data and biological samples were collected at a single time-point at study enrolment. 
Disease phenotype varied, but data collection took place in an outpatient setting from patients 
who were not “acutely unwell”.  Ethical approval was obtained (MREC/98/2/6) and all 
participants gave appropriate written informed consent. A copy of the patient questionnaire 
may be found in Appendix C, from which the range of clinical information collected for each 
subject can be seen. 
 
All biological specimens from the cohort participants were collected prior to the start of the 
work presented in this thesis, and had been processed by laboratory technical staff. In brief, 
40mL whole blood was obtained from each participant for the extraction of DNA by the 
phenol-chloroform method. After extraction, DNA was quantified and diluted to 50ng/µL for 
storage at 4˚C. An additional 10mL whole blood was obtained for centrifugation and serum 
collection. Serum was stored frozen at -80˚C. 
 
Previous genotyping projects using this cohort led to the identification of a number of ex-
paternity families who were excluded from analysis at the outset. In addition only participants 
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of self-reported white European ethnicity were included. The final cohort used for the 
analyses presented in chapter 3 therefore consisted of 496 SLE probands of white European 
ethnicity along with their family members. The availability of data on family members varied 
such that the final cohort broke down into 323 parent/proband trios, 173 single-parent 
families (consisting of proband, parent and sibling) and 370 additional unaffected siblings. 
By the time the analyses presented in chapter 8 were performed, recruitment of additional 
cases and family members had resulted in an expansion of the cohort to a total of 2211 
individuals from 585 families (418 parent/proband trios and 167 additional families). Subsets 
of this cohort were employed for different components of the analysis presented in this thesis 
and full details can be found in chapters 3 and 8. 
 
2.1.2: Filipino SLE families (Cohort 2).  
 
The Filipino cohort is a growing resource collected in collaboration with Dr Sandra Navarra 
(University of Santo Tomas Hospital, Manila, Philippines). At the time this work was carried 
out it consisted of 328 ethnic Filipinos with SLE. Each proband met ACR 1982 revised 
criteria for diagnosis (Tan et al 1982). Additional data was also available on 308 unaffected 
family members, leading to a complex family structure as follows: 
 
• 27 Proband/two parent trios 
• 36 Proband/one parent/sib (or sibs) families 
• 57 Proband/single parent (no sibs) families 
• 62 Proband/sib or sibs (no parents) families 
• 146 Probands with no other relatives 
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Data collection followed the model from cohort 1, with DNA, serum and clinical information 
collected at a single timepoint at patient recruitment and clinical information obtained via the 
same questionnaire (Appendix C). Written informed consent was obtained from each subject, 
and the study protocol was approved by the Institutional Review Board and Ethics 
Committee of the University of Santo Tomas (UST) Faculty of Medicine and Surgery and 
UST Hospital. This cohort was employed for the analyses presented in chapter 4. 
 
2.1.3: African-American population cohort (Cohort 3). 
 
This cohort consisted of 594 unrelated individuals of African-American origin. These 
individuals were from two sources, provided by collaboration with Prof. Philip de Jager 
(Harvard Medical School/Partners Healthcare Center for Genetics and Genomics, Center for 
Neurologic Diseases, Brigham & Women’s Hospital and Harvard Medical School and 
Program in Medical and Population Genetics, Broad institute of Harvard and Massachusetts 
Institute of Technology, USA), Prof. Carlos Mendes de Leon (Rush Institute for Healthy 
Aging, Department of Internal Medicine, Rush University Medical Center, Chicago, USA) 
and Prof. Jorge Oksenberg (Department of Neurology, University of California, San 
Francisco, USA). Cohort 3a consisted of 294 subjects from the Chicago Health and Aging 
Project (CHAP), which is a population based study of community-dwelling adults aged 65 
years old and over, from the Chicago area, IL, USA. Details on the recruitment and data 
collection for these individuals may be found in the published literature (Bienias et al 2003). 
Cohort 3b consisted of 150 unrelated multiple sclerosis (MS) cases and 150 controls from the 
UCSF Multiple Sclerosis Genetics Group. Ascertainment protocols, clinical and demographic 
characteristics have also been published (Cree et al 2004; Oksenberg et al 2004). Recruitment 
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to both cohorts received institutional review board approval and written informed consent 
was obtained. These cohorts were employed for the analyses presented in chapter 5. 
 
2.1.4: UK Rheumatoid Arthritis cases (Cohort 4). 
 
This cohort consisted of 281 UK white European rheumatoid arthritis cases, provided in 
collaboration with Dr Sophia Steer (Kings College London School of Medicine, University of 
London, UK). Details on the collection of this cohort have been published elsewhere (Steer et 
al 2005). In brief, patients were recruited consecutively from rheumatology clinics across 
South London; each met 1987 ACR criteria for diagnosis, although disease activity and 
duration varied between patients (Arnett et al 1988). Data was collected for rheumatological 
parameters including the DAS 28 disease activity score broken down into its constituent 
components of a tender and swollen joint count for 28 defined joints, physician and patient 
global assessments of disease activity (on a 10 point visual analogue scale) and an 
erythrocyte sedimentation rate (ESR). Each patient had a single CRP measurement performed 
on a sample collected simultaneously to the ESR sample (Prevoo et al 1995). This cohort was 
employed for the analysis presented in chapter 6. 
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2.2: Genotyping 
 
2.2.1: Selection of SNPs for Genotyping 
 
An extensive array of SNPs has already been identified for the genes investigated in this 
thesis, and these data are available on public databases. I therefore decided not to devote 
resources to DNA sequencing in the search for novel polymorphisms. For the primary genes 
under investigation, namely CRP and C3, the aim of the work conducted in Cohorts 1-3 was 
to build a comprehensive map of common genetic variation at the loci. The selection of SNPs 
for typing followed a similar pattern for each cohort. Firstly, the Tagger facility of Haploview 
(using an r2=0.8 threshold) was used to select tagSNPs that defined the haplotype block or 
blocks for the relevant gene from the most ethnically appropriate HapMap panel 
(http://www.hapmap.org/) (Barrett et al 2005; Gabriel et al 2002). For cohort 1 this was taken 
to be the HapMap European (CEPH) panel, for cohort 2 the HapMap Han Chinese (CHB) 
panel and for cohort 3 the HapMap Yoruban (YRI) panel. Since Filipinos are not specifically 
represented in the HapMap datasets the ethnicity considered evolutionarily most closely 
related to this population, namely Han Chinese, was selected (however see discussion point 
in section 4.5.4) (Nei & Roychoudhury 1993). 
 
In addition to these tagSNPs, I also aimed to genotype all SNPs on which there was published 
association data at the time of project planning. While in some cases this was predicted to 
provide redundant genetic information I felt it was important to perform this typing to 
facilitate a direct comparison with existing literature. For the CRP analysis in cohort 3 
(African-Americans) the additional step was also taken to select SNPs to address the question 
of genetic admixture (the presence in the population of genetic elements of recent European 
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origin on a background ancestral West African genome). Three SNPs for typing were 
therefore selected from the HapMap datasets as being monomorphic in the YRI population 
but polymorphic in CEPH population. 
 
For the study of cohort 4 a different approach was taken. In this study I aimed to assess the 
association between CRP variation and acute phase CRP expression, in a population whose 
CRP architecture had already been established from the work in cohort 1. For cohort 4, I 
therefore only genotyped the minimal selection of tagSNPs required to define the common 
CRP haplotypes 
 
Finally, for some analyses, additional genotyping was undertaken at other loci (namely IL1B, 
IL6 and APOE), with the intention of using these data as genetic covariates in the primary 
association analyses. Resources precluded a full tagSNP approach for these genes (the LD 
across IL1B in particular is rather weak and would require a considerable number of SNPs to 
map fully). For IL1B and IL6 we therefore selected a number of SNPs which have been 
suggested in the literature to have a potential functional role, while for APOE we selected the 
two non-synonymous SNPs which determine Apo ε serotype. 
 
2.2.2: Genotyping by mass spectrometry – theoretical aspects 
 
The majority of genotyping for the work described in this thesis was performed by me using 
Matrix-Assisted Laser Desorption and Ionization-Time Of Flight (MALDI-TOF) mass 
spectrometry (Sequenom, Hamburg, Germany), available at the Imperial College Genome 
Centre, Hammersmith Campus. The protocol I used varied during the course of this research 
as the technology for high multiplex assays developed from the Homogeneous 
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massEXTENDTM (HME) assay, to single base extension assays (iPLEXTM and iPLEX GoldTM 
protocols). 
 
MALDI-TOF mass spectrometry allows allele specific DNA products to be separated on the 
basis of their molecular weight (Oeth et al 2005; Ross et al 1998; Storm et al 2003; Tang et 
al 2003). The initial step for all protocols is the amplification of an approximately 100 base-
pair fragment containing the SNP of interest, followed by treatment with Shrimp Alkaline 
Phosphatase (SAP), to dephosphorylate unincorporated dNTPs that would interfere with 
subsequent steps. An allele specific fragment is then synthesized in an extension reaction, 
using an extension primer binding to bases just adjacent to the polymorphic site. The mass 
separation of two products differing by a single base is 9-40Da, depending on the base 
substitution, and the mass spectrometry genotyping protocols are designed to optimise this 
allele-specific mass difference, and hence the accuracy of allele discrimination. In the earlier 
Homogeneous MassEXTEND (hME) protocol the reaction extended from the primer, 
through the polymorphic site, terminating with a further 2-3 base pair fragment: the 
additional mass of this fragment allowing larger mass separations between multiplexed 
products. The later iPLEX and iPLEX Gold protocols involve a single base extension only 
but using mass modified terminators. By ensuring good mass separation between the 
extension reaction products (as a consequence of the extension primer design), multiplexing 
of assays is possible (theoretically up to 36-plex reactions for the iPLEX Gold protocol). 
 
2.2.3: Genotyping by mass spectrometry – practical aspects 
 
Genotyping using Sequenom MALDI-TOF mass spectrometry is a highly automated 
procedure. All stages were carried out according to Sequenom recommended protocols, with 
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the exception of the initial PCR step where I used a modified touchdown protocol, previously 
established in our laboratory to improve genotyping efficiency. 
 
Assay pooling and the design of all primers was performed using Sequenom Assay Design 
Software v.3.1, with default settings applied. The software automatically optimises primer 
design to ensuring maximum assay plexing and to minimize primer-primer interactions. All 
primers were ordered from Metabion (Martinsreid, Germany). High purity HPLC purified 
extension primers were used, since contamination of the extension reaction with oligomers of 
similar molecular weight to the genuine extended primers can severely compromise the 
reliability of the assay. 
 
DNA at the required concentration was diluted from the 50ng/µl stock plates and aliquoted 
into 384well PCR plates (Abgene, Cambridge, UK) using a Biomek FX robot (Beckman 
Coulter, Luton, UK). The three laboratory steps are as follows (a full list of reagents and 
reaction conditions is given in Appendix A): 
 
1. Amplification of genomic DNA by Polymerase Chain Reaction. 
2. Dephosphorylation of unincorporated dNTPs using Shrimp Alkaline Phosphatase 
(SAP).  
3. Extension reaction: Either hME or iPLEX reaction 
 
Excess salts were then removed from the extension reaction mixture by the application of 
Clean Resin (Sequenom, Hamburg, Germany), mixing and centrifugation. Using a robotic 
nanodispenser, minute aliquots of the clear supernatant were dispensed onto a SpectroCHIP® 
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(Sequenom, Hamburg, Germany), which was inserted into the mass spectrometer for data 
acquisition. 
 
Following data acquisition, analysis was performed using Sequenom TYPER v.3.4 software. 
In essence this software is able to identify peaks on the mass spectrometer output at positions 
corresponding to the predicted mass of the allele specific extension product for each of the 
multiplexed assays. By assessing whether one (homozygotes) or two (heterozygotes) 
extension peaks are present the software can automatically assign a sample’s genotype. The 
algorithm is also able to base a decision to call a genotype on quality control parameters such 
as the level of noise in the background spectrum (often indicative of salt contamination), or 
the relative heights of the extended and unextended primer peaks (indicative of reaction 
efficiency). The default genotype calling settings were used throughout and in all cases 
genotypes were reviewed manually and considered to be sound calls. In a very limited 
number of cases additional manual calls were made where peaks could be clearly 
distinguished which were symmetrically centred on the line of predicted mass, but where 
automated calling may have failed on the basis of reaction efficiency. 
 
Genotyping for cohort 3a was performed using the Sequenom platform by colleagues at the 
Broad Institute Center for Genotyping and Analysis (Cambridge, MA, USA). The genotyping 
method employed for cohort 3a was therefore identical to that used for the in-house 
genotyping, and is a robust and recognised technology. Unfortunately, due to financial and 
organisational constrains, an exchange of DNA samples between centres to definitively 
ensure reproducibility of genotyping was not possible. 
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2.2.4: Genotyping – Quality Control 
 
To ensure genotyping was of high quality I adopted a series of pre-determined quality control 
criteria, below which data were considered unreliable for further analysis. These were: 
 
• Genotyping for any SNP successful in >90% of individuals 
• Genotyping in any individual successful for >80% of markers 
• Genotypes in Hardy-Weinberg equilibrium (Hardy-Weinburg Probability (HWP) 
P<0.01 as assessed by χ2). For family cohorts this was assessed in the subset of 
unrelated population founders. 
 
For the family cohorts data were also checked for Mendelian inconsistencies using PedCheck 
(O'Connell & Weeks 1998). Individuals were excluded from analysis if >10% of markers 
demonstrated Mendelian inconsistency. If this individual was a disease proband, or if it was 
ambiguous which individual in the family showed inconsistency then the whole family was 
excluded from analysis.  
 
2.3: Immunological assays 
 
2.3.1: CRP quantification – Immunoturbimetry 
 
Serum CRP was quantified by latex-enhanced immunoturbimetry using an Olympus AU2700 
analyser (Olympus Diagnostics, Southall, UK) in the Department of Clinical Chemistry, 
Hammersmith Hospital, London, UK. To summarise this fully automated procedure, CRP is 
quantified by mixing a 2μL serum aliquot with a suspension of anti-human CRP antibody-
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coated latex particles, resulting in the formation of insoluble aggregates. The absorbance of 
light passed through these aggregates is proportional to the CRP concentration in the solution 
(Whicher et al 1983). Using standard settings the analytical range (over which the 
relationship between absorbance and concentration is linear) is 0.2-480mg/L. The Olympus 
OSR1699 assay is well validated and used in routine clinical use. Local quality control was 
ensured by re-calibration of the immunoturbimeter every six hours.  
 
CRP quantification on the 294 individuals from cohort 3a was quantified by a particle-
enhanced immunonephelometric assay using a Dade-Behring BNII nephelometer at 
University of Vermont Laboratory for Clinical Biochemistry Research (Dade Behring, 
Deerfield, IL, USA). Although it was not ideal to use this additional method of CRP 
quantification, it should be noted that there are internationally recognised CRP reference 
samples which should ensure direct comparability between assays. 
 
2.3.2: C3 quantification – Radial Immunodiffusion Assay 
 
Serum C3 levels were quantified by Radial Immunodiffusion Assay (RID) using the method 
described by Mancini (Mancini et al 1965). 64μL sheep anti-human C3 antibody (The 
binding site, Birmingham, UK) were added to 10mL 1.2% Complement fixation test agarose 
(CFT dilutant tablets from Oxoid Ltd, Cambridge, UK). The molten agarose was allowed to 
solidify on a 64cm2 glass plate and 30 x 2mm wells were punched. Sample sera were thawed 
from -80˚C storage and kept on ice. 5μL was added to each well and then the plates were 
incubated overnight in a wet box at room temperature. After washing with phosphate 
buffered saline, the gels were dried onto Gelbond film (Cambrex Bio Science, New Jersey, 
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USA) and stained with Coomassie brilliant blue. The diameter of the stained ring of 
precipitation was measured to the nearest 1μm using a graduated eye piece. 
 
For each plate of assays the C3 concentration was determined by reference to a standard 
curve of dilutions of pooled human serum (whose concentration had previously been 
determined by validated assay in an external laboratory). Plate to plate consistency was 
ensured by the consistent use of control samples from two individuals with low and high C3 
respectively. To confirm that none of the C3 plates gave unexpected, outlying, results the 
Kologorov-Smirnov test was used to assess whether the distribution of control samples 
departed from the normal distribution expected due to standard measurement error. No 
significant deviation was seen (P=0.20). 
 
2.4: Statistical analysis 
 
In this section I have outlined the statistical methods used for the analysis of data presented in 
this thesis. A brief discussion of the theoretical background to some of these methods may be 
found in section 1.3. 
 
2.4.1: Data storage and management 
 
Data was stored and managed using BC/GENE v.2.2.5 software (Biocomputing platforms 
Ltd, Espoo, Finland). This facilitated the formatting of genotype and phenotype data, and the 
running of dedicated family-based genetic analysis packages directly through a customised 
interface. Except in cases specified below, all other statistical analyses were performed using 
the SPSS v. 14.0 (Statistical Package for the Social Sciences; SPSS inc., Chicago, IL, USA) 
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2.4.2: Heritability estimates 
 
The concept of heritability has already been introduced in section 1.3.2. In analyses presented 
in this thesis we have used a number of different methods to estimate the heritability of CRP 
and C3 in the family-based cohorts. The simplest method, applied in section 8.2.1 , was a 
regression based approach of estimating heritability from the slope of the line of the 
regression of offspring C3 on mean parental C3 (Khoury et al 1993; Visscher et al 2008). In 
this case an unaffected sibling was selected from each family at random for analysis. The 
alternative approach that was used was to fit a variance components model to estimate the 
variance attributable to additive genetic effects. In the CRP analysis presented in section 3.3 
this was done using a maximum likelihood approach within the qTDT package, modelling for 
polygenic additive genetic variance and common environmental variance (Abecasis et al 
2000; Hopper & Mathews 1982).  
 
For the revised C3 heritability estimate, presented in section 7.2.2, a Bayesian approach to 
variance components analysis was adopted, and modelled using WinBUGS (Burton et al 
1999; Lunn et al 2000). Variances were modelled for of additive polygenic effects, shared 
nuclear family effects and common sibling effects (i.e. not shared with parents). A weakly 
informative prior distribution was specified for the within family correlations (Half normal 
(0,10) distribution). This was felt to be more appropriate than a non-informative prior since 
family members are obviously correlated to some extent, while it would be inappropriate to 
give equal weight to all levels of correlation. Nonetheless, sensitivity to different prior 
distributions for the variance components was also tested by running the same models with a 
γ (2, 2) distribution, and different shapes of half normal distribution (0, 0.25) and (0, 0.4). 
The results did not change to any appreciable extent. 
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2.4.3: Data Imputation 
 
The level of missing genotype and phenotype data was low across all of the cohorts and, 
except where specified, analyses were conducted on “raw data” with no imputation of 
missing values. Nonetheless, even small amounts of missing data can lead to a considerable 
reduction in the size of the analysable cohort if multiple phenotypic or genotypic covariates 
are considered together in the same model. Therefore, for the analysis of cohort 3 a Bayesian 
approach was adopted for imputing missing data, by inputting a prior distribution for missing 
variables, with information from existing data updating these priors. For example, existing 
lnBMI data had a mean 3.32 kg/m2, s.d. 0.22, so a normal prior distribution with these 
parameters was used for missing values. A Bernoulli prior distribution was used for binary 
phenotype data. Missing SNP data was estimated using FastPhase (Scheet & Stephens 2006). 
In practise the levels of missing genotype data were low (see table 5.1) as were the levels of 
missing data for phenotypes collected in both halves of the cohort (0.18% for age and none 
for sex or multiple sclerosis affection). Data on BMI and other disease states were not 
collected for cohort 3b and hence were missing for 49.2% of the combined data set. It was 
only for these variables that the use of imputed data was likely to impact upon the observed 
results. To ensure that the use of these data did not dramatically alter our findings all 
significant models were also re-evaluated without the use of inferred values. This is discussed 
further in chapter 5. 
 
In the analysis of association between C3 genotype and SLE, presented in section 7.4.2., data 
imputation was used to estimate genotype at an extensive array of untyped SNPs. Using the 
pattern of LD predicted from the HapMAP CEPH panel data, and informed by existing direct 
genotype data, the programme BEAGLE 3.0 was used to impute 287 untyped genotypes 
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spanning the entire C3 gene. BEAGLE 3.0 uses a haplotype clustering algorithm and applies 
a Hidden Markov Model approach to inferring missing data: it is also capable of inferring 
data in family cohorts (Browning & Browning 2009; Browning & Browning 2007b).  
 
2.4.4: Haplotype imputation 
 
Population haplotype structure was inferred for each cohort using Haploview v.4.1 and the 
algorithm of Gabriel et al. with default settings applied (Barrett et al 2005; Gabriel et al 
2002). In the family cohorts haplotype inference was performed using the subset of 
unaffected cohort founders only. Some genetic association packages, including TRANSMIT 
and qTDT incorporate haplotype inference algorithms in their analysis, but do not provide an 
output of individual haplotypes on a case by case basis. Where explicit inference of 
individual haplotypes was required this was performed using PHASE v.2.1 (Stephens et al 
2001; Stephens & Donnelly 2003). For family cohorts, where particular genotypes or 
haplotypes may cluster in families, PHASE can potentially overestimate the occurrence of 
rare haplotypes. For family datasets I therefore re-checked haplotype assignment using 
MERLIN, which infers haplotypes on the basis of patterns of gene flow within families 
(Abecasis et al 2002). Haplotype cladograms were inferred using TCS: Phylogenetic network 
association using statistical parsimony v1.21 (Clement et al 2000). 
 
2.4.5: Association analyses 
 
Transformation of quantitative data was performed where relevant. The distribution of serum 
CRP in each of the study cohorts was positively skewed, so a logarithmic transformation was 
employed to approximate a normal distribution and facilitate analysis of data on the 
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continuous scale. Other than the presentation of basic CRP distributions within the cohorts 
(i.e. median and range) all analyses are performed on log-transformed CRP, unless specified. 
Serum C3 approximated a normal distribution in vivo so no transformation was required. 
 
For the population-based cohorts (Cohorts 3 and 4) the association between genotype and 
CRP or C3 as a quantitative outcome was assessed using linear regression, incorporating both 
continuous and categorical covariates. The clade-based haplotype association presented in 
section 5.4.3 was modelled by ANOVA using Treescan v1.0: a bioinformatic application to 
search for genotype/phenotype associations using haplotype trees (available at 
http://Darwin.uvigo.es) (Templeton et al 2005). A different approach was required to analyse 
association in the family cohorts (Cohorts 1 and 2), to account for the clustering of effects 
within groups of related individuals. Analysis of the association between genotype and serum 
CRP concentration was performed either by introducing a random effects factor into the 
linear regression models described above, or alternatively by using the dedicated family 
based analysis, qTDT, specifying the orthogonal model of association (Abecasis et al 2000). 
For the association of genotype with serum C3 a similar random effects factor was introduced 
for the maximum likelihood analysis. Bayesian association analysis was performed using 
WinBUGs with the familial clustering of data analysed through the modelling of variance 
components as for the heritability estimate (section 2.5.2). A standardised normal (0, 1) 
distribution was specified as a prior distribution for all model parameters. 
 
The analysis of genetic association with a binary (disease status) outcome was performed by 
logistic regression in the population based cohorts. In the family-based cohorts it was 
performed by transmission disequilibrium test using TRANSMIT (Clayton 1999). 
Association analysis of the imputed C3 genotype data was carried out by an allelic test 
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(Fisher’s exact test on the 2 x 2 table of transmitted/untransmitted allele) using BEAGLE 
(Browning & Browning 2007a). 
 
As outlined in section 1.3.4, I adopted one of two approaches to the adjustment of 
significance levels to account for multiple hypothesis testing. Either I used a modified 
Bonferroni correction to account for the degree of correlation between markers tested, or 
alternatively I used a permutation test-based approach (Armitage & Parmar 1986; Sankoh et 
al 1997; Westfall & Young 1993). 
 
2.4.6: Admixture Analysis 
 
As I outlined in section 1.3.4, a significant proportion of the African American genome 
(perhaps 10-30%) may arise from recent admixture with European populations (Wassel Fyr et 
al 2007). At the level of a single locus this may complicate analyses by distorting the inferred 
haplotype structure, if the pattern of LD differs between the background and the admixed 
genetic elements. It may also affect our ability to detect an indirect genetic association. For 
the analysis of Cohort 3 I therefore identified three SNPs (rs1255606, rs11585798 and 
rs17459580) predicted to be polymorphic in European populations but monomorphic in 
populations of an African origin. I used PHASE v.2.1 to explicitly infer a haplotype pair for 
each individual and I hypothesised that haplotypes containing these SNPs would have a 
European origin.  
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2.4.7: Model Choice Analyses 
 
The Bayesian model choice analyses presented in chapter 5 were performed using the 
association studies toolkit for WinBUGS, employing a reverse jump algorithm on the model 
space, in the Markov Chain Monte Carlo (MCMC) framework (Lunn et al 2000; Lunn et al 
2006). This Bayesian approach allowed me to make some prior assumptions about the nature 
of the genetic model, on the basis of existing literature. Firstly I assumed that the magnitude 
of genetic effect would be relatively small, and secondly that the genetic model would be 
most likely to incorporate one or two genetic effects but was much less likely to have more 
than three effects (regression parameters β and γ, normal distribution, mean=0, 
variance=0.25; number of genetic effects specified by a Poisson (2) distribution). In a 
duplicate analysis I re-ran the Bayesian model selection using vague prior assumptions; in 
other words making no assumption about the magnitude of genetic effect or number of 
markers in the model (regression slope parameters α, β and γ - normal distribution, mean=0, 
variance=100,000; residual variance (σ2) - inverse gamma distribution, shape 0.01, scale 
0001). By using vague priors similar results to those obtained using a classical approach 
would be expected. 
 
The weight of evidence to support a particular model was the assessed by the Bayes factor. 
Harold Jeffries suggested a scale for the interpretation of Bayes Factors and this is 
reproduced in table 2.1. (Jeffreys 1961). 
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Table 2.1. Jeffreys’ interpretation of Bayes Factors 
Bayes Factor Strength of Evidence favouring model 
<1 Negative Evidence (supports alternative model) 
1 to 3.2 Barely worth a mention 
3.2 to 10 Substantial 
10 to 32 Strong 
30 to 100 Very Strong 
>100 Decisive 
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CHAPTER 3 
 
CRP ASSOCIATIONS IN UK SLE FAMILIES 
 97 
3.1: CRP Associations in UK SLE Families – Study Aims 
 
The work presented in this chapter was planned as a family-based CRP association analysis 
in a cohort of white European ancestry. I aimed for comprehensive coverage of genetic 
variation through the use of CRP tagSNPs and, to ensure comparability with existing studies, 
I aimed to genotype all SNPs on which there was existing published CRP association data. I 
also planned to consider the effect of relevant trans-acting genetic variants, and to include 
these as genetic covariates in the CRP analysis. By using a family-based cohort I hoped to 
demonstrate robust associations between CRP genotype and serum CRP. In addition, using a 
variance components approach with this family data, I planned to estimate CRP heritability 
and to quantify the proportion of the genetic component of CRP variation accounted for by 
CRP genotype. Finally I planned to refine and extend the association between CRP genotype 
and SLE that was initially reported by Russell et al in a cohort that overlapped with the one 
presented here (Russell et al 2004).  
 
An initial power calculation, assuming 500 informative families, an allelic odds ratio of 1.2 
and SNP a minor allele frequency of 33% (based on the frequency of rs1205), suggested the 
power to detect an association between genotype and SLE at the P=0.05 level by TDT was 
45% (power calculator at http://pngu.mgh.harvard.edu/~purcell/gpc/dtdt.html). An estimate 
of power to detect a genetic association with serum CRP as a quantitative trait is more 
complex because it requires an estimate of effect of genetics on both the mean and the 
variance of the log-transformed CRP distribution, and in addition needs to incorporate an 
estimate of the within family correlation of CRP levels in this cohort of related individuals. 
This calculation would perhaps best performed by data simulation, however, since estimates 
for the variance of log-transformed CRP, and the within family CRP correlation are not 
 98 
widely reported the estimates of these parameter would be so speculative as to render the 
calculation almost meaningless.  A formal ad hoc power calculation was not therefore 
performed. Despite the relatively low estimated power of the disease-based analysis and the 
unknown power of the CRP-based study I felt it worthwhile continuing these studies because 
both associations had already been demonstrated by Russell et al in a smaller cohort which 
overlapped with the one presented here. The data presented in this chapter may be found in 
published form (Rhodes et al 2008a).  
 
3.2: UK SLE Cohort - Demographics, CRP Distribution and Heritability.     
 
Basal CRP was quantified in all family members from the first 294 families (numbered in 
order of recruitment and not systematically with respect to any phenotypic manifestation). 
Serum CRP was quantified in additional individuals from later families only if they carried a 
rarer CRP haplotype, whether or not they had SLE. Therefore, from the cohort of 1858 
individuals with genetic data, serum CRP was available for 1265. Median CRP was 2.01mg/L 
(0.19 to 161.51mg/L), mean age was 54.0, 66.1% were female and 24.8% had SLE. A linear 
regression model, presented in table 3.1, showed that CRP increased with age and had a trend 
towards higher levels in women. CRP was also higher in SLE probands.  
 
 
 
 
 
 
 
 
 
 99 
Table 3.1. Effect of age, sex and SLE affection on CRP 
Variable β-coefficient standard error t P-value 
Total cohort     
Age 0.018 0.003 6.450 <0.001 
Sex (Female) 0.148 0.077 1.920 0.055 
SLE (Affected) 0.233 0.089 2.623 0.009 
Cohort with CRP<10mg/L     
Age 0.017 0.002 6.992 <0.001 
Sex (Female) 0.171 0.068 2.510 0.012 
SLE (Affected) 0.024 0.08 0.301 0.764 
 
 
It is unknown whether basal and acute-phase CRP expression is regulated by the same 
genetic factors. Since epidemiological studies have suggested the 99th centile for CRP is 
10mg/L in a young adult population, we therefore excluded all individuals with a CRP 
>10mg/L from further analysis on the basis that their CRP may represent an acute-phase 
response (Shine et al 1981). Interestingly, however, the unaffected siblings in our cohort 
(generally healthy young adults) had CRP levels higher than this, with the 99th centile 
13.01mg/L. The cohort of individuals with CRP<10mg/L contained 1152 individuals with a 
mean age of 54.0. 65.2% were female and 23.4% had SLE. A linear regression model in this 
basal CRP cohort, (also presented in table 3.1) demonstrated, that basal CRP increased with 
age and in females. SLE itself showed no association with basal CRP once these individuals 
with acute-phase CRP levels were excluded (P=0.764). 
 
CRP heritability was estimated by variance components modelling in qTDT, which uses the 
cohort family structure to estimate environmental and genetic components of variance. This 
gave a maximum likelihood estimate of 27.7% hereditability (h2=0.277; P=1x10-7) after 
adjustment for age, sex and SLE affection. In an analysis restricted to unaffected family 
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members we estimated 21.3% hereditability (h2=0.213; P=0.001), the reduced level of 
significance presumably being a consequence of the smaller number of siblings in this subset. 
 
3.3: CRP Genetic Architecture 
 
Twenty-eight CRP SNPs and an [AT/-] insertion/deletion polymorphism were selected for 
genotyping, using the approach outlined above and in chapter 2. In addition five IL6 markers 
and four at IL1B were typed to encompass previous reports and provide additional coverage 
across these genes. Finally the two non-synonymous APOE polymorphisms required to infer 
Apo ε serotype were genotyped. Detailed marker information is presented in table 3.2. 
 
SNPs rs2794521 and rs2808630 were excluded from further analysis as they typed in <90% 
of individuals, while rs3095058, rs3093062, rs3093063 and rs16842502 were excluded as 
they had very low minor allele frequency in this population. The remaining SNPs were in 
Hardy-Weinberg equilibrium (χ2 P>0.05 in the subset of unaffected, unrelated population 
founders). Figure 3.1 demonstrates the haplotype structure in the 799 unrelated cohort 
parents on whom genetic information was available. Seven haplotypes, H1 to H7, occurred 
with a frequency >1% between rs11265257 and rs7553007. A full pairwise comparison 
between markers is presented in table 3.3. With the scale of fine mapping adopted in this 
study I was able to demonstrate a falling off of LD both upstream and downstream of the 
central CRP haplotype block. It should be noted, however, that this entire region would fall 
within the region of strong LD surrounding CRP on a genomic scale (as illustrated in figure 
1.3.) 
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Table 3.2. Typed SNPs demonstrating alleles and rare allele frequencies 
rs number SNP Location Rare allele frequency HWP
§ missing data (%) 
CRP SNPs      
rs11265263 G>T 5' flank 0.07 0.76 2.0 
rs10437339 C>G 5' flank 0.49 0.59 3.6 
rs12728740 G>T 5' flank 0.32 0.66 2.4 
rs7553007 C>T 5' flank 0.33 0.55 3.3 
rs1341665* C>T 5' flank 0.33 0.32 3.7 
rs2027471 A>T 5' flank 0.34 0.26 3.0 
rs2808632 A>C 5' flank 0.30 0.08 1.9 
rs17860488 AT>- 5' flank 0.34 0.69 5.7 
rs3093058 A>T 5' flank 0.00 N/A 2.2 
rs3093059* T>C 5' flank 0.07 0.06 3.1 
rs2794521 A>G 5' flank 0.30 0.24 14.8 
rs3093062 G>A upstream promoter 0.00 N/A 2.8 
rs3091244* C>T>A upstream promoter 0.29(T)/ 0.07(A) 0.07 1.9 
rs3093063 C>T upstream promoter 0.00 N/A 5.8 
rs1417938* A>T intron 1 0.30 0.81 2.2 
rs1800947* G>C exon 2 (synonymous) 0.07 0.59 5.5 
rs1130864* C>T 3'-UTR 0.30 0.98 3.6 
rs3093066 C>A 3'-UTR 0.00 0.97 2.4 
rs1205* G>A 3'-UTR 0.33 0.34 2.4 
rs2808630 A>G 3' flank 0.30 0.23 14.0 
rs3093077* T>G 3' flank 0.08 0.07 1.9 
rs2794520 G>A 3' flank 0.33 0.41 2.8 
rs2808628 C>T 3' flank 0.33 0.40 2.3 
rs876538 A>G 3' flank 0.22 0.21 3.2 
rs11265257 G>A 3' flank 0.38 0.67 3.6 
rs2027469 C>T 3' flank 0.18 0.94 2.5 
rs1935193 T>A 3' flank 0.32 0.26 5.0 
rs12749227 G>A 3' flank 0.29 0.71 2.6 
IL1B SNPs      
rs16944 C>T 5' flank 0.34 0.82 5.1 
rs1143634 C>T exon 5 (synonymous) 0.23 0.88 2.5 
rs7596461 G>A 3' flank 0.08 0.38 2.7 
rs4849124 C>T 3' flank 0.30 0.26 5.2 
IL6 SNPs      
rs1800796 G>C 5' flank 0.07 0.56 2.2 
rs1800795 G>C 5' flank 0.39 0.25 6.0 
rs2069837 A>G intron 2 0.07 0.31 3.3 
rs2069840 C>G intron 3 0.34 0.43 2.7 
rs1554606 G>T intron 3 0.43 0.70 3.6 
APOE SNPs      
rs429358 T>C exon 4 0.13 0.61 2.7 
rs7412 C>T exon 4 0.08 0.31 3.3 
SNPs highlighted in bold have been selected to tag the key CRP haplotype block. SNPs marked with a * have 
been previously associated with serum CRP levels (see table 1.2) § Hardy-Weinburg probability P-value 
calculated by χ2
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Figure 3.1. CRP haplotypes and LD structure.  
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The position of SNPs relative to CRP is shown in the top section of this diagram. The middle section 
demonstrates inferred haplotype structure with haplotype frequencies are shown to the right of each block. 
Thick line connect blocks occurring together in >10% of chromosomes and thin lines if in >1% of 
chromosomes. The lower section demonstrates the pairwise LD between markers (a graphical representation of 
the data in table 3.3) with haplotype blocks defined by the default algorithm of Gabriel et al (see methods 
section 2.4.4). The pairwise LD between any two SNPs is indicated by the colour coding of the corresponding 
square of the LD plot. High LD is indicated by a pink/red colour scheme (the dark red squares are linked with a 
D′ = 1 and a LOD score ≥ 2). Numbers within the squares correspond to the D′ score, with 96 representing a 
D′=0.96 and 44 a D′-0.44 etc. Where squares have no number the D′=1 
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In comparison with the Hapmap CEPH panel, the dense array of SNPs I have typed, in this 
large cohort, has determined that strong linkage disequilibrium extends 6.7 to 7.7 kb further 
downstream than previously estimated. SNP rs11265257 incorporates into the main CRP 
block and delineates a seventh haplotype. A proposed phylogenetic relationship between 
these haplotypes is presented in Figure 3.2.  
 
 
 
Figure 3.2. Cladogram of CRP haplotypes 
H6
rs2808628
rs2794520
rs1205
rs17860488
rs2808632
rs2027471
rs1341665
rs7553007
rs1800947
rs11265257
rs876538
rs2808632
rs3091244 (T)
rs1130864
rs1417938
H2
rs3093077
rs3091244 (A)
H3
H7
rs3093059
H4
H1
H5
 
Haplotypes are represented by circles corresponding to their population frequency. SNPs differing between 
haplotypes are listed next to the connecting lines, with the SNPs associated with basal CRP level marked in bold 
(the line length is arbitrary and does not represent evolutionary distance). Small dark circles on the connecting 
lines indicate ancestral haplotypes which were not observed but can be inferred to have existed in the history of 
the population. 
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3.4. – Genetic Associations with basal CRP 
 
3.4.1: Association of CRP SNPs with basal CRP 
 
Each SNP within the CRP haplotype block was evaluated for association with basal CRP in a 
multiple linear regression model incorporating age, sex and SLE affection as covariates. 
Although my initial analysis suggested SLE had no significant effect on basal CRP (see 
above) and hence I felt justified in including the full cohort in an analysis, I also considered it 
prudent to retain SLE affection as a covariate. Table 3.4 shows the regression parameters for 
each SNP, analysed assuming alleles act in an additive manner. For triallelic rs3091244 
models were constructed assessing each allele versus the remaining two: the most significant 
model (C vs. not-C) is shown. Seven polymorphisms, rs7553007, rs1341665, rs2027471, 
rs17860488, rs1205, rs2794520, and rs2808628 were significantly associated with basal CRP 
even after applying a partial Bonferroni correction adjusted for correlation between SNPs (16 
tests, mean correlation r=0.480). For each SNP the rare allele was associated with lower basal 
CRP. Weak effects were also seen for rs11265257 and rs1800947. I checked for departure 
from an additive model for each of the CRP markers, but none was found.  
 
The CRP SNP association was re-analysed using the orthogonal model of qTDT. Table 3.4 
also shows the significance of the associations determined using this method. Each of the 
seven key polymorphisms associated in the regression model were also significantly 
associated using the orthogonal test. It was noted that for the majority of SNPs the results 
obtained by linear regression and by TDT were in agreement. For SNPs rs1417938 and 
rs1130864, however, there was a minor discrepancy, with no evidence of CRP association 
seen by regression, but a result approaching significance seen with the orthogonal model of 
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qTDT. It is likely that this observation was a “chance” observation due to the differing 
methodologies used by the two tests. In particular the requirement of the TDT based tests to 
have informative data on parental genotype transmission means that the final set of families 
incorporated into the analysis may differ from the complete dataset employed in the 
regression based test. In any case it should be noted that the results from either methodology 
do not approach significance when the appropriate significance threshold is considered with 
regards multiple testing (P<0.012). 
 
 
Table 3.4. Single SNP associations with CRP 
Marker β-coefficient 
standard 
error 
t 
Regression* 
P-value 
Orthogonal model 
P-value 
rs7553007 -0.210 0.067 -3.110 0.002 0.004 
rs1341665 -0.191 0.066 -2.898 0.004 0.002 
rs2027471 -0.165 0.066 -2.506 0.012 0.005 
rs2808632 0.090 0.067 1.337 0.182 0.225 
rs17860488 -0.189 0.068 -2.766 0.006 0.011 
rs3093059 0.053 0.122 0.433 0.665 0.419 
rs3091244† 0.082 0.066 1.240 0.215 0.131 
rs1417938 0.075 0.074 1.014 0.311 0.035 
rs1800947 -0.233 0.120 -1.952 0.051 0.048 
rs1130864 0.084 0.073 1.145 0.252 0.044 
rs1205 -0.186 0.067 -2.755 0.006 0.002 
rs3093077 0.043 0.119 0.358 0.721 0.483 
rs2794520 -0.181 0.068 -2.668 0.008 0.003 
rs2808628 -0.183 0.067 -2.727 0.007 0.004 
rs976538 0.020 0.080 0.247 0.805 0.983 
rs11265257 -0.152 0.065 -2.330 0.020 0.021 
Covariate (age, sex and SLE affection) adjusted regression parameters for each CRP SNP. Significance 
determined by the orthogonal model of qTDT shown on the right. 
*Unadjusted P-values. An individual P-value <0.012 is required to achieve overall significance at the 0.05 level 
after applying a Bonferroni correction adjusted for correlation between SNPs (these P-values are highlighted in 
bold). 
†Modelled C vs. not-C alleles. 
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3.4.2: Trans-acting Genetic Effects 
 
A preliminary analysis was performed to determine which, if any, of the trans-acting SNPs 
were important to include as covariates in the primary model. This determined that IL1B 
SNPs rs7596461 was associated with basal CRP (P=0.012). The rare allele of rs7596461 was 
associated with lower CRP levels and. One IL6 SNP, rs1800796 was also associated with 
basal CRP, although this effect was restricted to the SLE probands (rs1800796*SLE P=0.18). 
Both rs7596461 and rs1800796*SLE were therefore also included as a covariate term in the 
CRP regression models presented below. For illustrative purposes the effect of these trans-
acting markers is shown in the CRP haplotype model (table 3.7). Genotype at CRP, IL1B and 
IL6 had an additive effect on basal CRP, with no evidence for higher order interaction. I did 
not find an association between APOE SNPs and basal CRP, either individually or as a 
haplotype (as would determine Apo ε serotype).  
 
3.4.3: Mixed genetic models 
 
The association of CRP SNPs with basal CRP was then reassessed in the multiple linear 
regression model, now incorporating the key trans-acting genetic effects (IL1B SNP 
rs7596461 and IL6 SNP rs1800796) as genetic covariate. This additional covariate model is 
presented in table 3.5. The level of significance attached to each of the CRP associations 
increased marginally with the addition of this additional genetic data. 
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Table 3.5. Single SNP associations with serum CRP with genetic covariates 
Marker β-coefficient 
standard 
error 
t 
Regression* 
P-value 
rs7553007 -0.230 0.068 -3.365 0.001 
rs1341665 -0.237 0.068 -3.462 0.001 
rs2027471 -0.197 0.068 -2.911 0.004 
rs2808632 0.107 0.069 1.542 0.123 
rs17860488 -0.231 0.070 -3.301 0.001 
rs3093059 0.106 0.124 0.850 0.396 
rs3091244† 0.103 0.067 1.535 0.125 
rs1417938 0.077 0.075 1.022 0.307 
rs1800947 -0.230 0.122 -1.885 0.060 
rs1130864 0.079 0.074 1.062 0.289 
rs1205 -0.226 0.069 -3.254 0.001 
rs3093077 0.096 0.123 0.784 0.434 
rs2794520 -0.220 0.070 -3.159 0.002 
rs2808628 -0.222 0.069 -3.209 0.001 
rs976538 0.011 0.081 0.140 0.889 
rs11265257 -0.153 0.066 -2.306 0.021 
Regression parameters for each CRP SNP adjusted for phenotypic covariates (age, sex and SLE affection) and 
trans-acting genetic covariates (genotype at IL1B SNP rs7596461 and IL6 SNP rs1800796). *Unadjusted P-
values. An individual P-value <0.012 is required to achieve overall significance at the 0.05 level after applying a 
Bonferroni correction adjusted for correlation between SNPs (these P-values are highlighted in bold). 
†Modelled C vs. not-C alleles. 
 
 
3.4.4: Influence of SLE affection on CRP associations 
 
Because it has been reported that the magnitude of the acute-phase rise in CRP (although not 
necessarily basal CRP levels) may be blunted in patients with SLE, I performed a parallel 
analysis in a subset of the cohort (n=558) consisting of all the unrelated, unaffected founders 
on whom serum CRP was available (i.e. all the parents and, if no parental data was available, 
an unaffected sibling selected at random). This avoided the need to adjust for familial 
clustering, while restricting analysis to individuals without SLE. The results of this analysis 
are presented in table 3.6.  
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Table 3.6. Single SNP associations in the unaffected, unrelated founders 
Marker β-coefficient standard error t P-value 
rs7553007 -0.179 0.061 -2.945 0.003 
rs1341665 -0.179 0.060 -3.013 0.003 
rs2027471 -0.190 0.060 -3.191 0.002 
rs2808632 0.022 0.064 -0.348 0.728 
rs17860488 -0.181 0.060 -3.040 0.003 
rs3093059 0.276 0.107 2.589 0.010 
rs3091244 0.165 0.055 3.006 0.003 
rs1417938 0.109 0.061 1.787 0.075 
rs1800947 -0.295 0.107 -2.766 0.006 
rs1130864 0.116 0.060 1.927 0.055 
rs1205 -0.172 0.060 -2.843 0.005 
rs3093077 0.243 0.107 2.273 0.024 
rs2794520 -0.177 0.061 -2.908 0.004 
rs2808628 -0.186 0.061 -3.062 0.002 
rs976538 0.097 0.072 1.339 0.181 
rs11265257 -0.169 0.060 2.830 0.005 
 
 
 
The same seven SNPs were significant in this subset analysis but, in addition, significant 
associations were observed with rs11265257 (P=0.005), rs1800947 (P=0.006), rs3091244 
(C vs. not C) (P=0.003) and rs3093059 (P=0.010). SNPs rs11265257 and rs1800947 were 
both weakly associated in the full cohort and the stronger association in this subset is likely 
due to the increased power attained by requiring no adjustment for familial clustering. For 
rs3093059 and rs3091244 the increase in significance appeared greater, and the estimated 
magnitude of effect was larger in this subset (β = 0.276 and 0.165 respectively). I specifically 
looked for rs3093059*SLE and rs3091244*SLE interactions in the full cohort but none was 
observed (P=0.581 and P=0.116 respectively). Again it is possible that the observed 
association may be due to increased power, rather than differential genetic regulation of basal 
CRP between people with and without SLE. 
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3.4.5: Haplotypic Association with basal CRP 
 
CRP haplotypes were evaluated with reference to commonest haplotype H1 in a multiple 
linear regression model and these results are presented in table 3.7. A pairwise comparison 
between haplotypes is presented in table 3.8.  
 
Table 3.7. The association of CRP with CRP haplotypes 
Parameter β-coefficient standard error t P-value 
rs7596461 (IL1B) -0.311 0.123 -2.535 0.012 
rs1800796*SLE (IL6) 0.844 0.252 3.342 0.001 
rs1800796*Healthy (IL6) 0.195 0.158 1.232 0.218 
H7 0.206 0.210 0.983 0.326 
H6 0.138 0.159 0.868 0.386 
H4 0.000 0.139 -0.002 0.998 
H1 Ref    
H3 -0.100 0.099 -1.007 0.314 
H2 -0.235 0.093 -2.533 0.012 
H5 -0.305 0.135 -2.270 0.024 
Hx 0.121 0.247 0.490 0.624 
Haplotypes modelled with reference to haplotype H1. Hx represents pooled haplotypes with frequency <1%. 
 
 
Table 3.8.  Pairwise comparison of CRP levels by CRP haplotype. 
Haplotype P-value 
H7 X       
H6 0.788 X      
H4 0.384 0.455 X     
H1 0.326 0.386 0.998 X    
H3 0.155 0.158 0.480 0.314 X   
H2 0.035 0.023 0.085 0.012 0.167 X  
H5 0.026 0.020 0.072 0.024 0.137 0.602 X 
Haplotype H7 H6 H4 H1 H3 H2 H5
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Haplotypes H2 and H5 appeared to form a group associated with lower CRP levels. Both 
carry the rare allele of all the strongly associated SNPs which are in tight linkage 
disequilibrium (mean pairwise r2=0.969). By reference to figure 3.2 we can see that H2 and 
H5 form a clade which is distinguished from the remaining haplotypes by eight of the typed 
SNPs. Seven of these are associated with CRP expression, while the remainder, rs2808632, 
also occurs at another position in the tree, explaining the lack of association with this SNP. 
The CRP levels associated with the H2/H5 clade are significantly lower than that associated 
with all other haplotypes combined (β -0.240; t -3.417; P=0.001). Using the regression 
parameters it could therefore be predicted that a healthy woman, aged 30 and homozygous 
for the common alleles of rs7596461 and rs1800796, would have a CRP of 2.99mg/L if she 
was homozygous for H2/H5 compared with 4.37mg/L if she carried no H2/H5 haplotypes. 
Haplotype analysis in unaffected founders only showed a similar pattern of association 
(tables 3.9 and 3.10), including the association of the H2/H5 clade with lower basal CRP (β -
0.183; S.E. 0.061; t -3.016; P=0.003). 
 
Table 3.9. The association of CRP with CRP haplotypes (unaffected founders) 
Parameter β-coefficient Standard error t P-value 
H7 0.228 0.177 1.288 0.198 
H4 0.175 0.119 1.475 0.141 
H1 Ref    
H6 -0.058 0.140 -0.418 0.676 
H3 -0.128 0.081 -1.566 0.118 
H2 -0.138 0.077 -1.785 0.075 
H5 -0.300 0.114 -2.638 0.009 
Hx 0.124 0.212 0.583 0.560 
CRP haplotypes modelled with reference to haplotype H1. Hx represents pooled haplotypes with frequency 
<1%. 
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Table 3.10.  Pairwise comparison of CRP levels with CRP haplotype (unaffected founders). 
Haplotype P-value 
H7 X       
H4 0.788 X      
H1 0.198 0.141 X     
H6 0.184 0.158 0.676 X    
H3 0.52 0.014 0.118 0.643 X   
H2 0.044 0.007 0.075 0.576 0.906 X  
H5 0.009 0.001 0.009 0.137 0.170 0.182 X 
Haplotype H7 H4 H1 H6 H3 H2 H5
 
 
3.5: Genetic contribution to total CRP variability 
 
Using the variance components framework within qTDT we can provide a measure of SNP 
effect on population CRP variability by estimating the polygenic component of basal CRP 
variation before and after addition of genotype. Of the seven associated CRP polymorphisms 
the proportion of CRP variance attributable to that SNP ranged from 0.51% (rs976538) to 
2.54% (rs2808628). Basal CRP variance explained by CRP haplotype as a whole was 3.77%. 
Given the estimated 28% CRP heritability, CRP haplotype therefore accounted for 
approximately 15% of the total genetic effect. SNPs rs7596461 and rs1800796 both have low 
rare allele frequency and hence a negligible effect on total basal CRP variation (<0.5%). In an 
analysis of healthy family members only we estimated CRP haplotype to account for 5.51% 
of basal CRP variance. Given the lower CRP heritability estimate for this healthy cohort CRP 
haplotype therefore accounted for approximately 26% of the total genetic effect. 
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3.6: CRP Genetic Association with SLE 
 
The association between SLE and CRP SNPs or haplotypes was assessed by transmission 
disequilibrium testing using TRANSMIT. No difference in allele or haplotype frequency was 
observed between probands and their relatives and hence no association with SLE was 
identified in this cohort (“best” haplotype association: P=0.22 for haplotype H4). 
 
3.7: CRP Genetics in UK SLE Families – Discussion 
 
3.7.1: Summary of Findings 
 
The data presented in this chapter confirm the genetic basis of basal CRP expression by 
demonstrating 28.7% heritability. Seven genotyped CRP polymorphisms were found to be 
associated with lower basal CRP. These span 30kb of CRP and lie upstream (rs7553007, 
rs1341665, rs2027471, rs17860488), downstream (rs2794520, rs2808628) and within the 3'-
UTR) (rs1205). I have clarified the haplotype structure of CRP and defined the limits of the 
haplotype block in this population. The rare alleles of all the consistently associated 
polymorphisms are carried solely on haplotypes H2 and H5 which are themselves associated 
with significantly lower basal CRP. These haplotypes form a distinct phylogenetic clade, thus 
strengthening the argument that a major functional SNP lies on this branch of the haplotype 
tree. My use of a variance components approach to estimate the magnitude of effect of 
associated SNPs on basal CRP variation is novel. Despite confirming that variation at CRP is 
associated with basal CRP, the total effect appears rather small, explaining only 3.77% of 
basal CRP variability. I was unable to demonstrate any association between CRP variation 
and SLE. 
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3.7.2: A Comparison with Existing Studies – cis-effects 
 
Of the SNPs associated with basal CRP level in this study, only rs1205 has also been 
associated with CRP in existing published studies (table 1.2) although, as discussed in 
section 1.3.3, it has not been associated in every study where it has been tested. Those studies 
which do show an association show the rare allele to be associated with lower CRP 
expression, as shown here. Studies which analyse CRP haplotypes (table 1.3) also generally 
confirm that haplotypes containing the rare allele of rs1205 are associated with low basal 
CRP. I have therefore extended this finding to a group of linked SNPs delineating “low-
producing” haplotypes. Recently published work suggests H2 may be further broken down by 
SNPs rs12029262 and rs3116654, although these additional haplotypes are also associated 
with low basal CRP and may have little additional functional consequence (Kathiresan et al 
2006). There is strong linkage disequilibrium between all of the associated SNPs in my study, 
making it difficult to determine a likely functional candidate on the basis of this genetic study 
alone. A detailed discussion of potential functional variants at CRP in the light of all the 
studies presented in this thesis can be found in section 8.4.5. 
 
The variance components estimate of the proportion of basal CRP variability accounted for 
by the typed genetic variants is of particular interest as this approach has not been used 
before, although other authors have made a similar sort of estimate in regression-based 
analyses using the partial r2 for associated CRP polymorphisms (see table 8.2). Both my 
results, and existing data, suggest that the effect of these typed cis-acting variants accounts 
for only a small proportion of the genetic component to CRP variability. In this study CRP 
haplotypes accounted for 3.77% of basal CRP variability. Given the estimated 28% CRP 
heritability this therefore represented only 15% of the total genetic effect. 
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3.7.3: A Comparison with Existing Studies – trans-effects 
 
I identified associations between IL1B SNP rs7596461 and IL6 SNP rs1800796 and basal 
CRP, although the latter was only significant in the SLE probands. Individually these SNPs 
have previously been associated with basal CRP, but they have not been included as 
covariates in large CRP haplotype analyses (Berger et al 2002; Eklund et al 2005; Latkovskis 
et al 2004; Vickers et al 2002). Perhaps the key point about these associations is that even 
within a so-called basal range, CRP expression may be influenced by classical inflammatory 
stimuli. I chose to confine the analysis to individuals with serum CRP <10mg/L, primarily to 
avoid the complicating factor of including patients with active SLE. Some other authors have 
taken a different approach and analysed complete cohorts including individuals with higher 
CRP. A more detailed discussion of the boundaries between basal and acute-phase CRP, and 
how this may affect the interpretation of CRP expression studies may be found in section 
8.3.1. At this point it suffices note that the inclusion of IL1B or IL6 genotyping could have 
been relevant in many of the large existing CRP studies, particularly, given the proposed 
inflammatory aetiology of atherosclerosis (section 1.3.5), those using CHD cohorts. 
 
3.7.4: A Comparison with Existing Studies – SLE association 
 
In this study I was unable to demonstrate an association between CRP genotype and SLE. 
While other authors have shown an association, it is perhaps notable that the reported effects 
have been modest and there is inconsistency over the key associated variants (section 1.3.4) 
(Edberg et al 2008b; Jonsen et al 2007; Russell et al 2004; Shih et al 2008). The negative 
findings were initially surprising since the cohort used in this study overlapped with that used 
for the study of Russell et al, (the difference being 200 individuals from 50 families) where a 
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positive association was identified. A detailed comparison of genotyping obtained in this 
study compared with that obtained by Russell (genotyping using RFLP) revealed no 
systematic errors in genotyping to account for this. A combination of cohort differences 
(Russell included a small number of non-European families, while a slightly different 
selection of siblings was genotyped due to plate re-organisations), and a small number of 
discrepant genotypes accounted for the loss of association. However it was clear that even 
with a cohort of the size presented in this study the power to detect a disease association was 
limited. As outlined in section 3.1, given the magnitude of effect reported by Russell et al the 
current study had only an estimated 45% power to detect an effect at the P=0.05 level. 
 
3.7.5: Key Study Features and Potential Limitations 
 
The primary aim of the work presented in this chapter was to fine-map the CRP locus, to 
enable me to draw together existing published work, and to re-evaluate the associations 
between CRP genetic variants, serum CRP and SLE. This is the first large scale CRP study to 
utilise a family-based approach. 
 
It is important, nonetheless to consider potential sources of error in this study. In any study, 
measurement error will occur, resulting in an analysis of data values that deviate from the 
“true” values for the individuals in the study. It is important to appreciate that measurement 
error can be divided into two components; systematic error and random error. Systematic 
errors are constant, theoretically predictable, factors leading to a systematic deviation in the 
mean of the measured values away from the true values. Random errors, on the other hand 
are due to unpredictable “random” factors influencing each measurement in a different way. 
Since these errors result in a measured value being randomly either higher or lower than the 
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true value they will increase the variance of the measured values in relation to the true values 
but will not influence the mean. The critical difference between the two sorts of measurement 
error is the effect they may have on the interpretation of study results. Systematic errors may 
result in the generation of false associations. On the other hand random errors may make it 
harder to demonstrate a true association (as it introduces so much “noise” into the data), 
however, it should not affect the validity of a significant association, should one still be 
demonstrated. 
 
It should be acknowledged that the work presented in this chapter forms a post-hoc analysis 
of CRP expression in a cohort collected for the purpose of the genetic analysis of SLE disease 
expression. The analysed cohort is therefore a mixture of related individuals, some of whom 
are healthy (although presumably enriched for SLE susceptibility genes) and some of whom 
have SLE. At first glance attempting to unpick the association between genetic variation and 
serum CRP in the context of SLE presents an insurmountable problem. I would argue, 
however, that this is not the case.  
 
Firstly, SLE itself is known to have a complex relationship with CRP expression (see section 
1.3.4) so the validity of including affected individuals in an analysis needs to be justified. In 
particular if SLE is exerting a systematic effect on serum CRP then this may introduce a 
systematic error, which would become important if alleles influencing CRP expression were 
also segregating in individuals with disease. Some existing studies suggest, within the basal 
CRP range, the presence of SLE does not exert much influence on serum CRP; indeed 
previous analyses have suggested that most individuals with SLE have basal levels of CRP, 
with a preserved relationship between basal CRP and cardiovascular risk (Szalai et al 2005a; 
Toloza et al 2004). Although there is only limited published data it would appear that the 
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dysregulation of CRP in SLE is related to a failure to mount an adequate acute-phase 
response (Pereira Da Silva et al 1980). Since the normal correlation between levels of CRP 
and IL-6 appears to be lost in patients with SLE, the block in maximal expression of acute-
phase CRP would seem to be a fairly late stage event in the cytokine pathways culminating in 
CRP expression (Williams, Jr. et al 2005). These studies provide evidence that there is a 
problem mounting an acute-phase response in SLE, but in an analysis confined to individuals 
with basal level CRP, SLE may not exert a significant influence. Nonetheless it was clearly 
necessary to control for potential systematic error through the consistent inclusion of SLE 
affection as a covariate in all the regression models, and my findings backed up the argument 
above, with no significant SLE effect observed when the cohort was restricted to individuals 
with serum CRP <10mg/L. I am therefore confident that the potential systematic bias 
introduced by the inclusion of individuals with SLE was, firstly, minimal and, secondly, 
controlled for in my analyses. I was able to add further weight to this argument, through 
additional analyses presented in section 3.4.3, where all individuals with SLE were excluded 
from analysis. If the role of CRP polymorphism in determining basal CRP is different in 
people with and without SLE then the effect is clearly very small. 
 
A related issue that could be raised regarding the use of patients with SLE is whether any 
adjustment was made for the level of disease activity. As I stated in section 2.1.1 the disease 
phenotype of the patients varied, but data collection took place in an outpatient setting from 
patients who were not “acutely unwell”. Although, broadly speaking, these were patients not 
in an active stage of their disease, there remains the potential for differences in overall 
disease activity (and hence potential differences in the effect of SLE on these patients CRP 
levels). This variation however falls within the “random error” category, because the data 
collection was performed in a cross-sectional study design in which venepuncture was not 
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performed at any particular time-point in relation to disease activity. We would therefore 
expect the “error” associated with the effect of disease activity on CRP levels across the 
cohort, over and above that due to genetic variation, to be random.  
 
A similar, but slightly different issue concerns the possibility of intra-individual variation in 
CRP concentration, irrespective of the presence or absence of disease. Clearly the greater the 
natural intra-individual fluctuations in CRP concentration with time, the greater the random 
measurement error associated with a single “snap-shot” CRP measurement as collected for 
this study, and hence the lower the power to detect a genetic association. The only available 
published data suggests remarkably consistent intra-individual serum CRP levels over time, 
nonetheless it should be recognised that an analysis of multiple CRP readings collected at 
different time-points is likely to significantly improve the prospects of identifying genetic 
influences on serum CRP levels (Danesh et al 1998; Kivimaki et al 2007; Ridker et al 1999). 
 
It should also be recognised that the CRP assay itself may be subject to measurement error, 
although I am confident that the amount of error, whether random or systematic will be 
insignificant. The immunoturbimetric assay itself is well validated and, in the setting of a 
clinical service, was subject to stringent local quality control. CRP itself is a robust molecule 
with limited degradation occurring either due to room temperature storage (as occurs when 
collected whole blood is posted to the laboratory for processing) or as a result of freeze-thaw 
cycles (Aziz et al 2003).  
 
A further issue concerns the potential for anti-CRP antibodies in SLE. Although not widely 
reproduced or validated, the presence of anti-CRP antibodies has been reported in 36-78% 
with SLE; most notably in patients with active disease, who are also strongly positive for 
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other antibodies (e.g. anti-dsDNA) which vary in parallel with disease activity (Bell et al 
1998; Sjowall et al 2002; Sjowall et al 2005). Current data suggests, however, that these 
antibodies are directed against monomeric subunits of CRP, and do not react with the intact 
pentamer (Sjowall & Wettero 2007). Furthermore no correlation between anti-CRP reactivity 
and CRP levels has been observed (Figueredo et al 2006). It would seem unlikely either that 
anti-CRP antibodies would interfere with the immunoturbimetric assay or that there would be 
any systematic link between the presence of anti-CRP antibodies and alterations in serum 
CRP, other than those due to the presence of SLE itself. At most, the presence of anti-CRP 
antibodies, if having any effect, will simply add to the random error associated with SLE 
measurement. 
 
The use of a family-based cohort also presents the potential for systematic study bias if 
analysed using standard population based techniques, since CRP levels are likely to cluster 
within families of genetically related individuals. Numerous ways have been developed to 
overcome this problem (as discussed in section 2.5.5.) including, as I have done in this 
analysis, the incorporation of a random effects parameter into the regression model. Provided 
the data is appropriately analysed, a family-based design offers advantages in terms of the 
robust control for biases such as population stratification, thus adding particular weight to my 
findings. The family-based approach also offers an advantage in allowing the checking of 
assigned genotypes for Mendelian consistency, thus offering an additional level of quality 
control. I am therefore confident that genotyping which passed the quality control criteria was 
of high quality.  
 
By considering each potential problem in terms of whether it is introducing systematic error 
(which is then adjusted for) or random error (which cannot be controlled for but should not 
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alter the statistical validity of the study), I believe the association analyses I have undertaken 
can be considered statistically robust. An understanding of measurement error is important 
for the interpretation of the data in each of the chapters in this thesis, and I will refer back to 
this section in later chapters. 
 
Finally, it should be mentioned that one area in which random error can result in erroneous 
results is in the estimate of heritability (Fisher 1951). We have already defined heritability in 
section 1.5.3 as the proportion of variance in phenotype that can be attributed to variance in 
genotype or, expressed another way: 
 
Heritability = Variance due to genetics/Total variance. 
 
Excessive total variance in the trait of interest introduced through measurement error (rather 
than genuine environmental causes of variation) will therefore reduce the overall estimate of 
heritability. With this in mind it is likely that we underestimate CRP heritability. 
 
3.7.6: Conclusions 
 
The data presented in this chapter confirm that genetic variation at CRP influences serum 
basal CRP levels, although it is likely that the magnitude of this effect is relatively small. It 
remains, however, uncertain which variant or variants are likely to play a direct functional 
role. The studies presented in chapters 4 and 5 use genetic analyses to attempt to answer this 
important question, firstly through the study of diverse ethnic populations, and secondly, in 
chapter 5, through the use of a model choice approach which considers the possibility of 
more than one functional effect at this locus. 
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CHAPTER 4 
 
CRP ASSOCIATIONS IN FILIPINO SLE 
FAMILIES 
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4.1: CRP Associations in Filipino SLE Families – Study Aims 
 
The Filipino population has been poorly studied genetically. Population based studies suggest 
a reasonably close genetic relationship with the Han Chinese, but few studies have fine 
mapped individual loci, or looked for disease associations (Nei & Roychoudhury 1993; Tian 
et al 2008b). The aim of the work presented in this chapter was to delineate the CRP genetic 
architecture in a previously unstudied cohort of Filipino SLE families, encompassing a 
similar genetic interval to the European data presented in chapter 3. I aimed to evaluate the 
association between CRP variants and serum CRP expression, although the limited number of 
larger families in this dataset meant the analysis was, by necessity, more restricted. Once 
again I also aimed to consider potential effects arising from trans-acting genetic variants. The 
overall expectation was that the Filipino genetic architecture may allow me to refine 
associations found in the white European populations.  
 
Although this cohort is being collected with the purpose of analysing genetic associations 
with SLE, the number of complete, informative families, at the time this study was performed 
was insufficient to have the power for a meaningful analysis of the association between CRP 
and SLE (less than half the number of families as the European dataset, which itself only had 
a 45% power to detect a disease association). The power to detect an association with serum 
CRP is also likely to be low, although difficult to formalise as explained in section 3.1. 
Nonetheless, given a fairly strong association between CRP variation and serum CRP was 
observed in the European cohort, I was keen to pursue this additional study. The data 
presented in this chapter may been found in published form (Rhodes et al 2008c). 
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4.2: Filipino SLE Cohort – Demographics and CRP distribution 
 
As I have already outlined in section 2.1.2. the cohort employed for the analyses presented in 
this chapter consisted of 328 ethnic Filipino families. Each family consisted as a minimum of 
one individual with SLE. The availability of data from unaffected relatives varied so that the 
overall family structure was complex. The mean age was 38.2 years, 79% were female and 
47% had SLE. The median CRP was 1.88mg/L (range 0.19 to 203.05). 
 
Therefore the final basal CRP cohort contained 509 individuals with a median CRP of 
1.50mg/L. The mean age was 38.2 years, 79% were female and 47% had SLE. In an initial 
regression model I evaluated the effect of age, sex and SLE affection on basal CRP, while 
incorporating a random effects factor to allow for clustering of CRP levels within families 
(table 4.1). Basal CRP increased with age and was higher in women and patients with SLE. 
These three factors were therefore included as covariates in all subsequent regression models. 
Because it yet to be determined whether basal and acute-phase CRP expression are regulated 
by the same genetic factors I excluded all individuals with a CRP>10mg/L from further 
analysis. 
 
Table 4.1. Effect of age, sex and SLE affection on CRP 
Variable β-coefficient standard error t P-value 
Age 0.015 0.006 3.226 0.006 
Sex (Female) 0.334 0.145 2.295 0.023 
SLE (Affected) 0.286 0.139 2.059 0.041 
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4.3: Filipino CRP Genetic Architecture 
 
Serum CRP and genotype data was available for all 285 Filipino SLE probands and 288 
unaffected family members. Nineteen CRP SNPs passed quality control checks and were 
included for analysis. Detailed marker information is presented in table 4.2.  
 
The CRP haplotype structure is outlined in figure 4.1, with haplotypes labelled F1 to F7 in 
order of their frequency within this population. Between rs16842502 and rs7553007 four 
haplotypes occur with frequency > 5%. Downstream SNPs rs2592887 and rs12093699 were 
not contained within this haplotype block. Figure 4.3 demonstrates the pairwise LD between 
markers (a graphical representation of the LD statistics presented in table 4.3.) Unfortunately 
downstream coverage was somewhat different to that used for the European analysis in 
chapter 3 (due to Sequenom pooling constraints) and it is therefore difficult to say whether 
the physical extent of the CRP haplotype block is different in this population. Figure 4.3 
shows the most likely phylogenetic relationship between these haplotypes on the basis of 
maximum parsimony for the mutational steps. A simple clade structure was predicted with no 
mutations duplicated on different branches of the tree. Haplotype F1 had the highest outgroup 
weighting probability (0.33) and was therefore proposed as the ancestral haplotype (Castelloe 
& Templeton 1994). A full pairwise comparison between markers is presented in table 4.3. 
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Table 4.2 Typed SNPs demonstrating alleles and rare allele frequencies 
rs number SNP Location 
Rare allele 
frequency 
HWPa 
missing 
data (%) 
CRP SNPs      
rs7553007 C/T 5’ flank 0.44 0.76 2.2 
rs2027471 A/T 5’ flank 0.41 0.92 0.9 
rs2808632 A/C 5’ flank 0.19 0.31 1.7 
rs17860488 AT/- 5’ flank 0.40 0.86 0.8 
rs3093059* T/C 5’ flank 0.17 0.65 2.2 
rs2794521 A/G 5’ flank 0.19 0.40 2.2 
rs3091244* C/A/T upstream promoter 0.17(A)/ 0.04(T) 0.78 0.6 
rs1800947* G/C exon 2 (synonymous) 0.12 0.65 3.0 
rs1130864* C/T 3’-UTR 0.04 0.23 7.9 
rs1205* G/A 3’-UTR 0.46 0.84 2.6 
rs2808630 A/G 3’ flank 0.20 0.41 4.0 
rs3093077* T/G 3’ flank 0.18 0.76 2.2 
rs2794520 G/A 3’ flank 0.43 0.70 2.5 
rs2808628 C/T 3’ flank 0.43 0.97 2.0 
rs1935193 T/A 3’ flank 0.37 0.40 4.5 
rs12749227 G/A 3’ flank 0.04 0.34 1.2 
rs16842502 G/T 3’ flank 0.18 0.67 3.0 
rs2592887 A/G 3’ flank 0.43 0.80 2.8 
rs12093699 C/T 3’ flank 0.04 0.27 6.7 
IL1B SNPs      
rs4849124 C/T 3’ flank 0.06 0.28 7.0 
rs3917368 G/A 3’ flank 0.42 0.75 4.2 
rs1143634 C/T exon 5 0.03 0.59 2.6 
rs16944 C/T 5’ flank 0.42 0.27 3.3 
IL6 SNPs      
rs1800796 G/C 5’ flank 0.33 0.81 3.9 
rs2069837 A/G intron 2 0.25 0.71 2.6 
rs2069840 C/G intron 3 0.07 0.66 3.4 
APOE SNPs      
rs429358 T/C non-synonymous 0.05 0.54 4.7 
rs7412 C/T non-synonymous 0.11 0.32 10.0 
SNPs highlighted in bold have been selected to tag the key CRP haplotype block. SNPs marked with a * have 
been previously associated with serum CRP levels in any population (see table 1.2) aHardy-Weinberg 
probability P-value calculated by χ2 
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Figure 4.1. Filipino CRP haplotypes. 
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The position of the typed SNPs relative to CRP is demonstrated in the top part of the diagram. SNPs rs12093699 
and rs12749227 are predicted to lie downstream of the main CRP haplotype block. In the lower section of the 
diagram the equivalent European haplotypes have been illustrated, using the data presented in chapter 3, for 
SNPs that have been genotyped in common. 
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Figure 4.2. Graphical representation of LD at the Filipino CRP locus 
 
This diagram demonstrates the pairwise LD between markers (listed across the top) it is therefore a graphical 
representation of the data in table 4.3. The haplotype block is defined by the default algorithm of Gabriel et al 
(see methods section 2.4.4). The pairwise LD between any two SNPs is indicated by the colour coding of the 
corresponding square of the LD plot. High LD is indicated by a pink/red colour scheme (the dark red squares are 
linked with a D′ = 1 and a LOD score ≥ 2). Numbers within the squares correspond to the D′ score, with 96 
representing a D′=0.96 and 44 a D′-0.44 etc. Where squares have no number the D′=1 
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Figure 4.3. Cladogram of CRP haplotypes.  
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4.4: Genetic Associations with basal CRP  
 
4.4.1. Association of CRP SNPs with basal CRP 
 
Each SNP within the CRP haplotype block was tested for association with basal CRP in a 
multiple linear regression model. Age, sex and SLE affection were incorporated as covariates 
along with a random effects factor to adjust for familial clustering of data. Biallelic SNPs 
were modelled assuming alleles acted in an additive manner. For triallelic SNP rs3091244 
each allele was assessed against a pool of the remaining alleles, with the most significant 
model (C vs. A/T) shown. The results of these analyses are presented in table 4.4. An 
individual P<0.014 was required to achieve study wide significance if a partial Bonferroni 
correction is applied (17 SNPs mean correlation, r=0.558). Two SNPs, rs3091244 (C vs. 
A/T) and rs3093077 therefore demonstrated an association with basal CRP expression, with 
the rare allele associated with higher CRP. SNPs rs3093059 and rs16842502 approached 
significance. 
 
4.4.2: Trans-acting Genetic Effects. 
 
I evaluated trans-acting effects from three genes, APOE, IL1B, and IL6, which are potentially 
associated with basal CRP expression. Once again, age, sex and SLE affection were included 
as standard covariates. Because I suspected the dominant genetic effect on basal CRP arose 
from variation at CRP itself I also included the most associated CRP SNP, namely rs3093077 
as a genetic covariate. 
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Table 4.4. Single SNP associations with CRP. 
Marker β coefficient 
Standard 
Error 
t 
Regression 
P-valuea 
rs7553007 0.141 0.117 1.210 0.228 
rs2027471 0.193 0.119 1.617 0.107 
rs2808632 -0.095 0.115 -0.614 0.540 
rs17860488 0.187 0.119 -1.574 0.117 
rs3093059 0.359 0.151 2.369 0.019 
rs2794521 -0.088 0.167 -0.528 0.598 
rs3091244b 0.363 0.146 2.480 0.014 
rs1800947 0.238 0.179 1.327 0.186 
rs1130864 0.265 0.291 0.909 0.364 
rs1205 0.138 0.116 1.187 0.236 
rs2808630 -0.093 0.151 -0.614 0.540 
rs3093077 0.385 0.153 2.509 0.013 
rs2794520 0.124 0.118 1.058 0.291 
rs2808628 0.152 0.115 1.318 0.189 
rs1935193 0.130 0.123 1.055 0.292 
rs12749227 0.364 0.273 1.336 0.183 
rs16842502 0.350 0.156 2.239 0.026 
β-coefficient assuming increasing copies of the rare allele 
aUnadjusted P-values. A P<0.014 is required to achieve study wide significance at the P=0.05 level after 
applying a partial Bonferroni correction (see text). 
bSNP modelled as C vs. A/T alleles. 
 
 
In an initial analysis I assumed the derived apolipoprotein ε (Apo ε) serotypes acted in an 
additive manner on basal CRP expression. Table 4.5 shows regression parameters for this 
model, with increasing copies of the rarer ε2 or ε4 type modelled by reference to the common 
ε3 type.  
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Table 4.5. Trans-acting effects with a significant CRP association 
Variable Β coefficient 
Standard 
Error 
t 
Regression 
P-valuea 
APOE     
Additive model     
ε2 0.198 0.227 0.869 0.386 
ε4 -0.089 0.255 -0.348 0.728 
Recessive model     
ε2 1.495 0.531 2.815 0.005 
ε4 1.106 0.690 1.603 0.111 
     
IL6     
rs1800796 -0.241 0.189 -1.275 0.204 
rs1800796*no SLE 0.387 0.187 2.063 0.040 
aRegression model adjusted for age, sex, SLE affection and rs3093077 genotype 
 
 
The trend was towards a higher basal CRP in carriers of ε2 and a lower basal CRP in carriers 
of ε4 although this was not significant. I also investigated the possibility that Apo ε types 
acted in a dominant or recessive manner. In this model a highly significant effect on basal 
CRP was seen in individuals with ε2 ε2 type acting recessively. This remained significant at 
the P<0.05 level even after applying a conservative Bonferroni correction for 6 tests (three 
Apo ε types each tested in additive and recessive models). Using these regression parameters 
it could be predicted that an average unaffected 30 year old female, homozygous for the 
common allele of rs3093077, would have a basal CRP of 2.86mg/L if she carried the ε2 ε2 
Apo ε type, compared with 1.56mg/L if she carried any other combination of Apo ε type. 
 
Each IL1B and IL6 SNP was also examined for its effect on basal CRP. Furthermore, and in 
view of the findings presented in section 3.4.2, I also assessed for interaction between 
genotype and SLE. No significant association was seen between genotype at any IL1B SNP 
and basal CRP. I also failed to observe an association between IL6 genotype and basal CRP 
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in the cohort as a whole, but a weakly significant interaction between SLE and genotype at 
rs1800796 was observed (table 4.5). This interaction was such that, in unaffected individuals, 
the rare allele of rs1800796 was associated with higher basal CRP, while in SLE patients no 
such effect was observed, and indeed the rare allele of rs1800796 appeared to have a negative 
effect (albeit not significant) on basal CRP. 
 
4.4.3: Mixed Genetic models 
 
The association of CRP SNPs with basal CRP was then reassessed in the multiple linear 
regression model, now incorporating the key trans-acting genetic effects presented in section 
4.4.2. This analysis is presented in table 4.6. The significance level attached to the four SNPs 
identified in the initial analysis  (rs3091244 (C vs. A/T), rs3093077,  rs3093059 and 
rs16842502) increased notably, with all four now falling well below the threshold for 
significance required according to the correction for multiple hypothesis testing. 
 
It was noted as a chance observation that the inclusion of rs1800947 as a covariate increased 
the significance of all the associated SNPs (also shown in table 4.6). A highly significant 
association with basal CRP was then also seen for rs2027471, rs17860488, rs2794520 and 
rs2808628 with weaker effects for rs7553007, rs1205 and rs1935193. In addition rs1800947 
itself demonstrated a greater significance with basal CRP when modelled with another 
independently associated SNP; the minor allele being associated with higher basal CRP (for 
example if modelled with rs3093077 the regression parameters for rs1800947 were: β 0.440, 
SE 0.208, t 2.118, P=0.036). 
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Table 4.6. Single SNP associations with serum CRP with genetic covariates 
Marker β coefficient 
Standard 
Error 
t 
Regression 
P-valuea,b 
1800947 
adjusted β 
1800947 adjusted 
P-valuea,c 
rs7553007 0.274 0.135 2.027 0.044 0.353 0.011 
rs2027471 0.331 0.135 2.456 0.015 0.397 0.004 
rs2808632 -0.031 0.169 -0.185 0.853 0.070 0.704 
rs17860488 0.331 0.135 -2.448 0.015 0.396 0.004 
rs3093059 0.452 0.158 2.860 0.005 0.504 0.003 
rs2794521 -0.014 0.184 0.078 0.938 0.001 0.996 
rs3091244d 0.433 0.158 2.743 0.007 0.499 0.002 
rs1800947 0.251 0.202 1.244 0.215 NA NA 
rs1130864 0.155 0.310 0.501 0.617 0.104 0.738 
rs1205 0.274 0.135 2.027 0.044 0.353 0.011 
rs2808630 -0.015 0.170 -0.088 0.930 0.079 0.668 
rs3093077 0.470 0.161 2.912 0.004 0.506 0.003 
rs2794520 0.255 0.132 1.935 0.055 0.351 0.009 
rs2808628 0.299 0.131 2.282 0.024 0.384 0.005 
rs1935193 0.268 0.140 1.909 0.058 0.362 0.014 
rs12749227 0.285 0.302 0.945 0.346 0.257 0.394 
rs16842502 0.451 0.164 2.752 0.007 0.474 0.006 
β-coefficient assuming increasing copies of the rare allele 
aUnadjusted P-values. A P<0.014 is required to achieve study wide significance at the P=0.05 level after 
applying a partial Bonferroni correction (see text). 
bRegression model corrected for age, sex, SLE affection, Apo ε2 and rs1800796 genotype. 
cRegression model additionally adjusted for rs1800947 genotype 
dSNP modelled as C vs. A/T alleles. 
 
 
4.4.4: Haplotypic Association with basal CRP 
 
The association between CRP haplotype and basal CRP was assessed for the five most 
common haplotypes. The full regression model, also showing the covariate parameters is 
presented in table 4.7. 
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Table 4.7. The association of CRP with CRP haplotypes 
Variable β coefficient 
Standard 
Error 
t-test 
Regression 
P-value 
Age 0.014 0.005 2.689 0.008 
Gender (female) 0.381 0.167 2.280 0.024 
SLE (affected) 0.540 0.216 2.499 0.013 
Apo ε2 ε2 1.474 0.584 2.526 0.013 
rs1800796 0.272 0.222 1.227 0.222 
rs1800796*no SLE -0.563 0.216 -2.618 0.010 
F1 Refa    
F2 0.205 0.184 1.111 0.268 
F4 0.441 0.222 1.984 0.049 
F5 0.445 0.342 1.304 0.194 
F3 0.596 0.187 3.185 0.002 
Fx 0.276 0.288 0.960 0.339 
aHaplotype parameters modelled with reference to commonest haplotype F1. Fx represents the group of rare 
haplotypes in the population (<3%). 
 
 
There is clearly a significant difference in basal CRP levels associated with commonest 
haplotype F1 (low basal CRP) and F3 (high basal CRP). F2 appears associated with 
intermediate basal CRP, while F4 and F5 are also associated with higher CRP (this is of 
borderline significance for F4 but not significant for F5, presumably because of the small 
numbers in this group). During haplotype inference it was noted that the sixth and seventh 
commonest haplotypes (present on 2.5 and 1.8% of chromosomes respectively) shared 
significant sequence homology with F1, and could be assigned to the F1 clade (figure 4.1 and 
figure 4.3). Neither of these haplotypes, individually or combined, was common enough to 
draw any significant conclusions, however we did find that the H6/H7 group was associated 
with a similar, low,  β-coefficient to F2 (compared to F3: β -0.564, S.E. 0.371, t -1.369, 
P=0.173), suggesting they may be genuinely “low producing” haplotypes. 
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4.5: CRP Genetics in Filipino SLE Families – Discussion 
 
4.5.1. Summary of Findings 
 
In this chapter I explored the relationship between genotype and basal CRP in a cohort of 
Filipino SLE families. I was unable to re-examine the association between CRP genotype and 
disease as, with a rather unconventional cohort structure, there was insufficient power to 
perform this analysis. Instead I aimed to explore the genetic architecture of CRP in this 
previously unstudied Filipino population, with the intention of identifying novel haplotypes 
that aid the identification of functional SNPs or to utilise differences in population allele 
frequency to identify new associations.  Four SNPs were found to be associated with higher 
basal CRP. The minor allele of three of these (rs3093059, rs3093077 and rs16842502) 
defined a haplotype, found in 17% of chromosomes, which was also associated with higher 
basal CRP levels in comparison with the commonest population haplotype. A similar strong 
association was seen with tri-allelic SNP rs3091244 with the commonest “C” allele 
associated with lower serum CRP than a combination of the “T” allele (carried on the above 
mentioned haplotype and the much rarer “A” allele (itself defining a low frequency 
haplotype). The association, albeit borderline (P=0.049), of the uncommon haplotype F4 
(characterised by the minor allele of rs1800947), with higher CRP than the reference 
haplotype (F1) prompted me to re-analyse the single SNP data proposing a functional role for 
rs1800947. In support of this hypothesis, the modelling of rs1800947 as an independent 
covariate increased the significance of all the associated SNPs. Trans-acting associations 
were also observed, in particular the association of lower serum CRP in individuals 
homozygous for the APOE ε2 serotype. 
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4.5.2: A comparison with existing studies – cis-effects 
 
A detailed comparison of inter-ethnic differences in CRP genetic architecture will be 
presented later (section 8.4.3). Nonetheless it is important to compare the data presented in 
this chapter with that presented in chapter 3 and elsewhere in the published literature. Each of 
the key associated SNPs identified in this Filipino cohort have also been associated with basal 
CRP expression elsewhere in the literature, again with the minor alleles associated with 
higher serum CRP (Kathiresan et al 2006; Miller et al 2005; Wang et al 2006). It is notable 
that the set of key associated SNPs identified in the analysis presented in chapter 3 was not 
significantly associated with serum CRP in this study, although the same alleles were 
observed to have a trend towards lower serum CRP (note that the minor/major alleles are 
swapped in this Filipino group, hence the positive β-coefficient on the regression analyses). A 
detailed discussion of why studies may highlight significant associations with different 
groups of SNPs (although all tend to agree on the trend in serum CRP seen with the different 
SNP alleles) is presented at a later stage (section 8.4.). 
 
The weak association of haplotype F4 and its unique SNP, rs1800947, with basal CRP was 
interesting. Existing studies typically find an association between low basal CRP and the rare 
“C” allele of rs1800947 along with the haplotype it defines (Kathiresan et al 2006; Lange et 
al 2006b; Miller et al 2005). A single study demonstrates a significant association between 
homozygosity for the minor allele and higher basal serum CRP (Crawford et al 2006). In this 
Filipino population rs1800947 “C”, along with haplotype F4 were almost twice as common 
as their white European equivalents and we therefore had greater power to detect an 
association. We found F4 to be associated with higher basal CRP than F1 (P=0.049). The 
inclusion of rs1800947 as an independent genetic covariate in the SNP association model 
increased the significance of all the associated SNPs, supporting a hypothesis that there is an 
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independent genetic effect arising from this SNP, or one in close LD with it. Phylogenetically 
this is also feasible if, as we propose, haplotype F4 forms a distinct clade diverging from the 
ancestral haplotype F1 independently of all the other haplotypes. There are a number of 
explanations why this effect is not commonly observed in the white European cohorts. It is 
possible that rs1800947 “C” is in linkage disequilibrium (LD) with a true functional SNP is 
Filipinos but not white Europeans: sequencing these haplotypes may be required to 
demonstrate this. In both white Europeans and Filipinos rs1800947 “C” is always found in 
association with the rs1205 “A” allele and other SNPs in strong LD with rs1205. Therefore 
an alternative explanation is that rs1800947 is truly functional but in white Europeans, 
because it is less frequent (approximate reported frequency 5-6%), its effect is swamped by 
an opposite functional effect arising on the rs1205 “A” clade. On the other hand in Filipinos 
where we observed rs1800947 at higher frequency (12%) we have greater power to observe 
an independent functional effect. 
 
4.5.3: A comparison with existing studies – trans-effects 
 
As with the analysis presented in chapter 3, the primary aim of including genetic data from 
trans-acting loci in the analysis was to reduce the levels of “background noise” (random 
measurement error) arising from other genetic influences, thus increasing the power of our 
analysis to identify cis-acting CRP associations. Of particular interest was my identification 
of an association between APOE polymorphism (defining Apo ε serotype) and serum CRP. 
The link between Apo ε variants and levels of serum CRP has been reported for nearly ten 
years, although there remains no convincing mechanistic explanation for this association. The 
knowledge that apolipoprotein E plays an important role in lipid metabolism and cholesterol 
transport, while lipid lowering statins also lower serum CRP, suggests a link through lipid 
regulatory mechanisms, although we lack any more detailed evidence. Of the three serotypes, 
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the Apo ε2 variant is rare in European populations, such that many of the published studies 
have no individuals of ε2 ε2 serotype in their cohorts. While the observation that carriers of 
the Apo ε4 variant have the lowest serum CRP is almost universal, the role of the Apo ε2 
variants is less certain because European studies are underpowered to detect any effect over 
and above the difference between Apo ε3 vs. Apo ε4 carriers (Chasman et al 2006; Judson et 
al 2004; Lange et al 2006a; Manttari et al 2001; Rontu et al 2006). In populations of an East 
Asian origin the Apo ε2 variant appears to be much more common. A study in Japanese-
Americans showed a higher frequency of the Apo ε2 serotype and found an association 
between Apo ε2 type and higher levels of CRP (Austin et al 2004). The finding from our 
Filipino population where the Apo ε2 variant was also more common appears to support this 
finding, although only when analysed in a recessive model. I suspect that ApoE type exerts a 
graded effect on basal CRP levels with Apo ε2 associated with highest levels, Apo ε3 with 
intermediate levels and Apo ε4 with lowest levels. Certainly a functional explanation limited 
to Apo ε4 would appear to be inadequate. 
 
I also demonstrated an association between IL6 variation and serum CRP, although only 
when modelled with SLE as an interaction term. Interestingly this same IL6 SNP was also 
highlighted in the European analysis presented in chapter 3. It is difficult to make a direct 
comparison of the two groups because of marked differences in allele frequency and patterns 
of linkage disequilibrium, nonetheless the demonstration of a consistent association between 
basal CRP and an IL6 variant adds weight to this being a true effect. Future work in basal 
CRP cohorts and further fine-mapping is required to fully delineate this genetic effect. 
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4.5.4: Key study features and potential limitations. 
 
The Filipino population has, to date, been poorly characterised genetically, with no existing 
reports looking at CRP: this, in itself, makes the data presented in this chapter of interest. It 
should be recognised, however, that this is a potential problem when aiming to ensure that 
genetic variation has been comprehensively captured using a tagSNP approached. As outlined 
in the methods chapter (section 2.2.1), the HapMap Han Chinese was used as the reference 
population for the selection of Filipino tagSNPs. Although the Filipino population is clearly 
closer related to Han Chinese than any of the other HapMap reference populations, the 
relationship is not that close, raising the possibility that there may be differences in haplotype 
structure, or even entirely novel variants that have not been identified in the current study. 
This could really only be addressed by the complete resequencing of the CRP locus in a 
representative sample of, say 50-100 Filipino’s. Also not addressed was the possibility of 
underlying population admixture, for example with recent southern European (Spanish) 
elements, although to some extent the family-based design of the study should overcome this 
potential problem.  
 
As with the data presented in chapter 3, I am confident in the quality of genotyping and, since 
this was a family based cohort, a Mendel error check provided an additional level of 
confidence in the assigning of genotypes. There are, however, clear limitations to this 
analysis, in particular related to the familial structure of the cohort, and the reduced level of 
power to detect genetic associations that occurs as a consequence.  As stated in the 
introduction to this chapter, the Filipino cohort is currently under recruitment and at the time 
of analysis was limited, particularly in terms of data from family members. As outlined in 
section 2.1.2 only 27 complete proband/parent trios were available for analysis. Even by 
inferring parental genotype by making use of genotype data from other siblings (as used by 
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TRANSMIT) at most 100 informative trios would be available for analysis. This clearly was 
inadequate to identify even reasonably strong genetic associations using a transmission 
disequilibrium test. For this reason a disease-based genetic association analysis was not 
performed. The cohort structure also impacted on the power to perform a quantitative 
association analysis with serum CRP. In particular there were a limited number of families 
with data on additional siblings (again barely 300), although a few families had data on >5 
siblings. This lack of sibling data results in an imprecise variance components estimate of the 
intra-family correlation of serum CRP levels, and hence introduces significant random error 
into the SNP association analysis. 
 
There are clearly other significant sources of random error in this analysis, including the mix 
of patients affected and unaffected by SLE, and potential random error introduced by the 
potential for sampling affected patients at different stages of disease activity. These aspects, 
along with others of relevance to this analysis have already been fully covered in the 
discussion in section 3.7.5. 
 
4.5.5: Conclusions 
 
I have mapped the CRP locus in a novel cohort of ethnic Filipinos confirming strong LD 
across the locus in this population. I have replicated the association of a number of SNPs with 
serum basal CRP, although these SNPs were different from those found in the analysis of 
white European individuals presented in chapter 3. Nonetheless, with the exception of SNP 
rs1800947 a broadly similar trend in CRP levels was found for each SNP typed in common 
between the two studies. SNP rs1800947 was interesting because there was some evidence 
that a separate genetic effect may be arising from this SNP, or one in close LD with it. A 
further discussion of why different SNPs appear significant in different studies, and whether 
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there is evidence from other studies of multiple genetic effects arising from CRP may be 
found in section 8.4.
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CHAPTER 5   
 
CRP GENETICS IN AN AFRICAN-AMERICAN 
COHORT 
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5.1: CRP Genetics in an African-American Cohort – Study Aims 
 
The data presented in chapters 3 and 4 confirm an association between variation at the CRP 
locus and serum CRP levels. However, for reasons that will be discussed further in chapter 8, 
it remains difficult to establish which SNP or SNPs are likely to be functional variants, and in 
this respect my data simply replicates and extends existing published reports. In this chapter I 
aim to unpick the multiple reported CRP SNP associations to identify the most likely 
functional variants that can then be targeted for functional study. I do this both through the 
selection of the cohort for study, and through the analysis that I employed. 
 
As I have already discussed (section 1.5.3), populations of African ancestry generally 
demonstrate increased genetic diversity, with shorter and more diverse haplotype blocks. It is 
therefore likely that a CRP association analysis in an African-American population will, at 
least, limit the number of indirect associations observed, and thus will generate a more 
restricted range of potential functional variants. The number of existing studies in this 
population is limited. 
 
I also adopted a different analytic approach to help highlight key variants and resolve 
uncertainty in the literature. The focus of this study was not, therefore, to demonstrate an 
association between serum CRP and a string of individual variants; rather I attempted, 
through a formal model choice analysis, to identify the optimal genetic model, containing one 
or more SNPs which explain the overall CRP association. By using a Bayesian approach to 
analysis I was able to utilise existing data to make some simple prior assumptions about the 
nature of the CRP genetic effect. These prior assumptions were then built into a Bayesian 
model choice framework to identify the genetic model “best” explaining the CRP 
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distribution. The model could then be retested to assess its robustness to changes in prior 
assumptions.  
 
In a parallel analysis I adopted a clade-based haplotype association approach. The use of a 
haplotype based approach may itself offer increased power over an analysis of single SNPs, 
particularly if the overall phenotype is influenced by more than one SNP at a locus. The data 
presented in this chapter can be found in published form (Rhodes et al 2008b). 
 
5.2: African-American Population Cohort – Demographics and CRP distribution 
 
As I have already outlined in section 2.1.3. the cohort employed for the analyses presented in 
this chapter was an amalgamation of patients derived from two separate patient collections. 
As each cohort was relatively small it was felt that a study restricted to each cohort 
individually was likely to be underpowered. Subjects from cohort 3a (Chicago Health and 
Aging Project) had a mean age of 78.3 years (standard deviation (s.d.) 7.3) and 37.4% were 
male. Phenotypic data were available for Body Mass Index (BMI) (mean 28.24kg/m2, s.d. 
6.3), smoking status (10.5%) and an individual’s history of stroke (11.6%), cancer (23.8%), 
hypertension (81.0%) ischaemic heart disease (12.6%) or diabetes mellitus (30.3%). Median 
(95th percentile) CRP was 3.38 mg/L (0.18, 27.50). Subjects from Cohort 3b (UCSF Multiple 
Sclerosis Genetics Group) had a mean age of 43.5 years (s.d. 11.3) and 39.5% were male. 
50% had multiple sclerosis but otherwise no other phenotype data were available. Median 
(95th percentile) CRP was 1.79 mg/L (0.13, 16.81). 
 
Median (95th percentile) CRP was 2.52 mg/L (0.24, 22.75) in the combined dataset. A 
Bayesian model choice analysis was used to evaluate the combination of phenotypic 
covariates that best explained the CRP data. The highest posterior probability (P(M/D)) was 
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observed for a model incorporating age and BMI only (P(M/D)=0.98, representing 
overwhelming support). There was little support for models including sex or a diagnosis of 
multiple sclerosis (MS) and the marginal probabilities (Pmarg) for these covariates were small 
(Pmarg=0.002 and Pmarg=0.0003 respectively). There was even less support for other diseases 
including ischaemic heart disease and diabetes mellitus, although given the small numbers of 
affected individuals and the absence of data from cohort 2, this was not surprising. We 
looked for additional cohort specific effects and found strong evidence for no cohort effect 
(age, BMI, sex and MS adjusted: P(M/D)=0.008 for model with cohort effect, P(M/D)=0.992 for 
model with no cohort effect, Bayes factor >100) 
 
5.3: African-American CRP genetic architecture 
 
The 44 SNPs genotyped in the whole dataset are listed in table 5.1. Eight SNPs failed 
genotyping according to predetermined criteria and were excluded from further analysis. Due 
to slightly different SNP pooling constraints at each of the two sites at which the genotyping 
was performed, data were also available for an additional five SNPs for either cohort 3a or 3b 
only (table 5.2). With the exception of SNP rs11585798, which is highlighted in the table, all 
SNPs were in Hardy-Weinburg equilibrium both in the combined cohort and in cohorts 3a 
and 3b separately. Initially haplotypes were inferred both for cohorts 3a and 3b separately, 
which demonstrated that haplotype size, structure and diversity was similar in both cohorts. 
The only notable difference appeared to be a higher frequency of haplotype A2 in cohort 3a 
(15.3% vs. 20.1%) and this was largely accounted for by a lower frequency of the related 
haplotype A8 (2.6% vs. 4.4%). Since haplotypes A2 and A8 were closely related and formed 
part of the same haplotype clade I felt that this small difference in relative haplotype 
frequency was unlikely to impact on the validity of an analysis of the combined cohort. In 
view of this, haplotypes were re-inferred for the combined dataset, incorporating the 
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additional data from SNPs that were genotyped in either cohort 3a or 3b only. Figure 5.1 
demonstrates the position of these genotyped SNPs alongside the inferred haplotype 
structure, while table 5.3 shows the pairwise LD statistics between markers. For both these 
analyses individuals with one or more haplotype of predicted European origin were excluded 
(see Section 5.4.3). It should be noted that none of the additional SNPs typed in only one 
cohort defined a new haplotype or altered overall haplotype structure in any way. It should be 
emphasised that these additional SNPs were not included in the genetic association analysis 
but I felt that their inclusion in the haplotype inference allowed a useful direct comparison 
with data presented in other chapters of this thesis. 
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Table 5.1.  Typed SNPs demonstrating alleles and rare allele frequencies 
rs number Location alleles Rare allele 
frequency (%) 
HWPa missing 
data (%) 
CRP SNPs      
rs11265263§ 5' flank T>G 0.03 0.43 1.1 
rs12728740 5' flank G>T 0.10 0.96 0.9 
rs7553007 5' flank C>T 0.21 0.20 2.5 
rs1341665 5' flank C>T 0.19 0.24 4.8 
rs12079772 5' flank G>T 0.20 0.09 1.3 
rs2027471 5' flank A>T 0.20 0.56 0.7 
rs12084589 5' flank G>T 0.28 0.80 2.9 
rs3093058* 5' flank A>T 0.17 0.94 5.6 
rs3093062 upstream promoter G>A 0.16 0.64 0.9 
rs3091244* upstream promoter C>T>A 0.31(T)/0.25(A) 0.48 1.1 
rs3093063§ upstream promoter C>T 0.03 0.27 0.9 
rs1417938 intron 1 A>T 0.14 0.78 0.0 
rs1800947§ exon 2 (synonymous) G>C 0.02 0.67 0.5 
rs3093066 3'-UTR C>A 0.22 0.26 2.0 
rs1205* 3'-UTR G>A 0.18 0.92 0.9 
rs3093069 3' flank T>G 0.20 0.12 1.6 
rs2808630* 3' flank A>G 0.18 0.57 0.2 
rs3093077* 3' flank T>G 0.29 0.55 0.7 
rs2794520 3' flank G>A 0.21 0.75 0.4 
rs2808628 3' flank C>T 0.21 0.84 1.4 
rs11265259 3' flank A>G 0.06 0.27 8.8 
rs1572970 3' flank C>T 0.35 0.76 1.4 
rs12755606 3' flank G>C 0.10 0.82 0.9 
rs11265257 3' flank G>A 0.20 0.96 0.5 
rs2808626 3' flank C>A 0.08 0.80 0.2 
rs2369146 3' flank C>T 0.37 0.84 5.9 
rs17459580§ 3' flank T>G 0.03 0.43 0.7 
rs1935193 3' flank A>T 0.46 0.76 0.7 
rs10465953§ 3' flank C>T 0.02 0.67 0.2 
rs12749227 3' flank A>G 0.12 0.56 0.7 
rs16842502§ 3' flank G>T 0.04 0.78 15.6 
rs1470515 3' flank G>A 0.25 0.81 1.3 
rs16842493 3' flank T>C 0.20 0.20 0.9 
rs12093699 3' flank C>T 0.33 0.43 2.0 
rs12744244 3' flank G>T 0.05 0.68 1.4 
rs11585798§ 3' flank T>A 0.04 <0.001 2.7 
IL6 SNPs      
rs1554606 5' flank G>T 0.36 0.71 2.6 
rs1800796 5' flank G>C 0.08 0.89 0.2 
rs1800795 5' flank G>C 0.08 0.64 0.9 
rs2069837 intron 2 A>G 0.14 0.16 2.1 
rs2069840 intron 3 C>G 0.15 0.77 0.4 
IL1B SNPs      
rs3917368 3' flank G>A 0.20 0.56 2.3 
rs4849124§ 3' flank A>G 0.02 <0.001 11.0 
rs1143634 exon 5 C>T 0.14 0.09 1.2 
SNPs highlighted in bold have been selected to tag the key CRP haplotype block. SNPs marked with a * have 
been previously associated with serum CRP levels in African-American populations (see table 1.2) 
§excluded from analysis by pre-determined quality control criteria. 
a Hardy-Weinburg probability P-value calculated by χ2 
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Table 5.2. CRP SNPs typed in one cohort onlya 
rs number Location Alleles minor allele 
frequency (%) 
HWPb missing data 
(%) 
Cohort 3a      
rs3093059 5' flank T>C 24.15 0.13 5.7 
rs2794521 5' flank A>G 12.41 0.08 3.9 
rs876538 3' flank G>A 12.18 0.96 2.1 
      
Cohort 3b      
rs1130864 3'-UTR C>T 16.79 0.50 9.2 
rs2808627 3' flank A>T 15.46 0.06 0.3 
 aThese SNPs were incorporated into the inferred haplotype structure as outlined in section 5.3 but were not 
included in the genetic association analysis. 
bHardy-Weinburg probability P-value calculated by χ2 
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Figure 5.1. African-American CRP haplotypes.  
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The position of SNPs relative to CRP is shown in the top section of this diagram. Individuals predicted to carry 
haplotypes of a recent European origin have been excluded from this analysis, although the commonest of these 
haplotypes is shown at the bottom of the diagram for reference. The middle section demonstrates inferred 
haplotype structure with haplotype frequencies are shown to the right of each block. The lower section 
demonstrates the pairwise LD between markers with haplotype blocks defined by the default algorithm of 
Gabriel et al (see methods section 2.4.4). The pairwise LD between any two SNPs is indicated by the colour 
coding of the corresponding square of the LD plot. High LD is indicated by a pink/red colour scheme (the dark 
red squares are linked with a D′ = 1 and a LOD score ≥ 2). Numbers within the squares correspond to the D′ 
score, with 96 representing a D′=0.96 and 44 a D′-0.44 etc. Where squares have no number the D′=1
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5.4. African-American Genetic models 
 
5.4.1: Primary Bayesian Analysis 
 
It can be seen from table 5.3 that a number of SNPs formed highly correlated clusters (a 
consequence of our deliberate policy to select a broad number of SNPs to encompass existing 
reports from different ethnic populations). The presence of highly correlated variables can, 
however, cause problems fitting and interpreting linear models, and may even give the 
impression no variable is associated with the outcome, even if a strong association is seen for 
each variable individually. SNPs that were correlated with r2>0.8 were therefore not 
simultaneously entered into any genetic model choice procedure. For these clusters of 
correlated SNPs a single tagSNP was selected for analysis. SNP rs2808628 was selected to 
tag rs2794520, rs2027471, rs1341665, rs7553007 and rs1205 (mean pairwise r2=0.89); 
rs3093066 to tag rs3093069, rs12079772 and rs16842493 (mean pairwise r2=0.90); and 
rs3093062 to tag rs3093058 (r2=1.00). A particular feature of this model choice analysis was 
that the procedure selected over alternative codings of the triallelic SNP rs3091244, with 
genotypes encoded both for increasing copies of the T allele and the A allele (a model 
selecting both codings would implying that the baseline C allele was most important). This 
analysis was therefore able to objectively resolve inconsistency in the literature over the 
likely functional allele at this SNP. For each genetic analysis age, BMI, sex and MS affection 
were specified as covariates (sex and MS affection were thought important to include despite 
the lack of evidence for an effect). 
 
Table 5.4 shows the results of the Bayesian model choice analysis incorporating all genetic 
markers (but not the 5 SNPs genotyped in only cohort 3a or 3b). Highest posterior probability 
was attached to a model incorporating rs3091244(T) alone, representing overwhelming 
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evidence for a genetic effect (Bayes factor >100 vs. null model (no SNPs)). A secondary 
model incorporating both rs3091244(T) + rs12728740 had a smaller posterior probability. 
Evidence was weak for models using the alternative codings for rs3091244 [rs3091244(A) 
P(M/D)<1x10-4; rs3091244(A) + rs3091244(T) P(M/D)=0.003].  
 
 
Table 5.4. Bayesian models with >5% posterior probability. 
Model P(M/D) Pmarg Effect estimate (95% CI) 
rs3091244(T) 0.14 0.65 0.37 (0.21, 0.53) 
    
rs3091244 (T)+ 
rs12728740 
0.07 
0.65 
0.20 
0.45 (0.29,0.63) 
-0.32(-0.59,-0.05) 
    
null <0.01   
P(M/D) - Posterior probability of the model given the data, Pmarg – Marginal probability associated with each SNP 
in the model, Effect estimate (95% CI) – Effect estimate with 95% credible intervals. 
 
 
5.4.2: Secondary Bayesian Analyses 
 
Additional analyses were performed to explore and substantiate these primary findings. 
Firstly, having identified rs3091244 as the key SNP I investigated whether additive, 
dominant or recessive effects best explained this CRP association. This could be assessed 
directly by allowing the model algorithm to select over SNPs encoded for each of these 
modes of genetic effect. There was substantial evidence in favour of an additive model 
(Bayes factor 5.7 compared with dominant model). Secondly, the model choice analysis was 
re-run having specified only vague priors assumptions regarding the nature of the genetic 
model (see section 2.4.7). These data are presented in table 5.5. The highest posterior 
probability was again observed for an rs3091244(T) alone model, representing strong 
evidence for a genetic effect (Bayes factor 16.5 compared with the null model). The next 
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most likely model contained rs3093062 alone, although the evidence to select the 
rs3091244(T) model over this secondary one was relatively weak (Bayes factor 2.75). No 
other model had a posterior probability >0.05. Notably the posterior probabilities were small 
for models using alternative codings of rs3091244  [rs3091244(A) P(M/D)<1x10-4; 
rs3091244(A) + rs3091244(T) P(M/D)= 7.4x10-4] or for the model incorporating rs3091244(T) 
+ rs3093062 [P(M/D)=0.0017]. Compared with these models the evidence is overwhelmingly 
in favour of rs3091244(T) alone (Bayes factors >100). 
 
 
Table 5.5. Models with > 5% posterior probability (vague priors) 
Model P(M/D) Pmarg Effect estimate (95% CI) 
rs3091244(T) 0.66 0.69 0.38 (0.22,0.54) 
    
rs3093062 0.24 0.26 0.46 (0.25,0.67) 
    
null 0.04   
P(M/D) - Posterior probability of the model given the data, Pmarg – Marginal probability associated with each SNP 
in the model, Effect estimate (95% CI) – Effect estimate with 95% credible intervals. 
 
 
Thirdly, as the total dataset consisted of individuals from two original cohorts I explored the 
possibility of cohort specific effects. Models were re-run with the addition of “cohort” as a 
fixed phenotype effect, but this made negligible difference to the overall results (data not 
shown). Models were also re-run with the inclusion of cohort*genotype interactive terms. All 
the top models selected across these terms included genotype at rs3091244(T) +/- 
rs12728740, however there was some evidence to support a cohort*genotype interaction with 
genotype exerting a smaller effect in cohort 1 (Table 5.6). Consistent with this was an 
analysis of each cohort separately, with rs3091244 being the most significant SNP marginally 
in both cohorts, but with lower significance in cohort 1 (Pmarg = 0.58 in cohort 2 and Pmarg = 
0.10 in cohort 1).  
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Table 5.6 – Models with >5% posterior probability, (with genotype*cohort interactions) 
Model P(M/D) Pmarg Effect estimate (95% CI)* 
rs3091244(T) + 
rs12728740 + 
rs3091244(T)*Cohort + 
rs12728740*Cohort 
0.43 
1.00 
0.85 
0.81 
0.52 
0.58 (0.33, 0.84) 
-0.34 (-0.79, 0.00) 
-0.28 (-0.64, 0.00) 
0.15 (-0.18, 0.72)  
    
rs3091244(T) + 
rs12728740 + 
rs3091244(T)*Cohort  
0.28   
    
rs3091244(T) + 
rs12728740 + 
0.10   
*Effect estimates for each variable averaged over all models and expressed as the effect in cohort 1 (less effect) 
compared with cohort 2. 
 
 
Finally, to ensure that the use of inferred phenotype data was not distorting the results I re-ran 
the analysis while excluding BMI as a covariate (BMI being the only important phenotypic 
effect with substantial missing data). In these models the significance attached to both the key 
SNPs actually increased [for rs3091244(T) Pmarg = 0.90 and for rs12728740 Pmarg = 0.26]. 
The posterior probability of the two top models also increased [rs3091244(T) alone 
P(M/D)=0.19 and for rs3091244(T) + rs12728740 P(M/D)=0.11]. 
 
5.4.3: Haplotype Association Analysis 
 
Admixture analysis predicted 10.8% of the observed haplotypes were of recent European 
origin. 20.2% of the cohort carried one European haplotype and 0.73% carried two (European 
haplotypes being defined as those carrying the minor allele of SNPs rs1255606, rs11585798 
or rs17459580). Figure 5.2 presents a phylogenetic relationship between haplotypes, having 
excluded these individuals.  
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Figure 5.2. Cladogram of phylogenetic relationships between African-American haplotypes.  
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Each haplotype is represented by a circle whose size is roughly proportional to the population frequency. 
Connecting lines are annotated by the SNPs which distinguish one haplotype from another. Small dots along 
these lines represent haplotypes which are no longer observed but can be inferred to have existed in the 
population history. The loop at the centre of the tree represents uncertainty over the clade structure. Either 
rs3091244 (C/T) or rs1935193 may be the first mutational event, and consequently either rs3091244 (C/T) or 
rs1935193 must have mutated twice, from the wild type to the new allele, and then back to the wild type. These 
four explanations may be envisaged by removing any of the four branches labelled *a, *b, *c or *d. 
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As explained in the figure caption there are four possible resolutions of the tree, labelled *a, 
*b, *c or *d. Significant clade-based partitions were only observed for trees *a and *c (those 
where the rs3091244 C/T mutation occurs only once, but the rs1935193 mutation must have 
occurred twice, on different branches of the tree). The most significant partition was defined 
by the rs3091244 C/T mutation, segregating haplotypes A1, A2, A6, A7 and A8 as clade one 
and haplotypes A3, A4, A5 and A9 as clade two (For tree *a, F=8.91, P=0.006). Clade one 
was associated with higher CRP (β=0.312 95%CI 0.146, 0.491), although the overall 
proportion of CRP variance explained by this partition was quite small (5.20%). A weakly 
significant effect was also observed for a partition defined by rs3093062/rs3093058, 
separating haplotype A1 from all the others (for tree *a F=6.385, P=0.038), although this 
effect may be largely due to correlation with the rs3091244 C/T partition. The A1 haplotype 
was associated with higher CRP level than all the rest (β=0.448 95%CI 0.241, 0.655). No 
significant secondary partition was detected, although it should be noted the power to detect 
such an effect is dramatically reduced because of the smaller sample size consequent on the 
primary partition.  
 
5.5 CRP Genetics in an African-American Cohort – Discussion 
 
5.5.1 Summary of Findings 
 
The analysis presented in this chapter attempts to rationalise the multiple CRP SNPs found 
associated with serum basal CRP both in the analyses presented in chapters 3 and 4 and 
elsewhere in the published literature. I aimed to do this using a cohort of African-American 
origin, where the relatively lower LD would potentially narrow the interval over which a 
genetic association is observed, and by employing a formal model choice analysis, backed up 
by a clade-based haplotype analysis to highlight the most likely functional SNP at CRP. 
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This analysis provides good evidence that a single key variant, rs3091244 (or an unmeasured 
variant in strong LD with rs3091244), regulates CRP expression in African Americans. In 
particular the T allele acting in an additive manner explained most of the genetic component 
of variation in serum CRP levels. Consistent with previous reports this effect was modest, 
explaining only 5.20% of CRP variance. 
 
A model incorporating both rs3091244 and rs12728740 should also be kept in consideration. 
The posterior probability of this two-SNP model was smaller than the model with rs3091244 
alone but, because there are more possible two-SNP combinations, the Bayes factor gave it 
slightly more weight (Bayes factor = 6 in favour of the rs3091244 + rs12728740 model). The 
incorporation of rs12728740 into a model is interesting. Although not originally selected to 
tag the admixed European genome it became apparent that 96% of the minor alleles of 
rs12728740 were segregating with haplotypes of inferred European origin. In addition it was 
predicted to lie outside the main CRP haplotype block in our population. By reference to the 
HapMap CEPH panel it is clear that in Europeans rs1272870 is in much stronger LD with the 
main CRP SNPs, in particular with rs1417938 (r2=0.857), which tags the commonest 
European haplotype, and has been associated with higher CRP production in existing 
European studies . This does not downplay the importance of rs3091244 as the key regulator 
of CRP, but it does provide some evidence for a separate functional effect of recent European 
origin. 
 
We failed to demonstrate any role for SNPs at the IL6 and IL1B loci. 
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5.5.2. A comparison with existing studies 
 
Five studies to date have considered the role of CRP genetics on serum basal CRP in the 
African American population. The first concentrated on CRP levels associated with 
rs3091244 and rs3093062 only (Szalai et al 2005c). The authors’ key argument hinged on an 
interaction between rs3091244(T) and rs3093062 such that haplotype 
rs3091244(T)/rs3093062(G) was associated with high CRP, while haplotype 
rs3091244(T)/rs3093062(A), the equivalent to my haplotype A1, was associated with low 
CRP. There are therefore key differences between this paper and our data; we found little 
evidence for a role for both rs3091244 and rs3093062. Furthermore we found the 
rs3093062(A) haplotype to be associated with high rather than low CRP. 
 
Shortly after this initial report, data from the biracial CARDIA cohort was published (Carlson 
et al 2005). Tag SNPs were selected on the basis of sequencing a small number of individuals 
and hence failed to capture all the variation we detected. The authors also analysed both 
European and African ethnicities together (albeit with a “race” term in their regression 
models), which may be a suboptimal approach given the different SNP and haplotype 
frequencies between groups. Two subsequent studies in different cohorts used the same 
combination of SNPs, but with a separate analysis of African American participants 
(Crawford et al 2006; Lange et al 2006b). All these studies generated results broadly similar 
to ours, with haplotypes tagged by the C and T alleles of rs3091244 being associated with 
low and high levels of CRP respectively. Notably haplotype rs3091244(T)/rs3093058(T) 
(equivalent to my haplotype A1) was associated with highest overall CRP expression, as 
suggested by the data presented in this chapter.  
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The final study to report on CRP associations in an African-American cohort did not 
genotype rs3091244, making direct comparison with my data difficult (Lee et al 2009). 
Nonetheless a comparison of the haplotypes reported in this paper with the rs3091244 
carrying haplotypes in my data suggests a similar pattern of haplotype associations with 
higher and lower CRP as I observed. 
 
5.5.3. Key study features and potential limitations 
 
It should be recognised that, once again, the CRP analysis presented in this chapter represents 
a post-hoc analysis of data on a cohort recruited primarily for other purposes. The structure of 
this cohort offers some advantages compared with the cohorts presented in chapters 3 and 4, 
but there also some clear limitations which need to be discussed in detail. 
 
As a population based group of unrelated individuals, the nature of this cohort allowed for a 
dramatic simplification of analysis, using linear regression models with no requirement to 
adjust for the familial clustering of data. Secondly, none of the individuals was recruited 
specifically because they had a disease known to influence CRP expression. Multiple 
sclerosis is not generally associated with elevated inflammatory markers unless in a particular 
active phase of disease (confirmed in our analysis), while the coincidental recruitment of 
individuals with cardiovascular disease simply added to random measurement error 
(Giovannoni et al 2001; Soilu-Hanninen et al 2005). 
 
The two key difficulties arising from the analysis of this group of patients concerned, firstly, 
the use of a cohort derived from an amalgamation of two separate collections of African-
American samples and, secondly, the ethnic background of the cohort itself. The first 
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problem was therefore unique to this study, while the second is a generic problem with all 
studies in admixed populations. 
 
Ideally if cohorts are to be merged for study such as this then it is important that both are 
heterogeneous groups, and that there are no significant differences in their baseline 
phenotypic characteristics. It can be seen from the cohort summary in section 2.1.3 that the 
patients in these two source cohorts differed both in their phenotypic characteristics, and in 
the degree of available phenotypic data. In particular there were considerable age differences 
between the two groups (mean 78.9 years vs. 43.5 years), while there was minimal 
phenotypic information available for the younger group compared with the older. To 
compound the potential problems was the fact that the biological assays were performed at 
different sites and, in the case of the CRP quantification, by different assays (albeit highly 
validated). This is a situation that has been noted as a frequent source of bias in genetic 
studies (Clayton et al 2005). We explored this problem using a “cohort” term as a fixed 
phenotype effect, using genotype*cohort interaction terms and, in addition, we examined 
each cohort separately. These secondary analyses suggested that there were some quantitative 
differences between cohorts in terms of the magnitude of SNP effect, but there were no 
qualitative differences in terms of which were the key SNPs, or SNP combinations, 
associated with CRP levels. The likely explanation for the less extreme SNP effects in cohort 
1 (older individuals) is that with higher disease burden (both documented and occult) a 
greater proportion of the observed CRP level is due to stimulated acute-phase expression 
rather than truly basal CRP. This increase in “background noise” may decrease our power to 
detect CRP associations. Although these secondary analyses provide some reassurance 
regarding the validity of the results presented in this chapter, the construction of the study 
cohort should still be recognised as shortcoming. 
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A further, partly related, problem concerned my use of inferred phenotype data. It is well 
recognised from all the early CRP genetics papers that a significant proportion of the 
variability in basal CRP can be attributed to measureable phenotypic characteristics, notably 
those considered typical cardiovascular disease risk factors such as BMI, blood pressure, 
smoking status etc. Our inability to control for basic phenotypic parameters was notable in 
the analyses presented in chapters 3 and 4, and may reduce the power to detect true genetic 
effects. I was therefore keen to maximise the use of available phenotype data, without 
omitting genetic data from individuals on whom phenotypes were not available: this was 
done through the inference of missing phenotype data. The technical details are provided in 
section 2.5.3 but to summarise in lay terms an inferred phenotypic value is “randomly” 
assigned for each individual where data is missing, such that the overall mean and 
distribution of these inferred values matches that seen for the true measured phenotypic 
values. Theoretically the error introduced by inserting these missing values will be the 
equivalent of random measurement error (see section 3.7.5), and will not introduce 
systematic bias. Clearly, however, the inference process is not perfect, in particular if the 
amount of missing data that is inferred is large. In practice, in the analysis presented here, the 
only key variable for which levels of missing data were great enough for this to be an issue 
was BMI. To assess the potential effect of the inferred data I performed a secondary analysis, 
with the complete omission of BMI.  The greatest significance was still attached to a model 
containing the same key SNPs; in fact the significance of the top models increased somewhat. 
While recognising the limitations of having incomplete BMI data, I have no evidence to 
suggest that if these additional data were available it would change the overall genetic 
conclusions. 
 
The African-American ancestry of the cohort itself also presented issues that require further 
discussion. I have already outlined the problems that can be associated with genetic 
association studies in admixed populations (section1.5.4). At the level of a single locus 
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genetic admixture may also complicate analyses by distorting the inferred haplotype structure 
if the pattern of LD differs between the background and the admixed genetic elements. It may 
therefore affect our ability to detect an indirect genetic association. I did not have the 
resources to type an extensive panel of genome-wide ancestry informative markers; indeed 
such panels were not publically available at the time this project was planned. Instead I 
adopted the approach of at least attempting to highlight CRP haplotypes in this population 
that may have a European origin. Three SNPs were identified from the HapMap dataset that 
were predicted to be monomorphic in African Populations but polymorphic in white 
Europeans. Individuals in the study cohort were defined as having haplotypes of recent 
European origin if they carried the minor allele of one or more of these SNPs. These 
individuals were excluded from further analysis. This is therefore a rather crude approach as 
clearly not all European haplotypes will be identified this way, while other individuals may 
have unjustifiably been excluded from analysis: nonetheless even this approach is likely to be 
more effective than no consideration of admixture at all. 
 
I should also briefly discuss here the clade-based haplotype analysis. A clade-based approach 
offers distinct advantages over a conventional haplotype analysis, particularly in populations 
such as this one, where there are quite a number of haplotypes, each of moderate or low 
frequency, at a particular locus. A conventional analysis would be penalised both in terms of 
power (because of the low numbers of these rarer haplotypes) and in terms of multiple 
hypothesis testing (if the levels of CRP associated with each haplotype is compared with the 
rest). With a cladistic approach, rather than each haplotype being analysed in isolation, 
haplotypes are nested into clades defined by their proposed evolutionary relationship. The 
assumption is that the functional effect of a mutation will be found across the whole clade of 
haplotypes on which it is found. This approach increases the power of an analysis by looking 
at larger groups of haplotypes, and also limits unnecessary multiple comparisons by 
 165 
restricting tests only to evolutionarily relevant clades (Templeton et al 2005). The key 
premise of the haplotype approach is that the genetic locus has evolved by single mutational 
steps, with little or no ancestral recombination, and for a locus such as CRP where LD is 
strong this seems a reasonable assumption to make. Nonetheless it is slightly unsatisfactory 
that the African-American haplotype tree could not be determined with certainty, and that all 
of the possible constructions for this tree depended on one SNP or another mutating from one 
allele to another and then back again as a distinct separate event. As discussed in section 
8.4.4, the mutational rate in the human genome is so low that this would have to be a highly 
improbable event. The question must therefore arise whether the double switching of alleles 
truly occurred, or whether the initial mutation was followed by a recombination event in the 
ancient history of the CRP locus. 
 
5.5.4. Conclusions 
 
The analyses presented in this chapter point to the triallelic promoter variant rs3091244 (or 
an untyped variant in strong LD with it) as being the most important SNP regulating CRP 
expression in this African-American cohort. This was highlighted using both a Bayesian 
model choice approach and a classical haplotype cladistic analysis.  
 
Identifying the genetic determinants of CRP expression remains an important question and 
the use of ethnically diverse cohorts may make this possible.
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CHAPTER 6 
 
GENETICS OF ACUTE-PHASE CRP 
EXPRESSION 
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6.1: The genetics of acute-phase CRP Expression – Study aims 
 
The analyses presented in chapters three to five provide evidence that genetic variation 
influences serum CRP level in the setting of the low-level, basal CRP seen in people without 
active inflammatory disease. However, in the presence of infection or inflammation serum 
CRP levels increase dramatically due to accelerated hepatocellular transcription. The 
quantification of this acute-phase CRP is commonly used in routine clinical practice to 
diagnose and monitor the activity of inflammatory diseases. As I outline in section 1.3.3, very 
few studies address the question of whether genetic variation influences the magnitude of this 
acute-phase CRP rise. Of these studies none are conducted in cohorts of individuals with 
chronically elevated CRP due to persistent inflammatory disease activity. 
 
The aim of the work presented in this chapter was to perform a pilot study to investigate 
whether the genetic variants I have highlighted in chapters three to six are also associated 
with the magnitude of acute-phase serum CRP in patients with rheumatoid arthritis, a well 
characterised inflammatory disease. 
 
6.2: Rheumatoid Arthritis Cohort – Demographics and CRP distribution 
 
As I have already outlined in section 2.1.4. the cohort employed for the analyses presented in 
this chapter consisted of 281 UK white European rheumatoid arthritis cases, unselected for 
their level of disease activity. Mean age was 61.2 (s.d. 12.1) and 79% were female. Median 
serum CRP was 11 mg/L (range, 1 to 195; 5th, 95th percentiles, 5.0, 74.2). The distribution 
of CRP values had a similar positive skew to that observed with basal CRP, although 
obviously right-shifted towards higher CRP values. In view of this, log-transformed CRP was 
again used for all analyses. Non-disease related phenotype data were available and included 
age, sex and smoking status. An initial linear regression model (table 6.1) demonstrated a 
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negative association between age and acute-phase CRP, but no association with age or 
smoking status. 
 
 
Table 6.1. Effect of age sex and smoking on acute-phase CRP 
Variable β-coefficient 
standard 
error 
t P-value 
Age -0.005 0.002 -2.431 0.025 
Sex (Female) -0.103 0.062 -1.648 0.100 
Current smoker 0.033 0.060 0.553 0.581 
 
 
In view of the findings from this preliminary phenotype regression model, age was retained 
as a covariate for all subsequent genetic association analyses. 
 
6.3: CRP genetic architecture. 
 
SNPs were selected for genotyping on this basis that they tagged the main CRP haplotypes 
already defined in the large UK white European cohort presented in chapter 3. Unfortunately, 
due to financial constraints, only SNPs that could be genotyped simultaneously in a single 
pool by the Sequenom method were selected, and this precluded the genotyping of rs3091244 
which I will argue later is the most likely functional SNP in the context of basal CRP 
expression. It can be seen with reference to figure 3.1 that the T allele of rs3091244 tags the 
common white European haplotype H1, and we can therefore infer that effects attributable to 
the H1 haplotype in this analysis would also be shared with the T allele of rs3091244. 
Detailed marker information is presented in table 6.2. Inferred CRP haplotypes are presented 
in table 6.3. 
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Table 6.2. Typed SNPs demonstrating alleles and rare allele frequencies 
rs number SNP Location Rare allele 
frequency 
HWPa missing data 
(%) 
rs2808632 A>C 5' flank 0.28 0.12 0.70 
rs3093059 T>C 5' flank 0.06 0.48 0.00 
rs1800947 G>C exon 2 (synonymous) 0.08 0.43 3.51 
rs1205 G>A 3' flank 0.35 0.48 0.00 
rs876538 A>G 3' flank 0.21 0.31 0.00 
rs11265257 G>A 3' flank 0.39 0.45 0.35 
aHardy-Weinburg probability P-value calculated by χ2 
 
 
All SNPs passed basic quality control checks. As expected, marker frequencies in this white 
European population accorded well with those observed for the UK SLE cohort (refer to 
table 3.2), and the frequency of common inferred CRP haplotypes was also similar (refer to 
figure 3.1). 
 
 
 
Table 6.3.  Frequency of common CRP haplotypes 
Haplotype rs
11
26
52
57
 
rs
87
65
38
 
rs
12
05
 
rs
18
00
94
7 
rs
30
93
05
9 
rs
28
08
63
2 
Frequency 
H1 G G G G T A 0.294 
H2 A G A G T A 0.271 
H3 G A G G T C 0.221 
H4 G G G G C A 0.078 
H5 A G A C T A 0.062 
H6 A G G G T C 0.048 
H7 G G G G T C 0.019 
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6.4: Genetic associations with acute-phase CRP  
 
Each genotyped CRP SNP was evaluated for association with acute-phase serum CRP, 
assuming an additive genetic effect. Table 6.4 demonstrates the regression parameters and 
significance for each SNP. Even with no consideration for the level of disease activity in 
these patients, a significant association was seen between genotype at rs1205 and serum 
acute-phase CRP. This association remained significant after applying a partial Bonferroni 
correction adjusted for the correlation between SNPs (6 tests, mean correlation r=0.416). A 
borderline association was also observed between CRP and SNPs rs11265257 and 
rs1800947. 
 
 
Table 6.4. Single SNP associations with CRP 
Marker β-coefficient 
standard 
error 
t 
Regression* 
P-value 
rs2808632 -0.002 0.041 -0.047 0.963 
rs3093059 0.094 0.067 1.398 0.163 
rs1800947 -0.133 0.062 -2.133 0.034 
rs1205 -0.090 0.037 -2.443 0.015 
rs976538 -0.020 0.042 -0.471 0.638 
rs11265257 -0.083 0.036 -2.310 0.022 
* Unadjusted P-value. An individual P-value <0.018 is required to achieve overall significance at the P=0.05 
level after applying a Bonferroni correction adjusted for the correlation between markers).  
 
 
In a similar manner to the basal CRP analysis in chapter 3, I also modelled the association of 
acute-phase CRP with CRP haplotypes, with reference to the commonest haplotype, H1. 
Haplotypes with a frequency <5% were pooled for this analysis. Full linear regression 
parameters for each of the covariates in the model are presented in table 6.5. Compared with 
H1 the lowest CRP was observed for haplotype H5. Lower levels of serum CRP were also 
seen with haplotype H2, and the highest levels with haplotype H4. 
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Table 6.5. The association of CRP with CRP haplotypes 
Marker β-coefficient 
standard 
error 
t 
Regression* 
P-value 
Intercept 1.470 0.142   
Age -0.004 0.002 -2.061 0.040 
H1 ref    
H2 -0.084 0.045 -1.836 0.068 
H3 -0.061 0.050 -1.221 0.223 
H4 0.044 0.073 0.545 0.568 
H5 -0.183 0.068 -2.744 0.006 
Hx -0.005 0.070 -0.074 0.941 
Haplotypes modelled with reference to haplotype H1. Hx represents pooled rare haplotypes. 
 
 
The magnitude of difference in acute-phase CRP between carriers of different CRP 
haplotypes can be appreciated by using the regression β-coefficient to back-convert the 
transformed CRP data to untransformed values. Using this approach, a representative 40 year 
old patient with rheumatoid arthritis would be predicted to have a geometric mean (95% C.I.) 
CRP of 20.4mg/L (10.7, 38.9) if they carried two H1 haplotypes but only 8.79mg/L (4.7, 
16.0) if they carried two H5 haplotypes. Carriers of two H4 haplotypes would have an even 
higher CRP of 25.00mg/L (12.7, 47.2). This difference between CRP values between H4 and 
H5 can also be demonstrated as significant (P=0.013) although both are of low frequency, 
limiting the power of this comparison. 
 
Having demonstrated an association between CRP genotype and acute-phase serum CRP, I 
extended this analysis to include an adjustment for the level of disease activity. This was 
attempted in two ways, firstly by the use of the incorporation of the ESR, an alternative 
marker of inflammation which is not, itself, known to be directly influenced by the level of 
CRP (or CRP genetic variants), and secondly by the incorporation of the disease activity 
(DAS) score for each individual as a covariate in the regression model. The DAS score is a 
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commonly used composite measure of disease activity in rheumatoid arthritis, and is widely 
used as a marker of clinical improvement in rheumatoid arthritis drug trials (Prevoo et al 
1995). The DAS is calculated by an algorithm which incorporates the tender and swollen 
joint count, a physician and patient “global score” of disease activity, and the ESR, using the 
following equation: 
 
DAS = (0.56 x √tender joint count) + (0.28 x √swollen joint count) + (0.7 x lnESR) + (0.014 x global score) 
 
The DAS therefore incorporates both objective and subjective measures of disease activity. 
My expectation was that, by incorporating either the ESR or the DAS to control for the level 
of underlying inflammatory stimulus driving acute-phase CRP production, it would become 
easier to isolate the effect of genetics on acute-phase serum CRP level.  
 
The association between serum CRP and CRP genotype at each of the typed SNPs was again 
assessed in a linear regression model incorporation age and either ESR or DAS as covariates. 
Results are presented in table 6.6. It can be seen from these analyses that the inclusion of 
ESR as a covariate results in a marked increase in the significance of the association between 
genotype and acute-phase CRP for both rs1205 and rs11265257, while the association with 
the rarer rs1800947 remains borderline. Interestingly, the inclusion of DAS as a covariate has 
much less of an effect on the observed associations, suggesting the DAS quantifies the level 
of acute-phase stimulus less accurately than ESR alone in active rheumatoid arthritis. In all 
analyses the same pattern of SNP effects was seen, with the lowest overall acute-phase CRP 
observed with the minor allele of rs1800947, and the highest acute-phase CRP observed with 
the minor allele of rs3093059. Neither of these individual SNPs reached significance, 
however, presumably because both have low minor allele frequency.  
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Table 6.6. Single SNP associations with CRP, controlling for ESR or DAS 
Marker 
β-
coefficient 
standard 
error 
t 
Regression* 
P-value 
ESR adjusted     
rs2808632 -0.028 0.033 -0.849 0.397 
rs3093059 0.130 0.055 2.356 0.019 
rs1800947 -0.097 0.050 -1.918 0.056 
rs1205 -0.085 0.030 -2.833 0.005 
rs976538 -0.017 0.035 -0.499 0.618 
rs11265257 -0.093 0.029 -3.183 0.002 
DAS adjusted     
rs2808632 -0.017 0.037 -0.446 0.656 
rs3093059 0.094 0.062 1.505 0.134 
rs1800947 -0.093 0.058 -1.609 0.109 
rs1205 -0.084 0.034 -2.489 0.013 
rs976538 -0.034 0.039 0.877 0.381 
rs11265257 -0.079 0.033 -2.380 0.018 
 
 
Table 6.7 and table 6.8 demonstrate the haplotype association when either ESR or DAS are 
included in analysis, with ESR again appearing to provide a better control for the level of 
acute-phase response. 
 
Table 6.7. The association of acute-phase CRP with CRP haplotype, controlling for ESR. 
Marker β-coefficient 
standard 
error 
t 
Regression* 
P-value 
Intercept 1.266 0.116   
ESR 0.009 0.001 11.959 0.005 
Age -0.005 0.002 -3.126 0.002 
H1 ref    
H2 -0.092 0.037 -2.505 0.013 
H3 -0.053 0.040 -1.317 0.189 
H4 0.066 0.059 1.120 0.264 
H5 -0.168 0.055 -3.061 0.002 
Hx -0.101 0.057 -1.766 0.079 
Haplotypes modelled with reference to haplotype H1. Hx represents pooled rare haplotypes. 
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Table 6.8. The association of acute-phase CRP with CRP haplotype, controlling for DAS. 
Marker β-coefficient 
standard 
error 
t 
Regression* 
P-value 
Intercept 1.019 0.147   
DAS 0.103 0.015 7.033 <0.001 
Age -0.004 0.002 -2.157 0.032 
H1 ref    
H2 -0.093 0.042 -2.216 0.028 
H3 -0.074 0.046 -1.598 0.111 
H4 0.026 0.067 0.391 0.696 
H5 -0.160 0.063 -2.542 0.012 
Hx -0.038 0.064 -0.599 0.549 
Haplotypes modelled with reference to haplotype H1. Hx represents pooled rare haplotypes. 
 
 
6.5: The genetics of acute-phase CRP Expression – Discussion  
 
6.5.1: Summary of findings 
 
To my knowledge this study is the first to consider the association between CRP genotype 
and acute-phase serum CRP in the context of a chronic inflammatory disease. The key study 
finding is that it is possible to identify cis-acting genetic variants influencing serum CRP, 
even in this relatively small cohort of individuals. Interestingly, these associations can be 
demonstrated even when making no attempt to adjust for the underlying level of 
inflammatory stimulus, although there is a clear increase in the level of significance when 
such an adjustment is made through the inclusion of ESR as a covariate. The magnitude of 
genetic effect on acute-phase CRP appears considerable, with a threefold difference in 
geometric mean CRP predicted for carriers of two “lowest-producing” haplotypes (H5) 
compared with two “highest-producing” haplotypes (H4). 
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6.5.2: A comparison with existing studies 
 
As I have already outlined in section 1.3.3, only a limited number of studies have looked for 
genetic associations within the acute-phase CRP range. The study of D’Aiuto et al, in patients 
with periodontitis, suggested carriers of the minor allele of rs1130864 had higher acute-phase 
CRP levels (D'Aiuto et al 2005). The genetic data I present in chapter 3 demonstrates that 
rs1130864 tags the commonest CRP haplotype (which I have termed H1). In this acute-phase 
study I did not directly genotype rs1130864, or any equivalent SNP, which is unique to H1, 
although I could use alternative SNPs to infer H1 haplotypes. In my haplotype analysis (table 
6.5, table 6.7 and table 6.8) I observed a similar pattern, with the H1 haplotype generally 
associated with higher levels of CRP and significantly higher than the H5 haplotype. My 
findings are also similar to those found by Suk et al, looking at the acute-phase CRP 
occurring after myocardial infarction (Suk et al 2006). They found lowest CRP levels in 
carriers of the rare alleles of rs1800947 and rs1205 and a haplotype containing both of these 
(equivalent to my haplotype H5). Highest CRP was observed in carriers of the A allele of 
rs3091244 (which is in strong LD with the rs1130864 variant identified by D’Aiuto) and the 
rare allele of rs3093059, with dramatically higher levels in individuals homozygous for these 
variants. Finally, the recent study by Perry et al also found lowest levels of acute-phase CRP 
rise following coronary artery bypass surgery in carriers of the rare allele of rs1800947 (Perry 
et al 2009). It is also notable that the general pattern of association between higher and lower 
serum CRP and specific genetic variants would appear to be preserved in comparison with 
my earlier studies of basal CRP.  
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6.4.3: Key study features and potential limitations    
 
It is important to recognise that the analysis presented in this chapter was intended as a pilot 
study to test the concept that we can demonstrate genetic associations with acute-phase CRP. 
The study was therefore limited in its scope. The cohort of 281 individuals is relatively small 
for a genetic study although, without good existing data to suggest what magnitude of genetic 
effect we would expect to observe in this setting, it was difficult to perform a meaningful 
power calculation. Current basal CRP studies suggest individual CRP variants have a 
relatively modest effect on serum CRP (see section 8.4.6). Whether or not this would prove to 
be the case for acute-phase CRP was uncertain, although the report of Suk et al suggested 
genetic effects on acute-phase CRP could be considerable. A relatively small number of 
SNPs were genotyped, although previous work suggested that these were adequate to capture 
common CRP variation in a white European population. I did not genotype SNPs at any 
trans-acting loci although this would clearly be interesting in future studies, particularly 
variants within acute-phase cytokine genes. Although the MALDI-TOF genotyping used for 
all the studies presented in this thesis appears to generate consistent results it could be argued 
that, in population data at least, a check of genotyping accuracy should be made by duplicate 
genotyping a proportion of individuals to assess for any inter-assay errors. This was not done 
in this study. 
 
A genetic study in a cohort of individuals with overtly “acute-phase” levels of CRP is always 
going to face methodological problems due to the considerable amount of random error 
introduced into an analysis by the inability to accurately quantify the level of inflammatory 
stimulus that drives the rise in serum CRP. Our ability to determine the component of CRP 
variability that is due to CRP genetics may therefore be swamped by the variability in CRP 
levels due to unquantified driving stimuli. There are a number of potential study designs to 
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help limit this problem. One approach would be to quantify the magnitude of CRP rise at a 
set time following a standardised inflammatory stimulus. Using this approach in healthy 
volunteers would be ethically inappropriate because the degree of tissue damage required to 
induce a notable acute-phase response would be relatively large. Alternatively one could 
consider the CRP rise following a standard surgical procedure (the approach taken by Perry et 
al 2009) although it would appear difficult to accurately quantify the nature and magnitude of 
tissue trauma from one operation to another. The approach of quantifying CRP after the acute 
inflammatory stimulus of a myocardial infarction has yielded some positive findings as we 
have seen above (Suk et al 2005). It would have been interesting to see how the significance 
of the genetic association changed if these studies were able to additionally quantify the 
degree of myocardial damage, perhaps by including in their regression models additional 
covariate terms for the magnitude of creatinine kinase rise (an enzyme released in myocardial 
necrosis), or perhaps an echocardiographic quantification of infarct size.  
 
A second approach would be to control for the degree of inflammatory stimulus through the 
measurement of an alternative acute-phase reactant. Ideally we would probably use a single 
biochemical maker such as serum amyloid A or interleukin-6, whose levels also reflect the 
degree of inflammatory response but are not directly influenced by CRP genetic variation. 
The level of these alternative markers could then be included as a covariate in the regression 
model of genetic variation on serum CRP levels. This may not provide the perfect adjustment 
because the time course and dynamic range of elevation of these proteins may vary compared 
with CRP. Caution would also need to be applied, particularly when considering trans-acting 
genetic effects, as these may be shared across the spectrum of acute-phase proteins, and 
hence inclusion of a second acute-phase protein variable may act as a source of confounding. 
Despite these caveats it is likely this approach would offer a significant advantage over the 
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alternative of no control at all and may well increase the power of such studies to identify cis-
acting CRP effects.  
 
In the study presented in this chapter we did not have available data for a single, alternative 
acute-phase reagent, but we did have concurrent erythrocyte sedimentation rate (ESR) data. It 
was formally recognised in the early years of the twentieth century that inflammatory or 
infectious states influenced rate of sedimentation of red blood cells (Westergren 1921). The 
factors contributing to the rise in ESR in inflammatory states are complex and poorly 
understood. It appears primarily related to changes in the intrinsic property of the red cell 
membrane, notably the membrane electrical potential, which influences its “stickiness” and 
tendency to clump together in rouleaux. To a lesser extent ESR may be influenced by the 
concentration of large plasma proteins such as immunoglobulin and fibrinogen, but there is 
no evidence that the concentration of small proteins such as CRP has any influence (Ropes et 
al 1939; Zlonis 1993). Although the biology may remain unclear, the use of ESR fulfils the 
requirement for an alternative marker of acute-phase response to include as a covariate in the 
CRP analysis. 
 
The final approach, also adopted in the study presented here, is to consider the level of acute-
phase serum CRP measured in individuals with chronic active inflammation, and to quantify 
the magnitude of the inflammatory stimulus through the use of a well validated clinical 
disease activity index that does not rely on serum CRP level itself as a scoring parameter. 
Rheumatoid arthritis is one such condition, with disease activity commonly quantified 
through the DAS-28 score. There are also drawbacks to this approach. Firstly, as I discussed 
when considering the inclusion of a specific alternative marker of acute-phase response, we 
could argue that shared genetic influences may determine both the level of acute-phase CRP 
and one or more of the parameters that influence the DAS score. The traditional DAS score 
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incorporates ESR as its objective measure of inflammation and, as stated above there is no 
evidence to suggest CRP concentration directly influences ESR. I would therefore think it 
highly unlikely that this is a source of confounding when looking at CRP cis-effects. 
 
The current data suggest that DAS score may actually be a rather poor summary of the level 
of acute-phase inflammatory stimulus, and not as good as simply measuring ESR on its own. 
Indeed it has previously been observed that the correlation between DAS score and markers 
of inflammation is poor (Keenan et al 2008). There are a number of possible reasons for this. 
Firstly the DAS makes no distinction between very large joints such as the knee or very small 
joints such as the 5th proximal interphalangeal joint, when the count of swollen and tender 
joints is made. Secondly, the inclusion in the score of “global assessments” by patient and 
physician introduce a subjective element that may be influenced by general factors such as 
fatigue, which do not specifically reflect the degree of overall inflammatory stimulus. If the 
relationship between DAS score and acute-phase response is poor then it is not going to fulfil 
the requirement of reducing random noise due to varying levels of inflammatory stimulus. 
The observation in the data presented here was that it was easier to detect CRP genetic effects 
by including ESR as a covariate compared with DAS as a whole, suggesting DAS is a less 
effective measure of inflammation per se in rheumatoid arthritis. One could envisage a 
scoring system that might fulfil this role better (for example one could perhaps count the 
swollen of tender joints and multiply these scores by a factor representing joint surface area), 
but since these are not in standard clinical usage they would require prospective collection in 
a new cohort. 
 
In section 3.7.5 I discussed, in relation to the study of basal CRP the problem of intra-
individual variation in CRP concentration and how this may limit our power to detect true 
genetic associations. For basal CRP it is likely this effect is small with available evidence 
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suggesting remarkable longitudinal stability in basal CRP. For a study of acute-phase CRP in 
a chronic setting it is likely that this intra-individual variation will be large due to underlying 
disease activity, unless highly accurate correction for the level of background inflammatory 
stimulus can be made and incorporated into the model. In this setting it is likely that a single 
snap-shot CRP level is going to be associated with considerable measurement error. A much 
better approach would be to consider longitudinal measurements of CRP each study 
participant over a period of time; in this way intra-individual variation can be quantified and 
accounted for in the analysis. 
 
Given the numerous difficulties discussed above, it is perhaps surprising that I was able to 
identify any genetic effect at all, given that my cohort was small and only a single CRP 
measurement per person was recorded. The consistency of genetic effect between this study, 
the limited number of other acute-phase studies, and even the basal CRP studies, makes it 
likely that the associations that I observed are true. It is possible that, in the context of acute-
phase CRP, the genetic effect is actually quite strong and demonstrable even in a study 
affected by large amounts of random measurement error. There are, however, enough 
positive findings from this study to warrant a more extensive analysis along similar lines. 
Certainly a number of well validated rheumatoid arthritis cohorts have been collected by 
investigators around the world which should offer improvements in terms of cohort size and 
longitudinal data. As I will discuss further in chapter 8, there are good reasons why an 
understanding of acute-phase CRP genetics should be a priority for further study. 
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CHAPTER 7 
 
COMPLEMENT C3 GENETICS IN UK SLE 
FAMILIES  
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7.1: Complement C3 genetics in UK SLE Families – Study Aims 
 
The key physiological roles played by the C3 component of complement and the existing 
evidence of genetic association with diseases such as bronchial asthma and age relate macular 
degeneration has been reviewed in sections 1.2 and 1.4. Only a single study has reported an 
association between C3 genotype and serum C3 levels; in a cohort of 87 Japanese individuals 
with SLE (Miyagawa et al 2008). These authors also reported an association between C3 
variation and SLE itself. Given the frequency with which false-positive genetic associations 
can be observed, these data can not be considered conclusive until replicated further.  
 
The primary aim of the work presented in this chapter was therefore to establish the 
heritability of serum C3 and, if shown to be a heritable trait, to delineate cis-acting genetic 
variants determining C3 expression. Finally we aimed to assess the association between C3 
genotype and SLE. The data presented in this chapter may be found in published form 
(Hunnangkul et al 2008; Rhodes et al 2009). 
 
7.2: Serum C3 – Distribution and Heritability 
 
7.2.1: C3 heritability – Regression Estimate 
 
Serum C3 had already been quantified in individuals from the first 103 families of cohort 1, 
by previous members of my supervisor’s laboratory. Serum C3 data from the parents and 
their unaffected offspring from this cohort was used to calculate a simple regression based 
estimate of heritability as outlined in section 2.5.2. This approach gave a raw heritability 
estimate of 40.2% (h2=0.402; 95%CI 15.9, 64.4). Adjusting for age gave a revised heritability 
estimate of 38.7% (h2=0.387; 95%CI 13.5, 63.9; P=0.003). 
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7.2.2: C3 heritability – Replication using Bayesian Methodology 
 
In order to replicate this heritability estimate, serum C3 was quantified on a further 1371 
individuals from 393 UK white European families from Cohort 1. This, therefore, represented 
an entirely independent cohort from that used for the regression estimate of heritability 
presented above. The mean age of these individuals was 53.9 (standard deviation 16.5) and 
33.7% were male. The mean serum C3 was 1054 mg/L (range 294 to 1564 mg/L). Table 7.1 
demonstrates the influence of age, sex and SLE affection on serum C3, assessed using both 
maximum likelihood and Bayesian methodologies. As expected, serum C3 was significantly 
lower in SLE probands; it was also lower in male participants and increased marginally with 
age.  
 
 
Table 7.1 Effect of age, sex and SLE affection on serum C3 
 Maximum Likelihood Analysis  Bayesian Analysis 
 β 
95% confidence 
interval 
P-value  β 
95% credible 
interval 
Age* 0.088 0.029, 0.147 0.003  0.038 -0.042, 0.119 
Female Sex 0.132 0.024 0.017  0.158 0.011, 0.303 
SLE  -0.477 -0.602, -0.351 <0.001  -0.525 -0.685, -0.362 
*Standardised age. Coefficient is for a change of one standard deviation (16.5 years) from the mean age of 53.9 
years) 
 
 
In a Bayesian variance components model of serum C3, adjusted for SLE affection, age and 
sex, C3 heritability was estimated to be 39.6% (h2 = 0.396; 95% Credible Interval 0.250, 
0.565). This estimate of heritability was robust to a range of prior assumptions in the model, 
 184 
and did not change by an appreciable extent when alternative prior distributions were 
specified as outlined in section 2.5.2. 
 
7.3: C3 Genetic Architecture 
 
All the 14 genotyped C3 tagSNPs passed quality control checks. Detailed marker information 
is presented in table 7.2.  
 
 
Table 7.2. Typed SNPs demonstrating alleles and rare allele frequencies 
rs number SNP Location 
Rare allele 
frequency 
HWP* 
missing data 
(%) 
rs2230199 C>G exon 3 (non-synonymous) 0.22 0.02 1.2 
rs11672613 A>G intron 17 0.41 0.36 1.9 
rs11569450 C>G intron 18 0.09 0.96 1.3 
rs423490 C>A exon 21 (synonymous) 0.26 0.56 1.5 
rs2287846 C>G intron 22 0.40 0.97 2.4 
rs3745568 A>C intron 27 0.12 0.79 0.9 
rs11569520 T>C intron 27 0.14 0.13 1.1 
rs344540 C>T intron 27 0.37 0.23 1.5 
rs344542 T>C intron 27 0.37 0.25 1.3 
rs7257062 G>A intron 29 0.46 0.70 1.1 
rs344550 C>G intron 33 0.36 0.99 1.2 
rs7951 C>T exon 35 (synonymous) 0.08 0.72 1.2 
rs2277984 A>G intron 36 0.50 0.92 1.1 
rs344555 G>A intron 37 0.23 0.52 1.2 
*Hardy-Weinburg probability calculated by χ2 
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Table 7.3 demonstrates the pairwise linkage disequilibrium between markers while Figure 
7.1 illustrates the haplotype structure calculated using Haploview. With the exception of 
rs344540 and rs344542 that were in tight linkage disequilibrium (r2 = 0.998), my data 
confirmed the relatively low level of linkage disequilibrium across C3 demonstrated in the 
HapMAP CEPH population. 
 
 
Table 7.3. Pairwise linkage disequilibrium between C3 SNPs, calculated from the unrelated 
parents. 
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rs2230199 X 0.017 0.017 0.009 0.003 0.036 0.029 0.002 0.002 0.004 0.049 0.011 0.009 0.028
rs11672613 0.204 X 0.151 0.233 0.455 0.095 0.067 0.152 0.152 0.430 0.002 0.03 0.003 0.054
rs11569450 0.756 1.000 X 0.036 0.069 0.014 0.017 0.022 0.023 0.069 0.013 0.009 0.001 0.031
rs423490 0.103 0.992 1.000 X 0.519 0.190 0.038 0.000 0.000 0.002 0.031 0.000 0.017 0.000
rs2287846 0.128 0.992 1.000 1.000 X 0.203 0.177 0.010 0.010 0.078 0.001 0.031 0.002 0.013
rs3745568 0.267 1.000 1.000 0.686 0.990 X 0.022 0.240 0.240 0.162 0.001 0.053 0.002 0.031
rs11569520 0.811 0.793 1.000 0.834 0.879 1.000 X 0.091 0.091 0.176 0.026 0.000 0.039 0.018
rs344540 0.059 0.621 0.352 0.015 0.158 1.000 1.000 X 0.998 0.337 0.000 0.010 0.001 0.009
rs344542 0.058 0.621 0.356 0.015 0.156 1.000 1.000 1.000 X 0.336 0.000 0.010 0.001 0.008
rs7257062 0.139 0.871 0.894 0.091 0.311 0.989 0.971 0.695 0.694 X 0.046 0.026 0.043 0.096
rs344550 0.312 0.053 0.262 0.224 0.042 0.128 0.545 0.010 0.011 0.316 X 0.048 0.556 0.540
rs7951 0.688 0.716 1.000 0.027 0.498 0.290 0.018 0.263 0.258 0.502 1.000 X 0.087 0.026
rs2277984 0.182 0.064 0.078 0.222 0.052 0.115 0.499 0.033 0.033 0.229 1.000 1.000 X 0.308
rs344555 0.174 0.349 0.304 0.020 0.257 0.862 0.609 0.223 0.220 0.615 0.996 1.000 1.000 X 
* r2 values presented at the top right and D’ values at the bottom left. 
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Figure 7.1. C3 haplotype structure.  
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Haplotype construction across C3 demonstrating the position of the genotyped SNPs relative to C3.  There are 
three haplotype blocks across the gene, haplotype frequencies shown to the right of each haplotype.  Thick line 
connect blocks occurring together in >10% of chromosomes and thin lines if in >1% of chromosomes. Inter-
block D' scores are shown below the gaps between haplotype blocks. SNP rs2230199 falls upstream of 
haplotype block 1, while rs7257062 is located between blocks 1 and 2. The lower section demonstrates the 
pairwise LD between markers with haplotype blocks defined by the default algorithm of Gabriel et al (see 
methods section 2.4.4). The pairwise LD between any two SNPs is indicated by the colour coding of the 
corresponding square of the LD plot. High LD is indicated by a pink/red colour scheme (the dark red squares are 
linked with a D′ = 1 and a LOD score ≥ 2). Numbers within the squares correspond to the D′ score, with 96 
representing a D′=0.96 and 44 a D′-0.44 etc. Where squares have no number the D′=1 
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7.4: Genetic associations with serum C3 
 
7.4.1: Association of C3 SNPs with basal C3 
 
It was noted that rs344540 and rs344542 were in tight linkage disequilibrium (r2 = 0.998) so 
rs344542 was dropped from further analysis, leaving 13 SNPs for association testing. Each 
C3 SNP was evaluated for association with serum C3 level using both Bayesian and 
maximum likelihood multiple linear regression models, incorporating age, sex and SLE 
affection as covariates.  Significant associations are shown in Table 7.4. Strong association 
was observed between serum C3 levels and SNP rs344555, with additional weaker 
associations also seen with SNPs rs2277984, rs7951 and rs423490. In particular the rare 
allele of rs344555 was associated with higher serum C3 levels in both maximum likelihood 
and Bayesian models. This association remained significant at P<0.05 even after applying a 
Bonferroni correction adjusted for the correlation between makers (13 SNPs mean r=0.2704). 
A global Chi-Square of association for all SNPs was also significant (P=0.026).  
 
 
Table 7.4. Significant C3 SNP associations with serum C3. 
 Maximum Likelihood Analysis  Bayesian Analysis 
 
β 
95% confidence 
interval 
P-value  β 
95% credible 
interval 
rs423490 0.121 -0.004, 0.246 0.058  0.133 0.002, 0.262 
rs7951 -0.220 -0.404, -0.037 0.019  -0.211 -0.402, -0.024 
rs2277984 -0.114 -0.216, -0.012 0.028  -0.111 -0.215, -0.005 
rs344555 0.172 0.048, 0.296 0.007  0.157 0.028, 0.290 
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By reference to Figure 7.1 it can be seen that rs344555, the key SNP associated with serum 
C3 level, forms part of a four SNP haplotype encompassing the 3' end of C3 downstream of 
intron 29. Also incorporated in this haplotype are rs7951 and rs2277984, both of which 
showed weak association with serum C3, with the rare alleles associated with lower serum 
C3. 
 
7.4.2: Trans-acting genetic effects 
 
In addition to analysing the association between serum C3 and C3 genotype, a post-hoc 
association analysis was performed using existing genotype data for IL6 and IL1B (presented 
in section 3.4.2 and table 3.2). No association was observed for the IL6 genotypes, but a 
borderline association was seen between serum C3 and two SNPs in IL1B, rs7596461 and 
rs1143634 (Table 7.5.).  
 
 
Table 7.5. Single IL1B SNP associations with serum C3. 
 Maximum Likelihood Analysis Bayesian Analysis 
 β S.E. 
95% confidence 
interval 
P-value β 95% credible interval 
rs4849124 0.055 0.060 -0.063, 0.172 0.363 0.070 -0.055, 0.195 
rs7596461 -0.168 0.096 -0.355, 0.019 0.079 -0.134 -0.331, 0.060 
rs1143634 0.113 0.065 -0.014, 0.239 0.082 0.133 -0.001, 0.267 
rs16944 -0.006 0.058 -0.119, 0.107 0.922 -0.103 -0.206, 0.001 
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7.5: C3 Genetic Association with SLE 
 
7.5.1: Analysis of genotyped SNPs 
 
I performed a family-based analysis of the association of C3 genotype with SLE using 
TRANSMIT, evaluating each SNP in turn for an association with SLE. A significant 
association was only observed with SNP rs3745568. Of 569 families with transmissions to 
affected offspring observed, there were 113 observed, compared with 134.58 expected 
transmissions of the rare allele to affected offspring (χ2 (1 d.f.) = 8.026, P=0.0046). This 
corresponded to P=0.030 after correcting for multiple hypothesis testing as above. No other 
markers approached even borderline significance with SLE. 
 
7.5.2: Refinement and replication of SLE association 
 
To evaluate the robustness of the association of rs3745568 with SLE we performed two 
additional analyses. Firstly, additional SNP genotypes were imputed across the C3 locus and 
then tested for association with SLE. Secondly I aimed to replicate this association in an 
independent study cohort. 
 
Using the pattern of linkage disequilibrium observed in the HapMAP CEPH panel, combined 
with the genotype data from the 14 SNPs typed in this UK SLE family cohort, the genotype 
of an additional 287 HapMAP SNPs spanning a 300kb interval incorporating the C3 locus 
(Chromosome 16: 6503308 – 6799220) was imputed as described in section 2.5.3. None of 
the imputed SNPs were associated with SLE (P>0.1), although rs3745568 remained 
significant (P=0.0045) with the C allele under-transmitted. 
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I aimed to replicate the association between rs3745568 and SLE in an additional independent 
cohort. I did this using existing genotype data available from the SLEGEN case-control 
genome wide association study (Harley et al 2008). Although rs3745568 was included 
among the SNPs on the Illumina 300 chip employed in this study, the assay unfortunately 
performed poorly, with successful genotyping in <40% of the study population. In an attempt 
to make some use of this data, C3 SNPs that were successfully genotyped in this SLEGEN 
GWA study were used to impute genotype at rs3745568, along with the 287 additional 
HapMAP SNPs discussed above. Using the raw, unimputed data (<40% genotyping) no 
significant association with SLE was seen (P=0.135 for an additive model). Even after data 
imputation to boost genotyping at rs3745568 to 769 cases and 3514 controls (P=0.350 for an 
additive model), no significant association was observed 
 
7.6: Complement C3 Genetics in UK SLE Families – Discussion 
 
7.6.1: Summary of findings 
 
The data presented in this chapter demonstrate that serum C3 is a heritable trait and, to the 
best of my knowledge, this is the only existing study to quantify C3 heritability. I 
demonstrate heritability initially in a cohort of healthy individuals (h2=0.387), and replicate 
this in a larger, independent cohort of SLE families, using alternative statistical methodology 
(h2=0.396). Using a tagSNP approach to genotyping, to ensure all common genetic variation 
at C3 was captured, I identify SNPs associated with both serum C3 level (rs344555) and with 
SLE (rs3745568). 
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7.6.2: Associations with serum C3 - discussion 
 
The strongest association with serum C3 was observed for SNP rs344555, located in intron 
37. The rare allele of this SNP was associated with higher level of serum C3, even after 
correction for the testing of multiple hypotheses. Haplotype analysis demonstrated that 
rs344555 was located in a distinct haplotype block, along with rs2277984, rs7951 and 
rs344550. The rare alleles of rs344555, rs2277984 and rs7951 each defined a distinct 
haplotype, with two additional haplotypes delineated by the rare allele of rs344550. SNP 
rs344555 therefore defined a haplotype associated with higher serum C3. SNPs rs2277984 
and rs7951, and the haplotypes they defined, were associated with lower serum C3, albeit 
with lower levels of significance. 
 
As I have discussed elsewhere, while the tagSNP approach to study design maximises the 
chance of identifying an indirect genetic association, it leaves unresolved the identity of the 
true functional variant, which may not have been genotyped, or even discovered. By 
reference to the location of rs344555 and the pattern of linkage disequilibrium observed both 
in our own data and in data from the HapMap CEPH panel it is possible, however, to make 
some broad statements about where the functional variant is likely to lie. There is very weak 
LD between the key variant rs344555 and SNPs in the C3 promoter or proximal coding 
sequence. There is moderate LD between rs344555 and sporadic SNPs in the downstream 
gene, TNFSF14, but it would seem unlikely that these SNPs alter serum C3 levels. Most 
likely, therefore, is that serum C3 is influenced by genetic variation in the distal end of C3. 
Since no amino-acid coding changes have been identified in this region, it is possible that the 
functional variant alters serum C3 levels by an effect on the stability or trafficking of C3 
mRNA. 
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Interestingly, the incorporation of rs344555 genotype as a covariate in our variance 
components model resulted in only a negligible change to the overall heritability estimate, 
suggesting that the key genetic effects accounting for C3 variability arise from trans-acting 
loci and currently remain unaccounted for. Since serum C3 level in healthy individuals will 
be determined both by the rate of C3 synthesis, and by the rate of low-level complement 
turnover, it is possible that variation in a large number of genes may account for the observed 
heritability. These may include acute-phase cytokine genes, early complement component 
genes or complement regulatory factor genes. We were unable to identify a clear association 
between serum C3 and the well described IL6 and IL1B variants we tested, although it should 
be noted that these SNPs do not constitute a comprehensive screen of either of these loci. 
 
7.6.3: Associations with SLE - discussion 
 
A different variant accounted for the effect on SLE susceptibility. The disease associated 
SNP, rs3745568, was located in a haplotype block encompassing the central region of C3 
(between intron 22 and intron 29). The imputation analysis failed to identify a stronger 
disease association in an extensive array of 287 known SNPs in and around C3, while no 
association was observed with the directly genotyped rs2230199, encoding the C3F/C3S 
structural variant. Interestingly, no association was observed between rs3745568 and serum 
C3, while there is no evidence from the HapMap CEPH panel of longer range LD between 
this SNP and the downstream gene TNFSF14. The mechanism underlying the association 
between this SNP (or variants in LD with it) and SLE therefore remains uncertain but, from 
our data, it does not appear to be a result of genetically determined alteration in serum C3 
level. 
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7.6.4: A comparison with existing studies 
 
To my knowledge this is the only existing study to report the heritability of serum C3. It is 
interesting to note, however, that our estimate of 39.6% heritability for serum C3 is of a 
similar magnitude to that reported for other acute phase plasma proteins, including C-reactive 
protein and fibrinogen (de Lange M. et al 2001; Fox et al 2008; Rhodes et al 2008a). 
 
Only one other study, in a Japanese population, has reported an association between C3 
polymorphisms and both serum C3 and SLE, and there are some notable differences in the 
genetic associations identified between my study and this one (Miyagawa et al 2008). The 
key SLE associated SNP in the Japanese population was rs7951, which we tested but found 
no disease association. Conversely we observed an SLE association with rs3745568, which 
was not tested in the Japanese study, but with reference to the HapMap Japanese panel does 
not appear to be in strong LD with either rs7951 or any other variant typed by these authors. 
One explanation for this difference is that neither study has typed the true functional variant, 
and that differing patterns of LD in these ethnically diverse populations explains differences 
in observed indirect associations. Alternatively our study simply lacked power to identify an 
association with rs7951, which was present at slightly lower frequency in our white European 
population. Assuming an disease odds ratio of 1.40 as determined in the Japanese study, a 
power calculation suggests a family based association study of our size would have only 30% 
power to detect an association at P<0.01. It also possible, that all present findings, although 
plausible, may be false positives, and future larger studies, with detailed fine mapping may 
help inform on this issue. 
 
In contrast to the disease associations a similar association was observed between C3 variants 
and serum C3 in the two populations. In the Japanese population an association between 
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rs7951 and serum C3 was observed in a cohort of 87 SLE probands, leading to the hypothesis 
that disease susceptibility is increased by a variant that also leads to lower serum C3 levels. 
Like this study we also observed a weak association with rs7951, although our key 
association was seen with rs344555, which was not typed in the Japanese study. Our data 
suggest that, in a white European population, distinct high and low C3 associated haplotypes 
within this block are tagged by rs344555 and rs7951 respectively. By reference to the 
HapMap Japanese population it appears the LD structure in this region of the gene is rather 
different from ours, with no notable LD between rs7951 and rs344555. Once again it is likely 
that the true functional SNP remains to be identified, but both studies highlight the 3' end of 
the gene as its most likely location. 
 
7.6.5: Key study features and potential limitations 
 
This study is the first to comprehensively map genetic variation across C3, and to look for 
association with both serum C3 levels and SLE. The family based-study design offers 
advantages in terms of control for bias due to population stratification, as outlined in section 
1.5.4. The haplotype tagging strategy I employed should ensure that all common genetic 
variation at C3 has been captured. A disadvantage of this approach, however, is that there 
remains uncertainty over the identity of truly functional alleles (which may not have been 
genotyped, or even identified). I attempted to address this issue through the use of a SNP 
imputation approach, utilising the extensive genotype data freely available from HapMAP. A 
standard maximum likelihood approach was taken for the association of genotype with 
disease, but for the heritability estimates and association of genotype with serum C3 an 
additional Bayesian model was employed. Bayesian analyses are increasingly popular in 
genetic studies and offer advantages in allowing us to test the sensitivity of our results for 
different prior assumptions regarding, for example, the within family correlation of serum 
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C3. The Sequenom iPLEX Gold methodology employed for the genotyping presented in this 
chapter appeared to produce high quality genotyping, with minimal missing data. In addition 
the family-based study design allowed for the checking of assigned genotypes for Mendelian 
errors, allowing an additional level of quality control. I am therefore confident the study 
design and genotyping were as optimal as possible. 
 
I am also confident that the Radial Immunodiffusion assays provided an accurate assessment 
of serum C3 concentration at the time the assay was performed. Although this is a relatively 
old and labour intensive technique, and has been replaced in standard clinical usage by newer 
automated assays such as nephelometry, existing published comparisons suggest it is no less 
accurate in terms of quantifying plasma protein level (Bouzek & Mancal 1989; Guiguet et al 
1983). Any assay is associated with random measurement error, but our use of control sera 
confirmed that the plate to plate variation in readings did not deviate significantly from the 
normal distribution expected due to this random error (Kologorov-Smirnov P=0.20 – see 
section 2.3.2). While this random, undifferential, error may reduce the power of a study to 
demonstrate a genetic effect, it should not alter the interpretation of a statistically significant 
association if one is still demonstrated. It should also be noted that anti-C3 antibodies may 
differ in their specificity for antigenic determinants on C3, including a difference in their 
ability to recognise C3 breakdown products, emphasising the importance of assay 
standardisation (Spath & Gabl 1976; Vladutiu & Winiarski 1976). The radial 
immunodiffusion assay technique and antibody reagents I employed were well standardised 
within our laboratory, and were indeed used for many years to quantify C3 for the clinical 
service at the Hammersmith Hospital. 
 
While I am confident that the C3 assay provided a reasonably accurate and reproducible 
quantification of serum C3 at the time the assay was performed, it is important to recognise 
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that this may not reflect the serum C3 level at the time the blood sample was collected. There 
is published evidence to suggest that the sample storage conditions prior to C3 quantification 
influence the measured value; in this respect C3 would appear to be a less robust molecule 
than CRP. For example there is there is evidence that intact C3 degrades in serum stored at 
room temperature (Davis et al 1972; Sinosich et al 1982). This is not, however, a universal 
finding (Sjoholm 1975). Given that many of the serum samples used in this study arrived 
through the post at room temperature, it is clear that this has the potential to introduce quite 
considerable error into the quantification of C3. However, since the duration of room 
temperature storage was entirely random with respect to any particular individual, disease 
manifestation or other phenotypic characteristic, the error it introduces will also be random. 
This adds to the level of random measurement error for the samples, but will not introduce 
any systematic bias. Just as I discussed for the measurement error associated with the assay 
itself, this may significantly reduce the power to detect a genetic association, but it will not 
affect our interpretation of a statistically significant association if one is still demonstrated. 
Although the only paper that specifically addresses the issue of freeze-thawing on the 
quantification of C3 suggests this is of negligible importance, to ensure consistency we only 
quantified C3 on serum aliquots that had never been thawed and re-frozen (Sjoholm 1975).  
 
It is important to recognise that this analysis of association between CRP genetic variation 
and serum C3 represents a post-hoc analysis of a cohort originally collected to study genetic 
associations with SLE. Consequently the study has limitations, and in particular it is 
important to consider the impact that the inclusion of individuals with and without SLE may 
have on my findings. This argument has also been covered in some detail in relation to CRP 
in section 3.7.2. We have already discussed in section 1.2.3 that there is a complex 
relationship between serum C3 concentration and SLE, with reduced C3 levels often seen in 
patients with SLE, and levels also fluctuating according to the level of disease activity. I 
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recognise that this adds significant and unwanted complexity to the analysis and 
interpretation of my data, however I do not feel it entirely precludes use of this data. Firstly, 
by including an “SLE” term as a fixed factor in the regression models, a crude adjustment for 
the overall effect of disease on serum C3 concentration can be made. Having already made 
this adjustment for the presence of disease, we can then consider the effect that unmeasured 
variation in disease activity may have on the results. It should be noted that the collection of 
serum samples from the SLE patients was performed in a cross-sectional study design in 
which blood collection was not performed at any particular time-point in relation to disease 
activity. We would therefore expect the “error” associated with fluctuations in disease 
activity (as opposed to the presence or absence of disease itself), over and above that due to 
genetic variation, to be random. Once again, as outlined above, this random error should not 
affect the validity of our associations. Although providing only indirect evidence, it is 
perhaps notable that the original, regression based estimate of C3 heritability (37.8%), in a 
cohort of healthy individuals only, was remarkably similar to the second estimate (39.6%), 
made in a cohort with SLE probands included, but adjusted for with a regression parameter. 
This similarity suggests that the generic “SLE” term included as a covariate in our association 
models was adequate to account for the effect of disease status on serum C3 levels. It should 
also be considered that serum C3 is a biological trait that, clinically, is really only measured 
in people with SLE: cohorts of healthy individuals with measured C3 levels do not exist and 
would have to be collected de novo. 
 
7.6.6: Conclusions 
 
The heritability estimates presented in this chapter demonstrate that there is a significant 
genetic element to the observed variability of serum C3 in our study populations. It should, of 
course, be recognised that heritability estimates are, strictly, only applicable to the population 
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for which they are calculated. While the inclusion of individuals with SLE made little 
relevant difference to the magnitude of the heritability estimate, it should be recognised that 
both populations we studied consisted of the family members of lupus probands, and hence 
may be genetically enriched for particular disease susceptibility variant. Despite this note of 
caution, the level of heritability that was seen, at the very least, suggests it may be feasible to 
identify genetic variants explaining the population variation in C3. 
 
I was subsequently able to demonstrate a significant association between a C3 SNP and 
serum C3 and, by reference to the pattern of LD across the gene would argue that any 
functional variant is likely to lie at the distal, 3', end of the gene. Although I was unable to 
replicate this association (due to the lack of access to any alternative large cohorts of 
individuals with both serum and DNA collected), my findings did agree to some extent with 
the only other published C3 genetic association paper, in a Japanese population (Miyagawa et 
al 2008). 
 
I was also able to identify a significant association between SNP rs3745568 and SLE. Unlike 
the Japanese study this SNP did not appear to be associated with serum C3 level. It was 
unfortunate that I was unable to replicate this association in a separate analysis of the 
SLEGEN GWA data. There was, of course, problems with the data from this study, not least 
the extremely poor quality of genotyping at the SNP of interest, which, in most circumstances 
would preclude its use from any analysis at all. I attempted to circumvent this by imputation 
analysis but again failed to find an association. This raises the possibility that the original 
association I demonstrated was a false positive, although of the loss of power in the 
replication study due to uncertainty around the inferred genotypes may be an alternative 
explanation. Perhaps some indirect evidence that a genetic interval incorporating rs3745568 
represents a true disease susceptibility effect is that other haplotype associations (in the 
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absence of any known coding SNPs) have been observed; notably an association between 
bronchial asthma and a similar central/downstream haplotype to that which we identified 
(Inoue et al 2008). 
 
The findings presented in this chapter are therefore interesting but clearly, before the genetic 
associations we identify can be considered definitive, further work will be required. In 
particular it will be necessary to replicate the findings in additional cohorts of similar 
ethnicity. Narrowing down the location of the true functional variants will require more 
detailed fine-mapping or gene sequencing. 
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CHAPTER 8 
 
CONCLUSIONS 
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8.1: Summary of thesis aims 
 
In the introduction to this thesis I reviewed our current understanding of the physiological 
roles of the serum proteins CRP and C3, and discussed current literature implicating these 
proteins in a number of disease processes, most notably atherosclerosis and SLE. The data 
presented in this thesis aimed to expand our understanding of the genetic basis of expression 
of these two proteins. In particular I aimed to answer the following key genetic questions: 
 
1. To what extent is the variability in serum level of the two studied proteins under genetic 
control (i.e. determined by an inherited underlying predisposition and not simply related 
to external factors such as pathogen burden, or subclinical disease processes)? 
2. Can we identify specific genetic variants accounting for variation in serum levels and, if 
we can, are these variants located in the CRP or C3 genes themselves, or at trans-acting 
loci? 
3. Is there a single major genetic effect or do multiple genetic variants each account for a 
small component of the variability in serum protein level? 
4. Do the same genetic variants account for the variability in the basal serum levels seen in 
healthy individuals, compared with the higher levels seen in individuals with disease? 
5. Are cis-acting genetic variants also associated with the diseases in which these proteins 
have been implicated? 
 
In the following sections I will summarise the results of the studies presented in this thesis, 
demonstrating that they make significant progress in answering the above questions. I will 
then discuss, in detail, points of general relevance to the studies presented here, which have 
not been covered in the individual chapter discussions. In particular I will discuss the identity 
of potential genetic variants that determine basal CRP, a topic which has been addressed in 
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three independent studies presented in this thesis (chapters 3, 4 and 5). Finally I will conclude 
by discussing the clinical relevance of these findings, and the future directions that this work 
may take. 
 
8.2: Summary of Study Findings 
 
The data and analyses presented in this thesis may be summarised in the following key 
messages: 
 
1. Both serum CRP and serum C3 are heritable traits with a significant proportion of 
variation in their levels attributable to genetic effects. 
2. Cis-acting genetic variants in both CRP and C3 are associated with serum levels, but 
these account for only a small proportion of the total genetic effect 
3. For CRP, strong LD across the gene results in the reporting of multiple indirect 
associations. By adopting a trans-ethnic mapping approach, and utilising appropriate 
model choice analysis, I identify a tri-allelic promoter SNP (rs3091244) as the most 
likely key regulator of CRP expression at this locus. 
4. Genetic variation also determines acute-phase CRP expression in the context of 
chronic inflammatory disease, a finding that has implications for how we use CRP to 
diagnose and classify inflammatory conditions. 
5. Only weak effects are identified from selected trans-acting loci. Recent whole 
genome association studies are more informative. 
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8.3: Serum CRP and C3 – General Considerations and Heritability 
 
8.3.1: Basal vs. acute-phase levels  
 
As I outlined in section 1.3.2, CRP expression has a vast dynamic range, from low levels in 
apparently healthy individuals to very high levels in patients with bacterial infection. The 
range of levels is so great that it is common to refer to “basal” CRP when talking about low-
level expression in healthy people, compared with “acute-phase” CRP in individuals with 
active inflammation. Indeed it is widespread in much of the literature to give “basal” CRP a 
different name, “highly sensitive” or “hsCRP”, although, of course, it is an identical molecule 
to the “acute-phase” protein. C3 levels are also increased in inflammatory conditions but 
because the change is less dramatic a distinction between basal and acute-phase expression is 
not usually made. When designing or evaluating a CRP genetic study it is important to 
consider whether this distinction between basal and acute-phase CRP is a matter of 
semantics, or whether there is a genuine difference in physiological regulation. There are two 
possibilities. Firstly CRP expression could be regulated in essentially the same way across its 
entire range, with the same intracellular and extracellular signals driving expression but to a 
greater or lesser extent. In this model, basal CRP would reflect low levels of ongoing 
inflammatory stimulus, either as a result of subclinical inflammatory disease, or in response 
to ongoing encounter with pathogens that are eliminated before causing overt disease. The 
alternative model is that CRP is constitutively expressed at low levels as a distinct regulated 
process, unrelated to classical inflammatory stimuli such as IL1β and IL6. In this model the 
production of acute-phase CRP would be a distinct event with unique regulatory steps. 
 
Although there is little direct evidence, as in vitro cell based systems all require treatment 
with acute-phase cytokines before measurable CRP can be detected, I suspect that the second, 
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dual regulation, scenario is most likely. This supposition is based on two lines of evidence. 
Firstly there is evidence from the data presented in chapters 2 and 3 that the association of 
interleukin 6 SNPs with serum CRP is restricted to individuals with SLE, suggesting genetic 
regulation of CRP expression may be different in inflammatory states. A recent GWA study 
(discussed in detail in section 8.5.2) also noted that the association of some of the loci, 
notable the interleukin 6 receptor gene IL6R , was weaker when individuals with serum CRP 
>10mg/L were excluded from the analysis (Ridker et al 2008). Secondly there is some in 
vitro evidence to suggest that the production of CRP in IL-1β and IL-6 stimulated cells is 
associated with increased binding of the specific transcription factor C/EBPβ, whereas other 
transcription factors such as STAT3 and Rel p50 remain bound to the endogenous, 
unstimulated CRP promoter (Young et al 2008). 
 
This issue of whether there is a true mechanistic different between basal and acute-phase 
protein levels is important, because if these processes are regulated differently then it is 
possible that different genetic variants, either at CRP itself, or at different trans-acting loci 
may account for variability in CRP expressed as part of either pathway: this in turn impacts 
on the design of studies aiming to highlight variants of interest. Numerous authors apply a cut 
off of CRP level above which individuals are excluded on the assumption they are mounting 
an acute-phase response. This seems logical if we assume basal and acute-phase CRP are 
distinct processes, nonetheless it does present other difficulties. For example, it is likely that 
some individuals with a CRP within the range of, say, 10-15mg/L are mounting a low grade 
acute-phase response. Other individuals, however, may not have an acute-phase response but 
simply have naturally high basal CRP. It is exactly these high basal CRP individuals who 
may be most informative in a genetic association analysis of basal CRP, and we will lose this 
useful information if they are excluded. Furthermore, by simply cutting off the end of the tail 
of the positive distribution of CRP values we may end up, after transformation, with a worse 
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approximation of a normal distribution, hence violating the assumption of normality that is 
essential for a parametric approach to analysis. 
 
The alternative approach again used in a number of studies (and adopted by myself in the 
analysis presented in chapter 5) is simply to include everybody. This approach would seem 
reasonable for population cohorts collected without reference to a specific inflammatory 
disease, particularly if a smooth distribution of CRP values is seen within the population. 
However, if too many of these individuals are mounting an acute-phase response it should be 
recognised that genetic variants specific to acute-phase production may be highlighted at the 
expense of variants influencing basal CRP 
 
8.3.2: Tissue specific expression 
 
I have discussed the possibility that genetic regulation of CRP expression may differ in basal 
and acute-phase situations. A related question is whether the genetic regulation of CRP or C3 
expression is tissue specific. As discussed in sections 1.3.2 and 1.4.2, the primary site of 
production of both these proteins is the liver, but notable sites of extra-hepatic production 
have been described. Presumably the contribution of these extra-hepatic sources to total 
circulating serum levels in the acute-phase situation is minimal and can essentially be 
ignored. Whether they may make a more marked contribution to basal serum levels is 
unknown but certainly it could be envisaged that, for example, CRP produced by the vascular 
endothelium my enter the circulation and contribute to serum basal CRP levels. If this extra-
hepatic CRP expression is regulated in a different way to hepatic CRP, and if its contribution 
to total serum CRP is not negligible then this may impact on our ability to identify genetic 
influences on serum CRP levels. It also has implications for the way we interpret and extend 
the results of genetic study. For example, genetic variants associated with serum basal CRP 
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may be irrelevant to our understanding of the role of CRP in atherosclerosis, if it is the local, 
vascular, production of CRP that is pathogenic, and this is regulated by distinct genetic 
mechanisms. These questions will be difficult to answer using currently available techniques. 
 
8.3.3: Influence of age and gender on serum levels 
 
Since age and sex were included as covariates in each of the analyses presented in this thesis 
it is possible to make some observations regarding their association with the levels of C3 and 
CRP. 
 
In the CRP analyses presented in chapters 2 and 3, and the C3 analysis presented in chapter 7 
higher serum protein levels were observed in women. It is interesting that this relationship 
was not observed for the cohort presented in chapter 5, perhaps because these individuals 
were generally of an older, post-menopausal, age. Higher serum CRP in females was also 
observed in the majority, but not all (Crawford et al 2006 being the notable exception) of the 
CRP studies presented in table 1.2, although none of the authors commented upon this 
specifically. It has certainly been noticed that oestrogen hormone replacement therapy 
increases CRP levels in post-menopausal women (Cushman et al 1999; Pradhan et al 2002). 
Circumstantial evidence would therefore suggest a genuine gender influence on serum basal 
CRP. I can find little evidence that this gender effect has been explicitly recognised before for 
serum C3, although oestrogen response elements have been demonstrated in the C3 promoter 
(Fan et al 1996). The presence of higher levels of inflammation associated proteins in women 
appears paradoxical given both the links between atherosclerosis and inflammation, and the 
reduced risk of cardiovascular disease in pre-menopausal women. It is certainly an 
observation that supporters of a causative role for CRP in the pathogenesis of atherosclerosis 
need to explain. 
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It should also be noticed that both basal CRP and C3 increased with age, although this is 
perhaps not surprising and probably reflects the increased burden of subclinical inflammatory 
pathology in an elderly population. On the other hand when we looked at high level CRP in 
the context of rheumatoid arthritis (chapter 6) we observed a different relationship, with 
lower acute-phase CRP levels overall in older patients. This is perhaps a reflection of the 
inability of the senescent liver to mount the high levels of acute-phase protein expression in 
comparison with younger individuals. 
 
8.3.4: Heritability 
 
In this thesis I have provided heritability estimates for both basal CRP (27.7%) and C3 
(39.6%): what conclusions can be drawn about these estimates?  
 
As I outlined in section 1.3.3 a number of other authors have estimated CRP heritability. I 
have summarised these existing reports in table 8.1. It can be seen that my heritability 
estimate is towards the lower end of the range of existing estimates and there are probably a 
number of reasons for this. Firstly twin studies inherently tend to give higher estimates of 
heritability than family studies. The basic premise of a twin study is that dizygotic and 
monozygotic twins are raised in an identical shared environment. This, however, is unlikely 
to be entirely true, with many arguing that intrauterine and external environmental factors are 
likely to be more closely shared between monozygotic compared with dizygotic twins 
(Phillips 1993). Twin-based heritability studies may therefore over-estimate the genetic 
component of trait variability (Harrap & Hopper 2001; Hopper 2000). Family studies may be 
better at identifying environmental influences on the trait of interest; these are revealed when 
different trait correlations are observed between different between groups of individuals with 
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identical genetic relatedness (e.g. parent vs. offspring compared with sib-pair). On the 
negative side, however, when the number of individuals available for study in a family cohort 
is relatively small, the uncertainty associated with the estimates of environmental and genetic 
effect can be large. 
 
 
Table 8.1. Current CRP heritability estimates. 
Study Cohort design Heritability (%) 
Pankow et al 2001 European-American two generation 
pedigrees 
40 
Vickers et al 2002 White European two generation pedigrees 
(proband with hypertension) 
39 
Austin et al 2004 Japanese-American two generation 
pedigrees 
27 
MacGregor et al 2004 UK female twins 52 
Lange et al 2006a Mixed ethnicity sibships (multiplex for type 
2 diabetes mellitus) 
39 
Saunders and Gulliford 2006 White UK two generation pedigrees 10 
Wessel et al 2007 European American twins 56 
Fox et al 2008 African-American two generation 
pedigrees 
45 
 
 
 
It is, perhaps, pedantic to argue which heritability estimate is “most accurate”, as each will be 
specific to the population under study in any case. It is probably sufficient to say that 
somewhere between 25% and 50% of the variation in basal CRP on a population basis can be 
attributed to genetic influences. 
 
In the case of serum C3, I am unaware of any previous attempts to calculate heritability for 
this trait. Certainly the estimated 39.6% heritability places it in a similar range to that 
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estimated for CRP. It is also similar to estimates for another acute-phase protein, fibrinogen 
(20-48%), suggesting all these acute-phase reactants may show similar levels of heritability 
(de Lange M. et al 2001; Friedlander et al 1995; Hamsten et al 1987). 
 
The general message that should be taken from the heritability estimates is that the genetic 
component of variation of both serum CRP and C3 is of a sufficient magnitude that the search 
for genetic variants accounting for this genetic effect is not only feasible, but also important if 
we are to maximise the use of these proteins as markers of human disease. 
 
8.4: Cis-acting Effects on Basal CRP – Discussion 
 
Each of the CRP studies presented in this thesis, along with multiple studies from other 
authors have demonstrated an association between CRP genetic variants and serum basal 
CRP. The evidence for a cis-acting genetic effect is now overwhelming. The question that 
remains is which variant, or variants are likely to have a true functional role. As I discussed 
in section 1.5.3, the final stage in the pathway of functional SNP identification must be 
functional experimentation to confirm that the SNP can alter the phenotype of interest. 
However, without a clear candidate identified on the basis of genetic study, a functional 
investigation of multiple SNPs is likely to be time consuming, expensive and, in many cases, 
futile. Table 1.2 summarised SNPs reported to be associated with serum basal CRP in the 
current literature. It highlights that multiple SNPs have been associated with serum CRP but 
none are consistently associated in each study where they have been tested. The three CRP 
studies presented in this thesis also highlight different genetic variants so, before we can 
hypothesise which variants are most likely to have a functional role, it is important to 
consider why this is the case.  
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8.4.1: Power 
 
In the sections below I explore specific reasons that may explain the multiple, but 
inconsistent, associations observed at CRP. All these explanations hinge on the issue of study 
power (Chasman et al 2009; Gordon & Finch 2005). The critical factors determining the 
power of a study to demonstrate a direct genetic association are the effect size (which for a 
quantitative outcome can be expressed as the proportion of phenotypic variance explained by 
the genotypes at that SNP), the minor allele frequency of the SNP, and the study sample size. 
When considering an indirect association (which the majority of studies will be identifying), 
the degree of LD between marker SNP and functional SNP, along with the relative difference 
in minor allele frequency between the two also become important considerations (Zondervan 
& Cardon 2004). There are, of course, many other factors influencing the power of a genetic 
study, in particular sources of random measurement error resulting in misclassification of 
either genotype or phenotype. These aspects have been discussed in detail in the various data 
chapters. 
 
8.4.2: Strong LD across CRP in European populations 
 
It is clear from the data presented in figure 3.1 and table 3.3 that the LD across CRP, in 
white European populations, is very strong and extends to encompass large upstream and 
downstream regions. Even in the African-American population we observe relatively high 
levels of LD, with D' scores approaching one for the majority of pairwise marker 
comparisons (table 5.3). This provides a simple explanation for the large number of genetic 
markers identified in different studies: clearly the higher the LD across a locus, the easier to 
demonstrate an indirect association. In the European population it is also notable that whole 
clusters of SNPs in high LD also have highly correlated minor allele frequencies, as 
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demonstrated by r2 values approaching one. In this situation it is difficult to identify, in all but 
the largest studies, which, out of a cluster of correlated SNPs, is likely to be a functional 
SNP. Any observed difference is just as likely to be a consequence of minor differences in 
genotyping success/accuracy as it is to represent a true difference in the degree of association. 
This will be an even greater problem where interest focuses on a SNP with relatively low 
minor allele frequency such as rs1800947 (MAF 7% in Europeans). 
 
8.4.3: Ethnic differences in CRP gene structure 
 
As in all areas of genetic study there is a clear bias in published CRP studies towards cohorts 
of a white European ancestry, making the data presented in this thesis of particular interest. 
Of the more extensive existing CRP genetic studies only five are in African-American 
populations (Carlson et al 2005; Crawford et al 2006; Lange et al 2006b; Lee et al 2009; 
Szalai et al 2005c), two in Hispanic Americans (Crawford et al 2006; Lee et al 2009), one in 
Japanese (Morita et al 2006) and one in Asians/Pacific Islanders (Lee et al 2009). This latter 
group I suspect represents a genetically rather heterogeneous population. 
 
The pattern that emerges from these studies and, in particular, the trans-ethnic mapping 
studies I present in this thesis is that there is increased genetic diversity in populations of 
primarily African origin. The overall LD across CRP remained strong in my African-
American population, to the extent that the physical size of the haplotype block was similar to 
that seen in the white European cohort (see figure 3.1 and figure 5.1). There was, however, 
an increased diversity of haplotypes in the African-American cohort and some quite notable 
differences in allele frequency for a number of markers. For example the frequency of the 
“A” allele of rs3091244 in African-Americans is over four times that observed in Europeans 
and there are additional SNPs that appear unique to the African-American population such as 
 212 
rs3093058 and rs3093063. Conversely, Europeans appear enriched for other alleles which are 
over twice as common in this group compared with African-Americans: this group includes 
rs1800947, rs1417938 and rs3093077. These findings are not surprising as we would predict 
that the more ancient African genome (and the related African-American genome) would 
offer the most genetic diversity; indeed this is illustrated by the LD architecture of Yoruba 
subjects from Nigeria, which is more diverse and shows more evidence of recombination than 
reference populations of European and East Asian ancestry (Gabriel et al 2002). 
 
This difference in genetic structure between populations means that we have increased power 
to detect effects arising from some, more frequent, alleles, but decreased power to detect 
effects arising from other, less frequent, alleles. If, for example, there were two functional 
SNPs at CRP, with divergent allele frequencies in two different ethnic populations, studies 
could find an association with one SNP in one population and the other SNP in the second 
population, even through the true picture may be two individual functional effects. The 
advantage of an analysis in an African population, however, is that we are less likely to report 
multiple indirect associations, because of the weaker overall LD. 
 
8.4.4: Problems with a tri-allelic SNP 
 
SNP rs3091244 has three alleles, implying that two separate mutational events have occurred 
at this single site. The rate of mutation of the human genome is so low (approximately 1.8 x 
10-8 mutations/bp/generation, but varying according to genomic location through processes 
that are poorly understood) that the presence of a tri-allelic SNP is an exceptional finding 
(Baer et al 2007; Kondrashov 2003). It also presents problems with analysis. Again there is 
the issue of power because the population is subdivided on the basis of three rather than two 
alleles. This is a particular problem when genotype models are used as there are six potential 
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genotypes and only small numbers of individuals will be homozygous for one or other of the 
minor alleles. Some authors overcome this by pooling the minor alleles and assessing the 
effect of the common “C” allele acting as an additive effect over the rare “A” and “T” alleles. 
However, should one, but not both, of the minor alleles be functional then this approach will 
result in a significant loss of power to detect the true effect. Alternatively if all possible 
models are assessed (i.e. “C” vs. “A+T”, “T” vs. “C+A” and “A” vs. ”C+T”) then this is 
going to entail a significant penalty in terms of correcting for the testing of multiple 
hypotheses. Most authors do not report the testing of all possible models, although one would 
suspect most perform unreported testing. 
 
The model choice analysis I present in chapter 6 appears to be the only serious attempt to 
address this issue. A key aspect of this approach is that it allows the selection over models 
containing rs3091244 encoded in each possible way, thus providing a real advantage in 
identifying the most likely functional alleles.  
 
8.4.5: Potential for problems with multiple functional SNPs at CRP 
 
It is quite possible that CRP gene expression is influenced by multiple functional SNPs. To 
give an example: at the SLE disease susceptibility gene IRF5, two, or possibly even more, 
functional effects are felt to mediate susceptibility to disease (Kozyrev & Alarcon-Riquelme 
2007). In the context of CRP the conventional approach of testing each genotyped SNP in 
turn for an association with CRP level may lead to erroneous results in the presence of 
multiple SNP effects, particularly if the different effects are carried on different CRP 
haplotypes. For example, imagine a locus with 5 haplotypes, A to E. If two different 
functional SNPs with a minor allele frequency of, say, 5%, are carried on haplotypes D and 
E, then a non-functional SNP with minor allele frequency of 10% carried on both haplotypes 
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D and E would show a stronger association than either of the true functional variants (which 
may indeed not show association themselves due to lack of power). An explanation such as 
this may also underlie the inconsistency in existing CRP studies. 
 
8.4.6: CRP functional SNPs – A hypothesis based on thesis data. 
 
It can be seen from the discussion in previous sections that there are a number of potential 
explanations for the lack of clarity over the key cis-effects in the current CRP literature. To 
some extent these problems remain despite the work presented in this thesis, although there is 
now probably enough circumstantial evidence, from my studies and other published data, to 
formulate a working hypothesis to guide further study. 
 
I propose, on the basis of my analysis in chapter 5 that rs3091244 is a strong candidate for 
being a functional SNP at this locus. The C allele of rs3091244 is commonest in all studied 
human populations, is found on the Chimpanzee and Macaque genome reference sequences, 
and has not been identified as polymorphic in these species (Rhesus Macaque Genome 
Sequencing and Analysis Consortium 2007; The Chimpanzee Sequencing and Analysis 
Consortium 2005). My cladistic analysis in Filipinos also gave highest outgroup weighting 
probability to CRP haplotypes carrying the C allele. It is therefore likely the C allele is 
ancestral, and a key functional moment in the evolution of the human CRP locus was the 
mutation of the rs3091244 alleles from C to T, thus increasing basal serum CRP expression. 
We can only hypothesise how this enhanced expression may have conferred an advantage to 
early humans. Perhaps basal CRP has a surveillance role in protecting against the early stages 
of bacterial infection; alternatively higher basal CRP may enhance clearance of apoptotic 
debris and thus protect against developing autoimmunity. Another explanation, although 
untested, is that rs3091244 also alters the magnitude or time-course of the acute-phase CRP 
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response. This may have additional functional consequences and is discussed further 
elsewhere. 
 
SNP rs3091244 is also an attractive candidate because it alters the CAnnTG E-box consensus 
sequence centred 497 bp upstream from the transcriptional start site. Szalai et al purport to 
have evidence from electrophoretic mobility shift assay (EMSA) for differential transcription 
factor binding associated with the “T” allele at this site (Szalai et al 2005c). Unfortunately 
they do not actually present their data, stating “EMSA targeting E-box 2 yielded discernable 
but very weak mobility shifts only with the -390T version (data not shown)”. One can only 
assume that the data was indeed weak, but these experiments would be worth revisiting in the 
light of my data. Another attempt to delineate key CRP SNPs used in vitro reporter assays 
with CRP promoter constructs varying at known SNP sites (Carlson et al 2005). As I have 
already eluded to in section 8.3.1., it is difficult to know how good a physiological 
representation of basal CRP expression these models are, particularly as the level of 
expression from the native CRP promoter in the absence of IL-6 is very small. The constructs 
contained several SNPs and there was no convincing segregation of promoter activity based 
exclusively on one SNP, making it difficult to draw firm conclusions from this study. 
Nonetheless the published results would certainly not be inconsistent with a functional role 
for the T allele of rs3091244. It has been noted that there are frequently discrepancies 
between genetic associations and in vitro functional data and, as it stands, the existing 
functional data is by no means conclusive (Ioannidis & Kavvoura 2006). 
 
While my data suggested a rather simple model of genetic effect at CRP in African-
Americans, we need to explain why other SNPs are consistently associated with CRP in other 
ethnic groups (including the European and Filipino analyses presented in chapters 3 and 4). 
In addition we need to explain why the T vs. C+A model for rs3091244 is not the 
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consistently best association in these other studies. Assuming that rs3091244 is a genuine 
functional effect then part of the explanation may be related to power and LD issues as 
discussed in previous sections. The degree of LD with the T allele of rs3091244 in African-
Americans, as measured by r2, was 0.138 for rs1205, 0.225 for rs1417938, 0.007 for 
rs1800947, and the equivalent in Europeans was 0.256 for rs1205, 0.990 for rs1417938, and 
0.035 for rs1800947. The association with these additional SNPs in Europeans may therefore 
be influenced by both their higher frequency and their stronger LD with rs3091244(T), with 
the true effect only becoming apparent in this African American cohort.  
 
I think, however, the most likely explanation here is that there is more than one functional 
SNP at CRP, and that this additional variant (or variants) is only found with sufficient 
frequency to be identified in non-African populations. This has, in fact, been formally 
proposed in a recent meta-analysis of studies published up to 2007 (Verzilli et al 2008). 
Bayesian model selection was used to identify variants exerting strongest independent effect 
on serum CRP. The model with the highest posterior probability (0.22) contained no less than 
four SNPs, although the inclusion of rs1800947 was rather dependant on the prior on the 
model space. SNPs rs1205 and rs3093077 were included in all models with a posterior 
probability >0.02. Interestingly rs3091244 was included in the meta-analysis but did not 
appear in the top models, probably (although it is actually not specified in the paper) because 
the C vs. T+A coding was used (in common with the majority of papers incorporated into the 
analysis). 
 
In their recent genome wide association study, Ridker et al performed backward selection 
models (using both maximum likelihood (AIC) and Bayesian (BIC) models) to identify a 
minimal set of variants from their GWA study accounting for CRP variability (Ridker et al 
2008). Although the authors do not provide a detailed methodology (e.g. specifying prior 
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distributions for the Bayesian models) it appears that even under stringent model conditions a 
minimum of four CRP variants account for the observed CRP variation. Interestingly 
rs3091244 was included in this group even though it was encoded as G vs. A+T (their assay 
presumably operating on the opposite strand). It is possible that the size of this cohort was so 
large that a significant association could still be observed with the inclusion of a non-
functioning, low frequency A allele in with the T allele group. Kathiresan et al also 
performed selection models (forward stepwise selection) using the 13 CRP SNPs typed in 
their study (Kathiresan et al 2006). Their best model contained one SNP only, rs3091244, 
with the next best model containing two SNPs (rs1205 and rs2808630). They do not, 
however, provide an analysis such as an AIC to enable us to assess the weight of evidence for 
their assertions. Finally I should also re-iterate the evidence from my Filipino analysis that 
there was some evidence for a separate functional effect arising from rs1800947. This has 
been discussed in section 4.4.2. 
 
Given the evidence for multiple SNP effects in non-African populations is there any evidence 
to highlight functional candidates other than rs3091244? In addition to the cross-species 
conservation analysis that I have presented in figure 1.4, I also used three publically 
available, web-based SNP assessment tools (PupasView (http://pupasuite.bioinfo.cipf.es), 
SNPselector (http://primer.duhs.duke.edu/) and TAMAL (http://neoref.ils.unc.edu/tamal)) to 
look for additional evidence of function for any known common CRP SNPs (Bhatti et al 
2006). None were found to lie within known regulatory sequences or to show significant 
cross-species conservation. Although there are no outstanding candidates on the basis of 
bioinformatics, two SNPs probably stand out above the rest. 
 
CRP does have a notably long 3'-UTR (1238 base pairs), raising the possibility, in theory at 
least, that control of mRNA degredation, transport or translation is an important regulatory 
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mechanism for CRP (Chen et al 2006). The location of rs1205 within the 3'UTR therefore 
makes it a reasonable functional candidate, although there is currently no direct evidence for 
this. SNP rs1800947, as a synonymous variant, could also be considered a potential 
functional candidate. Recent studies suggest synonymous base pair changes can have 
functional consequences as the substitution of rare for common codons leads to a delay in 
ribosomal translation and subsequently alters protein folding; whether this mechanism could 
also quantitatively alter protein levels is unknown (Tsai et al 2008). SNP rs1205 appears in 
all the best models proposed in the Bayesian meta-analysis, while rs1800947 was also in the 
top model and appears associated with basal CRP levels in many existing studies (Verzilli et 
al 2008). 
 
Ultimately, further functional work will be required to determine which SNP or SNPs truly 
influences gene expression. A combination of assessing CRP promoter variants by an in-vitro 
reporter assays of promoter mutants (say a luciferase based system), combined with an 
assessment of transcription factor binding (by EMSA or chromatin immunoprecipitation) 
seems reasonable. These approaches have been attempted (see above) but crucially these 
studies introduced multiple promoter mutants rather than considering a single variant, thus 
adding unnecessary complication. Also of interest would be to move away from hepatocyte 
cell lines to other cells reported to express CRP. 
 
8.4.7: Cis-effects explain a small proportion of basal CRP variance. 
 
Although there remains some uncertainty over the identity of the functional SNP or SNPs at 
CRP, all studies, including those presented in this thesis, agree that the proportion of CRP 
variance explained by known CRP variants is small (table 8.2). Most authors assess this 
through the partial r2 determined through linear regression analysis. My UK white European 
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family analysis has been the only attempt to address this through a variance components 
approach, suggesting CRP haplotypes accounted for 3.77% of basal CRP variability. Given 
the estimated 28% CRP heritability this therefore represented only 15% of the total genetic 
effect. It is possible, of course, that the mode of association between CRP SNPs and serum 
CRP is more complex than the simple models that have been currently analysed. In particular, 
genotype-environmental interactions may be important, in particular environmental factors 
acting as inflammatory stimuli (leading us back to the discussion of “basal” vs. “acute-phase” 
CRP in section 8.3.1). 
 
 
Table 8.2: Proportion of CRP variance explained by cis-acting effects in current studies 
Study Proportion of Variance  
UK SLE families (chapter 3) 3.8% 
African-American analysis (chapter 5) 5.2% 
Miller et al 2005 <5%* 
Crawford et al 2006 <3%* 
Kathireson et al 2006 1.4% 
Lange et al 2006b <6.4%* 
Ridker et al 2008 3.4% 
* Where more than one cohort is presented in a publication the largest proportion 
of variance is presented. 
 
 
There may also be important epistatic effects, or alternatively there may be a more complex 
relationship between genotype and serum CRP, perhaps with SNPs acting through effects on 
the variance of CRP rather than the mean (Chasman et al 2009). Unless these other effects 
are identified, however, we must assume that a significant proportion of the variance in 
population serum basal CRP is explained by trans-acting genetic effects. These will be 
discussed further in the next section. 
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8.5: Trans-acting Effects on Serum Basal CRP – Discussion 
 
As outlined above, cis-acting variation appears to explain only a small proportion of total 
serum CRP variability; this suggests that we must look at variation elsewhere within the 
genome to explain the remaining genetic effect. 
 
8.5.1: Trans-acting effects presented in this thesis 
 
When the work presented in this thesis was planned, existing literature on potential trans-
acting genetic effects focussed on three loci, APOE, IL6 and IL1B, and I therefore 
concentrated on genotyping at these loci. My aim by including this additional genotyping was 
to increase the power to detect effects arising from CRP itself by reducing overall variance 
due to additional genetic influences. I did not primarily intend a thorough evaluation of these 
additional loci, but nonetheless some interesting patterns did emerge. 
 
A number of existing studies report an association between variants at IL6 and IL1B and 
serum CRP (reviewed in section 1.3.3), and given the in vitro evidence for the role of these 
two cytokines as key regulators of CRP expression it is perhaps not surprising that some 
significant associations have been reported between serum CRP and variants at these two 
loci. 
 
In both the UK white European cohort and the Filipino cohort we observed an association 
between IL6 variant rs1800796 and basal CRP expression, although interestingly only when 
modelled as an interacting term with SLE. No such association was observed in the African-
American cohort analysis. Neither did we observe an association between the commonly 
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reported rs1800795 variant and serum CRP. The rs1800796 variant was particularly common 
in our Filipino population (minor allele frequency 0.33), mirroring previous studies in 
Chinese and Korean populations (Jang et al 2008; Paik et al 2007; Wong et al 2007). The 
data presented in this thesis therefore add to the inconsistency of IL6 SNP associations 
reported in the literature. There are probably a number of explanations for this, many of 
which would be similar to those already discussed in relation to CRP.  
 
I think a key issue is whether study participants are expressing basal or acute-phase levels of 
CRP. I would argue that the reason why I only observed an association between rs1800796 
and serum CRP in the context of SLE is because these are exactly the individuals mounting a 
low-grade acute-phase response. I suspect that the association between IL6 variants and 
serum CRP is strongly dependant on the level of acute-phase response being mounted. 
Additional evidence along these lines can be found from a recent GWA study (discussed 
below in 8.5.2) where the association between IL6R variants and serum CRP weakened when 
only individuals with low level CRP were included (Ridker et al 2008). As I have already 
highlighted in section 1.3.2., numerous IL6 genetic studies are conducted in cohorts of 
individuals with diseases such as CHD and diabetes. These are exactly the individuals in 
which there is going to be considerable ambiguity over what we are really measuring: a true 
basal CRP or a low grade, inflammatory acute-phase CRP. This issue will really only be 
resolved by a study in unambiguously healthy young individuals to assess the association 
with basal CRP, or a study in individuals with unambiguous active inflammatory disease to 
assess the acute-phase CRP association (as I have attempted in the study presented in chapter 
6). 
 
I also suspect that we have not yet fully delineated functional variants in IL6. An early in 
vitro functional study suggested that the role of IL6 promoter variants in determining 
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transcriptional activity was not simple, but depended on a haplotype effect (Terry et al 2000). 
Recent genetic studies have mapped the IL6 promoter region in more detail, and have begun 
to consider more complex functional effects arising from IL6 promoter haplotypes. Certainly 
extensive promoter haplotypes have been associated with disease, although the association 
between haplotypes and serum CRP has again been inconsistent in current studies asking this 
question, highlighting the need for cohort consistency (Fife et al 2005; Walston et al 2007; 
Yanbaeva et al 2009). Interestingly IL6 regulatory elements have also been identified at a 
considerable distance upstream from the gene, suggesting a more extensive search for 
functional variants may be also fruitful (Samuel et al 2008). 
 
To some extent the findings of existing IL1B studies mirror those for IL6, with early studies 
highlighting two SNPs (rs1143634 and rs16944) that demonstrate association with serum 
CRP, although often only in certain cohort subsets, or in certain ethnic groups identified in 
secondary analyses (section 1.3.3). I did not observe an association between either of these 
SNPs and serum CRP in any of the studies I present in this thesis. I did observe a fairly weak 
association between variant rs7596461 and serum CRP in the UK SLE family cohort. This 
SNP has not specifically been genotyped in other studies, so this is a preliminary association 
that will clearly need replicating. As with IL6 there have been some recent attempts to use 
more extensive genotyping efforts to analyse the association between IL1B haplotypes and 
serum CRP. Once again these reports are inconsistent emphasising the need for replication 
and cohort standardisation (Enquobahrie et al 2009; Rogus et al 2008). 
 
Our observed association between APOE variation has now been confirmed in two large 
recent genome wide association study (discussed in more detail in section 8.5.2) (Elliott et al 
2009; Ridker et al 2008). Interestingly, in both studies, this association was observed for 
SNPs closely flanking the APOE gene, and not those defining Apo ε serotype (which were 
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not genotyped). Unfortunately the Apo ε defining SNPs are not included in the HapMap 
dataset either, so it is impossible to infer whether the association observed in the GWA study 
is likely to be independent of the effect of Apo ε type. Chasman et al also typed additional, 
non-serotype defining APOE SNPs but observed no additional association (Chasman et al 
2006). They also measured Apo ε levels in their large cohorts and found that adjusting for 
Apo ε levels made little difference to the strength of association between Apo ε serotype and 
serum CRP, suggesting it was genuinely a qualitative rather than a quantitative difference in 
Apo ε that was influencing CRP expression. The true nature of this association can only be 
resolved by large scale studies involving extensive APOE mapping, quantitation of Apo ε 
levels and, ultimately, better functional characterisation of the Apo ε variants. 
 
8.5.2: Recent GWA studies 
 
With recent technological advances that now permit the simultaneous genotyping of over 
100000 SNPs, a whole genome association study, with serum CRP as a quantitative outcome 
measure, is the ideal way forward in the identification of novel trans-acting variants. 
Although the UK SLE cohort which I studied in detail has also been incorporated into 
existing whole-genome association projects with SLE as the outcome of interest 
unfortunately a pooled-sample methodology was used, which did not permit the identification 
of individual patient genotypes for a post-hoc analysis of serum CRP association.  
 
Since the experimental work presented in this thesis has been completed there have now been 
four GWA studies published for serum CRP; an example of how rapidly work in this field is 
progressing. Since the results of these studies both complement and extend my findings, it is 
worth considering each of them in more detail (data summarised in table 8.3). The first GWA 
study, published in late 2007, performed a family based analysis on 1012 related members of 
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the Framingham offspring cohort (Benjamin et al 2007). The relatively small size of this 
cohort, combined with the family-based design resulted in a rather under-powered study. In 
addition it used one of the earlier SNP chips, the Affymetrix 100K gene chip, which, at a 
genome-wide level, may leave significant gaps in genetic coverage. Other than confirming a 
cis-effect from CRP no further known genes were identified with genome-wide significance. 
 
Table 8.3. Genes associated with CRP expression in current GWA studies (P-values shown) 
Gene/Locus* P-value† 
 Benjamin et al. Melzer et al. Ridker et al. Sabatti et al. Elliott et al. 
CRP 2.83 x 10-8 6.36 x 10-6 6.16 x 10-28 2.92 x 10-22 7.6 x 10-44 
LEPR   6.52 x 10-21 3.76 x 10-7 3.1 x 10-14 
IL6R   1.93 x 10-8  1.8 x 10-14 
GCKR   6.73 x 10-15   
HNF1A   6.75 x 10-17  1.3 x 10-30 
APOE   8.70 x 10-21  4.5 x 10-27 
LEF1    2.71 x 10-11  
12q23.2   1.16 x 10-10   
5q23 1.2 x 10-6     
 † Unadjusted P-values are shown. Where studies demonstrate more than one SNP associated at a locus, the 
smallest P-value is shown. Study methodologies differed and only associations judged to have achieved 
genome-wide significance by the methodology of that paper are shown.  
* Genes encode known proteins: CRP – C-reactive protein; LEPR – Leptin receptor; IL6R – Interleukin-6 
receptor, GCKR – Glucokinase regulatory protein; HNF1A – Hepatic nuclear factor 1a; APOE – Apolipoprotien 
E; LEF1 – Lymphoid enhancer binding factor 1. 
 
The second study, from May 2008 was in a relatively small cohort of 1200 white European 
participants; primarily older individuals (Melzer et al 2008). Using genotyping from the 
Illumina HumanHap 500 chip, the authors looked for an association between genotype and 42 
biological proteins. The large number of genotypes and proteins tested in this analysis led the 
authors to select a very high level of genome-wide significance (2.4 x 10-9), and they limited 
their analysis to SNPs with a minor allele frequency >10%. Again the CRP cis-effect was 
confirmed but no significant trans-acting variants were identified. Published in the same 
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month was a much larger, well designed study in 6345 healthy women from the Womens 
Genome Health Study) (Ridker et al 2008). The Illumina HumanHap 300 chip was used to 
generate 336,108 genotypes, and all typed SNPs with a minor allele frequency >1% were 
included for analysis. In addition to CRP, a number of trans-acting effects were also 
identified. APOE was confirmed as an important trans-acting locus as discussed above in 
section 8.5.1. Very strong associations were also seen between LEPR variants and serum 
CRP, confirming the weak association seen in an earlier candidate gene study (Zhang et al 
2007). Associations were also seen between serum CRP and variants in HNF1A (encoding 
one of the key CRP transcription factors: see section 1.3.2), GCKR (encoding the 
Glucokinase Regulatory Protein) and IL6R (encoding the Interleukin 6 receptor). The 
identified association between serum CRP and HNF1A were confirmed in a separate paper, 
published simultaneously, which followed up the results of a small whole-genome scan (980 
individuals) with fine mapping of identified candidate genes in further cohorts of white 
European ancestry (Reiner et al 2008). The most recent GWA study analysed 329,091 
genotypes generated using the Illumina 370cnvDUO array, in a population of 4,763 
ethnically homogenous individuals from Northern Finland (Sabatti et al 2009). A number of 
quantitative metabolic traits, including CRP were analyses. Along with the now extensively 
replicated CRP cis-effect, the LEPR association was replicated, and a new association was 
identified with the LEF1 gene, encoding the Lymphoid Enhancer Binding Protein. The 
largest and most recent GWA study was conducted in a cohort of 17,967 participants (Elliott 
et al 2009). This cohort was homogeneous, containing individuals of Scandinavian, Western 
European and Asian Indian ethnicity, some of whom has CHD or metabolic syndrome, 
although this was accounted for by use of a principal components analysis. Replication of top 
hits was performed in a cohort of 13,615 individuals free from heart disease. Genotyping was 
by either Illumina 500K or Illumina 317K chip with additional SNP imputation across the 
whole dataset resulting in approximately 1.4 million direct or imputed genotypes per person. 
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Results largely mirrors those of the Ridker et al study, with the key genes associated with 
CRP level being CRP, LEPR, IL6R, HNF1A and APOE. 
 
Table 8.4 highlights the actual CRP SNP found most associated with CRP levels in these 
genome wide analyses.  
 
 
Table 8.4. Most significant SNPs at CRP in the current GWA studies. 
Study Key SNP Comments 
Benjamin et al  rs2794520 Directly genotyped. In strong LD with rs1205 
Melzer et al rs12093699  
Ridker et al rs3091244 A hand-picked SNP not on GWA chip (C vs. A/T coding reported) 
Sabatti et al rs2794520 Directly genotyped. In strong LD with rs1205 
Kooner et al rs7553007 An imputed SNP but in strong LD with rs1205 
 
 
It should be emphasised that the CRP coverage on genome-wide arrays is relatively sparse 
and does not include the key SNPs commonly reported throughout the literature i.e. rs1205, 
rs3091244 or rs1800947 (The 8 SNPs on the HapMap 500 panel being rs2808660, 
rs2592900, rs1146973, rs12744244, rs12083699, rs2592887 and rs2794520). GWA at its 
current level of coverage should not be regarded as a substitute for detailed fine mapping. 
Indeed the “top hit” reported in the Ridker et al study (rs3091244) was not actually on the 
GWA chip, but was part of a panel of additional hand-selected SNPs for genotyping. The 
“top-hit” reported in the Elliott et al study (rs7553007) was actually one of the imputed 
genotypes. Despite this, it is still possible to see consistency within the GWA literature. It can 
be seen with reference to figure 3.1 and figure 3.2 and table 3.3 that rs7553007 and 
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rs2794520, which are highlighted in the GWA studies, are both in strong LD with each other 
and both are in strong LD with the commonly reported rs1205 variant: all three SNPs fall on 
the same two CRP haplotypes. 
 
8.5.3: Trans-acting effects – the current picture and future work 
 
Recent GWA studies highlight a number of new trans-acting genetic influences on basal CRP 
expression. I think that the function of these novel candidates, within metabolic pathways, 
provides good evidence that basal CRP is regulated as a distinct non-inflammatory process. 
The focus of further work on trans-acting effects therefore moves away from cytokine genes 
such as IL6 and IL1B, which, nonetheless, may play an important role in the variation of 
acute-phase CRP expression. The Ridker GWA study is interesting in that it estimates the 
proportion of CRP variance explained by each of the identified loci. The total estimated 
variance explained was 10.1%. This figure will probably be revised upwards when the 
genetic effect from each of these loci is refined by detailed mapping studies, nonetheless, it 
suggests we have still only identified approximately half of the total genetic component of 
CRP variation. Whether or not we are likely to identify further loci is a point of discussion. It 
is possible that the remaining genetic influence on CRP variation is determined by multiple 
genes (for arguments sake say 50-100) each of which are contributing only a small amount to 
total CRP variability. It is possible that we may never identify these weak effects because to 
have sufficient power to detect the associations would require a cohort several magnitudes 
larger than those currently available. 
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8.6 CRP, C3 and Disease 
 
While an increasing number of studies report an association between genetic variants and 
serum CRP, the number of studies reporting CRP associations with disease remains small. A 
key finding from my analysis presented in chapter 3 was my inability to detect an association 
between CRP variants and SLE, although I have argued that our power to detect such an 
association was actually quite low. Notably the last 12 months has also seen the publication 
of three GWA studies in SLE cohorts and in none of these did CRP variants approach 
genome wide significance (Graham et al 2008; Harley et al 2008; Hom et al 2008). Although 
these studies were large, they did not reach the size of cohort used for GWA studies in 
diseases such as diabetes mellitus, and it could be argued that the power to detect more 
modest effects was limited. The coverage of markers across CRP in these studies was of 
course also more limited than that employed in candidate gene studies. As I discussed in 
section 1.3.4, four relatively small scale candidate gene association studies have reported 
association between CRP variants and SLE, but there is no consistency between the identified 
genetic variants in each of these studies. A link between CRP expression and SLE is 
theoretically attractive although on the basis of current evidence we must be cautious about 
whether there is true genetic effect arising from this gene, or at least accept that any effect is 
likely to be relatively weak. 
 
While none of the studies presented in this thesis addressed the question of association 
between CRP and cardiovascular disease, it is important to recognise that there remains a 
paucity of published data suggesting that such an association exists. 
 
As I outlined in section 1.4.3 the most frequently observed association between C3 variants 
and disease are for age-related macular degeneration and renal allograft survival (for the 
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C3F/S variant), and bronchial asthma (for probable non-coding effects). Although there are a 
number of theoretical reasons why C3 variation may be of relevance in SLE, published data 
supporting this is limited. The data presented in this thesis suggests that there was an SLE 
association, supporting an existing Japanese study but highlighting a different SNP 
(Miyagawa et al 2008). Unfortunately the different ethnicity of the two cohorts makes a 
direct comparison difficult. Notably, C3 variants were not highlighted in the three recent 
GWA studies in SLE, although with the overall LD across C3 being relatively weak it is 
likely that the density of genetic coverage offered by these GWA chips was inadequate to 
convincingly exclude an association at this locus. 
 
8.7 Concluding Remarks and Future Work 
 
We can use genetics to answer two simple questions regarding serum CRP and C3: are 
genetic variants associated with the levels of these two proteins and are variants in these 
genes associated with disease. More sophisticated questions, however, that are of greater 
clinical relevance are: does genetics provide evidence for a direct causal role of these proteins 
in disease and, even if they are not directly causal factors, can we use genetics to improve the 
predictive power of these proteins as markers for disease. We have seen from the section 
above that for CRP, the evidence from genetics to implicate physiological levels of basal 
CRP (or at least circulating serum CRP) as a causal factor in both atherosclerosis and SLE is 
weak. Despite the size of the recent negative Mendelian Randomisation study, it remains 
possible that studies are hampered by a lack of power particularly as the influence of 
individual loci on CRP variability is small (Zacho et al 2008). Plans for a collaborative effort 
to repeat this sort of experiment on a larger scale (at least 37,000 CHD cases and 120,000 
controls) and with comprehensive genetic coverage should answer this question definitively 
(CRP CHD Genetics Collaboration 2008). This is not to say that unmeasured locally acting 
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CRP within tissues may have a pathological role. It is also important to stress that even if no 
genetic effect is found, either supra-physiological administration of CRP, or the use of CRP 
inhibitors may have a role in the treatment of disease. Both CRP and its inhibitor have indeed 
been shown in early studies to have a potential therapeutic role in SLE and cardiovascular 
disease (Pepys et al 2006; Rodriguez et al 2005; Rodriguez et al 2006). What is suggested by 
current genetic studies is that lifelong, genetically determined minor variation in CRP 
concentration may have a minimal role in the development of disease. 
 
The second question is whether we can make use of the available CRP genetic data to 
improve the utility of basal CRP levels as a predictive biomarker. In section 1.3.5 I 
commented on calls for CRP to be used as a routine clinical measure of coronary risk 
(Danesh et al 2004; Pearson et al 2003). If we are able to understand the genetic influences 
on basal CRP level then it is possible that the use of a “genetically adjusted” CRP level in 
these predictive models will provide improved risk estimates. Unfortunately current evidence, 
including the work presented in this thesis suggests that routinely adjusting CRP for genetic 
influences will not be practical in the foreseeable future. Current evidence suggests multiple 
genetic variants both cis- and trans-acting each account for a small proportion of CRP 
variability. Even if we were to conclusively identify all the true functional variants, a 
genetically adjusted CRP would require the genotyping of multiple variants; a prospect that is 
not currently feasible for routine clinical practice. 
 
For CRP, I think that interest will now focus much more on the genetics of acute-phase CRP 
expression. Acute-phase CRP has also been built into clinical algorithms to compare disease 
activity between patients and to predict future clinical events, most notably in the field of 
rheumatoid arthritis (as discussed in section 1.3.3). A review of the literature over the past six 
months suggests a rapid growth in the number of clinical scenarios in which acute-phase CRP 
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has been proposed to have this predictive role. These include: mortality in oral squamous cell 
carcinoma, spread of gastric carcinoma, risk of recurrence of atrial fibrillation following 
cardioversion, survival from adult respiratory distress syndrome, progression to joint 
replacement in rheumatoid arthritis, all-cause hospital mortality, non-relapse mortality 
following bone-marrow transplantation and prognosis in colorectal cancer determining need 
for adjuvant chemotherapy after surgery (Artz et al 2008; Bajwa et al 2009; Khandavilli et al 
2009; Kim et al 2009; Koike et al 2008; Kompoti et al 2008; Mazza et al 2009; Poole et al 
2008). Although the number of studies looking at acute-phase CRP are limited, the available 
evidence from these suggest that the role played by genetics in determining the magnitude of 
acute-phase CRP may be relatively strong. Despite the problems faced by all these studies in 
quantifying the magnitude of inflammatory stimulus and hence reducing random error 
associated with differing levels of inflammatory activity (see section 6.4.3) all studies were 
able to demonstrate significant genetic associations. In addition there appears to be some 
consistency in the literature, particularly surrounding the association of rs1800947 with lower 
acute-phase CRP and, probably, with rs3091244 and higher CRP. Studies of acute-phase 
CRP may be harder to design, but the usefulness of a genetically adjusted acute-phase CRP 
level is likely to impact across a wide range of medical fields. With this in mind I have 
already established a further collaboration with the aim of replicating my own acute-phase 
CRP findings. The new cohort consists of a further 500 patients with rheumatoid arthritis. 
This cohort has the added benefit of having multiple paired CRP/ESR measurements for each 
patient, which will considerably increase the power of the study, hopefully confirming and 
strengthening the preliminary finding I presented in chapter 6. 
 
While the clinical measurement of serum C3 is more restricted, it has a particular role in the 
monitoring of disease activity in systemic lupus erythematosus. Similar to CRP, it has also 
been reported to predict risk of future clinical events, namely hypertension, future risk of 
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diabetes mellitus and outcome in IgM nephropathy (Engstrom et al 2005; Engstrom et al 
2007; Myllymaki et al 2006). The study of the genetics of C3 expression and the relationship 
between common C3 variants and susceptibility to SLE is at a preliminary stage, consisting 
of the data presented in this thesis and one other study. Unfortunately I was unable to 
replicate the existing Japanese study findings that a single C3 SNP influences both C3 levels 
and disease susceptibility, although my findings were not inconsistent with genetic effects 
reported for other diseases. Clearly further work is required in this field. For the study of 
genetic effect on serum C3 analysis of a cohort of individuals without SLE would probably 
provide the most unambiguous results. For the genetic association with disease a detailed 
fine-mapping study in alternative large SLE cohorts will be required. 
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A – Sequenom reagents and reaction conditions 
 
 
PCR reagents (HME protocol) 
 
Using 2.5ng template DNA dissolved in 2μL TE buffer. 
Reagents per reaction for a 3-6plex PCR making a total reaction volume of 5μL 
Reagent Volume/reaction 
Nanopure H2O 1.930μL 
10x PCR Buffer (inc. 15mM MgCl2) 0.500μL 
25mM MgCl2 0.200μL 
10mM dNTPs 0.100μL 
PCR Primer Mix (100nM each) 0.250μL 
HotstarTaq DNA polymerase(5U/ μL ) 0.020μL 
 
 
PCR reagents (iPLEX and iPLEX gold protocols) 
 
Using 10ng template DNA dissolved in 2μL TE buffer. 
Reagents per reaction making a total reaction volume of 5μL 
Reagent Volume/reaction 
Nanopure H2O 0.850μL 
10x PCR Buffer (inc. 15mM MgCl2) 0.625μL 
25mM MgCl2 0.325μL 
25mM dNTPs 0.100μL 
PCR Primer Mix (500nM each) 1.000μL 
HotstarTaq DNA polymerase (5U/ μL )* 0.100μL 
*increased to 1U/reaction for plexes >27. 
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PCR step thermocycler conditions (all protocols) 
 
1. 95˚C for 15 mins 
2. 95˚C for 20 seconds 
3. 65˚C for 30 seconds 
4. 72˚C for 1 minute 
5. Steps 2 to 4 repeated 4 times 
6. 95˚C for 20 seconds 
7. 58˚C for 30 seconds 
8. 72˚C for 1 minute 
9. Steps 6 to 8 repeated 4 times 
10. 95˚C for 20 seconds 
11. 53˚C for 30 seconds 
12. 72˚C for 1 minute 
13. Steps 10 to 12 repeated 37 times 
14. 72˚C for 3 minutes 
  
SAP reagents (all protocols) 
 
Added to 5μL PCR reaction mix to form a 7μL SAP reaction. 
 
Reagent Volume/reaction 
Nanopure H2O 1.530μL 
10xSAP buffer 0.170μL 
Shrimp Alkaline Phosphatase (1U/μL) 0.300μL 
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SAP step thermocycler conditions (all protocols) 
 
1. 37˚C for 20 minutes 
2. 85˚C for 5 minutes 
3. 4˚C forever 
 
Hme Reaction Reagents 
 
Primer concentration altered according to plexing level. Total mix for 384 plate given. 2μL 
added to 7 μL SAP reaction mix to form a 9μL reaction. 
 
 3-plex 4-plex 5-plex 6-plex 
Nanopure H2O 925.3 898.9 872.5 846.1 
hME termination mix 105.9 105.9 105.9 105.9 
Thermosequenase (32U/μL) 9.6 9.6 9.6 9.6 
Primer Mix (100μM each) 79.2 105.6 132 158.4 
 
 
Hme Reaction thermocycler conditions 
 
1. 94˚C for 2 minutes 
2. 94˚C for 5 seconds 
3. 52˚C for 5 seconds 
4. 72˚C for 5 seconds 
5. Steps 2 to 4 repeated 55 times 
6. 4˚C forever 
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iPLEX Reaction Reagents 
 
Added to 7μL SAP reaction mix to form a 9μL reaction. 
 
Reagent Volume/reaction 
Nanopure H2O 0.755 μL 
iPLEX Buffer (10x) 0.200 μL 
iPLEX termination mix 0.200 μL 
Primer Mix 0.804 μL 
iPLEX enzyme 0.041 μL 
 
 
iPLEX Reaction thermocycler conditions 
 
7. 94˚C for 30 seconds 
8. 94˚C for 5 seconds 
9. 52˚C for 5 seconds 
10. 80˚C for 5 seconds 
11. Steps 3 to 4 repeated 5 times 
12. Steps 2 to 5 repeated 40 times 
13. 72˚C for 3 minutes 
14. 4˚C forever 
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B – Radial immunodiffusion reagents. 
 
Complement fixation test buffer 
 
CFT buffer reconstituted from tablets (Oxoid Ltd, Cambridge, UK). A 1% solution contains: 
Barbitone   0.575g/L 
NaCl   8.5g/L 
MgCl2   0.168g/L 
CaCl2   0.028g/L 
Barbitone soluble  0.185g/L 
 
Phosphate Buffered Saline 
 
PBS was reconstituted from tablets (Sigma-Aldrich, Gillingham, Dorset, UK) and pH 
adjusted using small aliquots of HCl. The reconstituted solution contained: 
 
Phosphate buffer 0.01M 
KCl  0.0027M 
NaCl  0.137M 
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Coomassie stain 
 
Coomassie stain was made by dissolving Coomassie Brilliant blue R250 (Sigma-Aldrich, 
Gillingham, Dorset, UK) using the following reagents: 
 
Coomassie Brilliant blue R250 2.5g 
Ethanol     225mL 
ddH2O    225mL 
Glacial Acetic acid  50mL 
 
Destain solution contained ethanol, ddH2O and acetic acid only in the same ratio. 
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C – UK and Filipino Recruitment Questionnaire 
 
Project Title: Genetic Susceptibility in Systemic Lupus Erythematosus 
 
Principal Investigator: T. Vyse 
 
 
Full Name:             
 
Date of Birth (day/mo/yr)      Family #   Ind  
Office use only 
 
If you have read the Information Sheet and agree to participate in this study, please sign below. 
 
 
Signed:________________________________________Date:___________________ 
 
 
Please circle your GRANDPARENTS ethnic group: 1) Afro-Caribbean  2) Caucasian 
 
3) Asian (Indian/Pakistani)  4) Asian (Oriental)  5) Other (please specify) 
 
 
When were you diagnosed having SLE? Month  Year   WEIGHT st
 lb  
 
kg  
When did you first notice any symptoms? Month  Year   
   
           HEIGHT m…… 
Do you smoke?      YES  NO 
 
If so, how many per day?   …………….. 
 
 
Please answer each of the following questions carefully.  If a question is unclear or you don’t know 
the answer please write “unsure” in the space provided.  Please feel free to call us for clarification. 
 
Please circle your correct answer 
 
 
1. Have you ever suffered from any type arterial disease: 
 
a) Stroke         YES   NO 
 
b) TIA (minor stroke)       YES   NO 
 
c) Heart attack        YES   NO 
 
d) Angina (pain in your chest)      YES   NO 
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Name      Family #     Individual # 
 
 
2. Lupus can sometimes affect your kidneys 
 
 
a) Have you ever been told that Lupus has affected your kidneys? YES   NO 
 
b) Have you had a renal (kidney) biopsy?     YES   NO 
Date  Hospital    
 
c) Have you had any significant protein in your urine?   YES   NO 
 
 
3. Have you ever suffered from thrombosis (blood clots): 
 
a) Deep vein (leg) thrombosis      YES   NO 
 
If YES, how many times?        
 
b) Pulmonary (lung) embolism      YES   NO 
 
c) Have you ever had a thrombosis in any other part of your body? YES   NO 
 
 
 
4. Have you ever had a low platelet count (thrombocytopenia)?  YES  
 NO 
 
 
5. Have you ever been diagnosed with: 
 
a) Pleurisy        YES   NO 
 
b) Pericarditis        YES   NO 
 
If YES please provide details: 
 
 
6. Have you ever been diagnosed with Raynaud’s phenomenon  YES  
 NO 
 
(colour changes to your fingers and/or toes in cold weather)? 
 
 
7. Have you ever had a DEXA (bone density) scan?    YES  
 NO 
 
 If so, please give Date and Hospital 
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Name      Family #     Individual # 
 
 
8. Have you ever had/suffered : 
 
a) Serious depression  (requiring medication)    YES   NO 
 
b) Seizures (fits)        YES   NO 
 
c) Hallucinations        YES   NO 
 
 
9. Have you ever had a spontaneous miscarriage?    YES  
 NO 
 
If YES, how many?          
 
 
10. Do you have any children? 
 
 If YES, please give their year of birth: 
 
 
11. Have you ever been diagnosed with Sjögren’s syndrome   YES  
 NO 
 
(prolonged dry eyes and/or dry mouth) ? 
  
 
12. Have you more than once suffered oral (mouth) ulceration?  YES  
 NO 
 
 
13. Have you ever suffered from arthritis in the hands, wrists or feet? YES  
 NO 
 
If YES please provide details: 
 
 
14. Have you ever suffered from skin rashes?     YES  
 NO 
 
Are these skin rashes worsened or triggered by exposure to sunlight? YES   NO 
 
If YES please provide details: 
 
 
15. Have you even been admitted into hospital in the past five years due to lupus? 
               
Please provide details:      YES   NO  
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Name      Family #     Individual # 
 
 
Previous Medical History 
 
 
16. Have you ever been diagnosed with any of the following: 
 
Systemic lupus erythematosus      YES   NO 
 
Rheumatoid arthritis        YES   NO 
 
Diabetes mellitus        YES   NO 
 
If YES, AGE of onset   ? Insulin therapy  ? 
  
Thyroid diseases (Graves’ disease, Hashimoto’s thyroiditis)  YES   NO 
 
Multiple sclerosis        YES   NO 
  
Optic neuritis         YES   NO 
 
Inflammatory bowel disease (Crohn’s disease or ulcerative colitis)  YES   NO 
 
Liver disease (chronic autoimmune hepatitis     YES   NO 
primary biliary cirrhosis)  
 
 
17. Do you have any other medical conditions?    YES  
 NO 
Please provide details: 
 
 
18. Do you take any medications regularly?     YES  
 NO 
Please provide details: 
 
 
For Lupus sufferer only:  Please write: the name of your hospital Lupus doctor(s) and your GP(s) 
 
Lupus doctor(s):        GP: 
 
Hospital:   Hosp. Record No    Surgery: 
 
Town          Address: 
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